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Resumo 
Nos últimos anos, o contexto de negócios no qual a indústria de processos opera mudou 
drasticamente, tornando-se mais desafiante e competitivo de um ponto de vista operacional. No caso 
particular da indústria farmacêutica, a diminuição do tempo de vida efetivo das patentes e o 
subsequente aumento da concorrência por parte dos medicamentos genéricos impulsionaram, tanto 
a indústria como a investigação, a perseguir novas estratégias de desenvolvimento e produção. Não 
só o tempo necessário para colocação de novos produtos no mercado se tornou uma questão central, 
mas também aspetos de sustentabilidade como a utilização eficiente dos recursos disponíveis e a 
gestão de resíduos, potenciaram o desenvolvimento de abordagens inovadoras baseadas em 
otimização para alcançar a excelência operacional. 
Novas estratégias para aumentar a capacidade de resposta das empresas e a sua competitividade 
devem combinar decisões tomadas durante o ciclo de desenvolvimento de novos medicamentos com 
decisões de produção. Estas abordagens requerem a integração de decisões de longo- e curto-prazo, 
abrangendo problemas complexos que englobam não só múltiplos níveis hierárquicos, mas também 
diferentes escalas de tempo e espaço dependentes entre si. Neste contexto, métodos de otimização 
bem estabelecidos, focados exclusivamente em problemas de planeamento e escalonamento de 
produção, já não são adequados, pois geralmente negligenciam as incertezas e os riscos associados à 
interdependência entre decisões e ignoram requisitos de sustentabilidade e flexibilidade do contexto 
de negócios atual. Apesar de algumas contribuições importantes já terem sido apresentadas 
abordando a integração de vários níveis de decisões, o desenvolvimento de uma metodologia eficaz 
permanece ainda como um importante desafio de investigação. Para melhorar significativamente o 
desempenho geral dos sistemas, devem ser consideradas abordagens holísticas coordenadas e 
multifuncionais. Dessa forma, soluções globalmente otimizadas que efetivamente apoiarão a 
estratégia de negócios serão alcançadas. 
Este trabalho de investigação pretende, assim, preencher esta lacuna, compreendendo as fragilidades 
operacionais do setor e explorando o real valor e impacto de uma tomada de decisão integrada, 
considerando aspetos como a variabilidade da procura e diversidade de produtos, a incerteza 
associada a cada nível de decisão e questões de sustentabilidade. O principal objetivo desta 
investigação é desenvolver abordagens baseadas em otimização focadas nas decisões de 
planeamento estratégico e tático sob incerteza, considerando complexas interações com níveis mais 
baixos de decisões operacionais. Espera-se que estas abordagens contribuam para um processo de 
tomada de decisão mais informado, com o objetivo de: i) maximizar o lucro das empresas; ii) 
minimizar futuras mudanças no processo de produção; e iv) melhorar a eficiência dos processos, 
particularmente em relação à utilização de recursos e gestão de resíduos. 
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Abstract 
In recent years the business context in which process industry runs has dramatically changed, 
becoming operationally more challenging and competitive. In the particular case of the 
pharmaceutical industry, the decrease of effective patents life and the subsequent increase of generic 
drugs competition have forced, both industry practitioners and researchers, to pursue new 
development and manufacturing strategies. Not only the time-to-market has become a key issue, but 
also sustainability aspects concerning the efficient utilization of the available resources and waste 
management have driven the development of more innovative optimization-based approaches to 
achieve operational excellence. 
To be responsive and competitive, new strategies must couple decisions made during the drug 
development cycle with manufacturing decisions. These approaches require integrated decision-
making from long to short-term perspectives, where complex problems comprising multiple 
hierarchical levels, covering dependent time and spatial scales, need to be addressed. Here, well 
established optimization methods, solely focused on planning and scheduling problems, are no 
longer suitable, since they do not really consider the uncertainties and risks associated with the 
interdependency between decisions and they ignore the sustainability and flexibility requirements 
of the business context. Although important contributions have already been presented addressing 
multi-level integration in decision-making, to the best of our knowledge, an effective modeling 
solution still remain as an important open challenge. To significantly improve the overall systems’ 
performance, coordinated and cross-functional holistic approaches must be considered. In this way, 
globally optimized solutions, that will effectively support the business strategy will be achieved. 
This research aims at filling this gap by understanding the industry’s operational weaknesses and by 
further exploring the real value and impact of integrated decision-making, considering aspects such 
as the fluctuating demand and product variety, the uncertainty associated to each decision level, or 
some relevant sustainability issues.  
The main goal of this research is to develop optimization-based approaches focused on the strategic 
and tactical planning decisions under uncertainty, considering complex trade-offs and interactions 
with lower levels of operational decisions. This approach is expected to contribute to a more 
informed decision-making process and aims at: i) maximizing the profit of the companies; ii) 
minimizing unnecessary capital investments; iii) minimizing future changes in the production 
process; and (iv) improving processes efficiency, particularly regarding to resource utilization and 
waste management. 
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1. Introduction 
In this chapter the main motivation and objectives of this research will be described. The scope of 
the study and the research questions will be defined, in order to clearly outline the problem being 
addressed and give guidelines for a sound development of this work. 
The research structure and methods will be also presented as well as the overall thesis outline. 
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1.1. Motivation and research objectives 
Healthcare is one of today’s most valuable social and economic assets, laying the foundations for a 
sustainable and economically developed society. Having a sustainable access to quality healthcare 
services, although being a complex task, is a main global priority as highlighted in the health policy 
framework for Europe Health2020 (WHO, 2013). Regional governments and policy makers have the 
main responsibility in this task by providing the necessary resources to enable a sound and fair 
healthcare system. 
In this context, the research-based pharmaceutical industry stands at the core of any country’s 
healthcare system, by providing high quality medical drugs and treatments, responsible for 
preventing, treating, and curing diseases, in an attempt to improve or maintain people’s health. Along 
with these direct benefits for the populations, medicines also contribute to significant cost reductions 
in the overall healthcare systems, by reducing the need for expensive surgeries and/or long-term 
care in hospitals. Considering that healthcare spending is continuously growing in the OECD 
countries  (OECD, 2017), the pharmaceutical sector plays a fundamental role in offsetting the medical 
costs incurred by governments (Pfizer, 2014). Representing on average only about 16% of the global 
health expenditure across the OECD countries in 2015 (OECD, 2017), some studies (see Afendulis et 
al. (2011); Congressional Budget Office (2012); IFPMA (2015)) suggest that for every dollar spent on 
prescription drugs in the United States, a saving of more than two dollars is expected in 
hospitalization costs (IFPMA, 2015). 
Due to this pivotal role in supporting the healthcare structures, and its direct impact on population’s 
well-being, the pharmaceutical industry has been under great pressure to enhance responsiveness, 
foster affordability, and provide generalized access to high quality medicines. As world economies 
evolve, it is expected to have more sustainable and reliable healthcare systems and an increased 
demand for innovative medical drugs with demonstrated therapeutic value.  
 
Figure 1.1 Worldwide total prescription drug sales (2008-2022) (Pharma, 2017). 
 
 
 
1. Introduction  
4 
 
According to Pharma (2017), the worldwide prescription drug sales is expected to grow at a 6.5% 
CAGR (Compound Annual Growth Rate) in the period 2017-22 (Figure 1.1). This trend of growth also 
anticipates a more global and competitive marketplace, tendentially more difficult to manage by the 
pharmaceutical companies. 
In this way, as the market becomes increasingly dynamic and competitive, management challenges 
related to the production, distribution, and delivery of medical drugs, also become more critical and 
complex.  
However, being a highly regulated sector, the pharma business model and its operations have 
remained relatively unchanged and highly inefficient over decades, having some of the poorest 
supply chain performance metrics (Shah, 2004; Kaitin, 2010; Yu, 2016). With long development 
cycles, and high R&D investments with very low success rates, the time-to-market is pointed as the 
most critical driver in this industry (Shah, 2004). Additionally, considering its high dependence on 
patent effective life to recover investments, companies are now, more than ever, under great 
pressure to deliver medical products faster and more efficiently. 
In that sense, operational performance that was somehow neglected for decades, has been gaining 
an increasing relevance in recent years, and operational efficiency is starting to emerge as a key 
differentiation factor in this sector. Therefore, chemical-pharmaceutical companies are now starting 
to move from their traditional business model almost exclusively dedicated to product innovation, to 
a more cost-efficient operating mode (Kaitin, 2010; Gautam & Pan, 2016). 
This transition, however, is still at its infancy of development, companies having to face some major 
management challenges yet to overcome. Namely, the high complexity of the current pharmaceutical 
supply chain, the lack of coordination between operational functions, the declining R&D productivity, 
the need for effective production/capacity planning and asset utilization, and the ability to efficiently 
align the goals of different decision-levels. 
In this regard, decision-making tools can play a key role in supporting this transition process. Being 
inherently associated with operational performance indicators, they aim to support business and 
improve operational decisions. Thus, the development of new decision support tools incorporating 
the unique complexities of the pharmaceutical industry is, therefore, crucial and urgent, to overcome 
these challenges, and to achieve the required levels of efficiency to sustain competitiveness. 
In this context, Process Systems Engineering (PSE) and Operations Research (OR) communities have 
been developing reliable decision tools in the past years based on analytical systems such as 
simulation, optimization, and hybrid simulation-optimization based approaches, covering a broad 
diversity of problems (Kallrath, 2002; Shah, 2004; Floudas & Lin, 2005; Verderame et al., 2010; 
Laínez et al., 2012; Moniz et al., 2015c; Grossmann et al., 2016b; Reklaitis, 2017). However, well 
established enterprise-wide optimization applications, such as those developed for planning and 
scheduling, exhibit important limitations in accurately capturing some relevant dynamics of the real 
supply chain behaviour (Naraharisetti et al., 2009; Dias & Ierapetritou, 2017). Typically, these models 
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seldom consider the plethora of factors and external disturbances affecting the business and its 
strategy within a sustainable and flexible supply chain context. For instance, the variety of decisions 
spanning across different hierarchical levels and business functions are typically considered 
individually, and their interactions and coordination are poorly understood and often neglected.  
Moreover, some of the available tools are highly complex to understand and implement within a real 
organization, where business responsiveness asks for simpler and more intuitive models in which 
the decision-maker’s participation is not only a valuable insight, but also a paramount building 
component of the decision-making process.  
Therefore, this research work aims at meeting the pharmaceutical industry main challenges, in their 
path for enhanced operational efficiency by understanding their main operational fragilities in the 
current business context, and by developing effective solution approaches for (strategic and tactical) 
planning during the new product development (NPD) phase. In this way, it aims at addressing four 
main research goals (RG): 
RG 1. mapping the current state of the pharmaceutical business and production context and their 
decision-making processes; 
RG 2. understanding the current market dynamics and the expected business evolution, as a basis 
for developing a generalized reference framework for the most relevant decision problems 
arising from the complexities of the new pharma paradigm;  
RG 3. developing optimization-based approaches to enhance the integrated strategic and tactical 
planning decisions under uncertainty, and to improve the overall operational efficiency; 
RG 4. incorporating the decision-maker risk-attitude in the characterisation of strategic decisions. 
The joint development and successful accomplishment of these four research goals will have a 
positive operational impact in the chemical-pharmaceutical industry, by achieving the following 
expected outcomes (O): 
O1. a comprehensive decision-making reference framework to provide a structured support to 
academic researchers and industrial practitioners in systematizing their problems, while 
taking into account all the relevant factors affecting future supply chain operations. 
O2. a unified decision support tool to address the stochastic product launch planning problem 
in the pharmaceutical industry, which includes: 
O2.1. a simulation-optimization based approach to improve overall operational 
efficiency, by integrating process design and production planning decisions under 
a highly uncertain environment; 
O2.2 a multi-objective approach, explicitly considering the decision-maker preferences, 
to determine the strategic design solutions that improve the productivity level 
during product development. 
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1.2. Scope of analysis and research questions 
According to the research goals defined in the previous section, two different levels of analysis are 
considered. On one hand, regarding the first two research goals (RG 1 and RG 2), the work is centred 
on the pharmaceutical business and production context and its SC operations. Specifically addressing 
the related decision-making processes as the main unit of analysis, this thesis is focused on their 
conceptual characterization and respective future challenges.   
On the other hand, to meet the last two research goals (RG 3 and RG 4), this study is concentrated on 
the new product development (NPD) process, as this is the most critical and challenging stage in the 
pharmaceutical product lifecycle. The work specifically addresses the operations during the clinical 
trials activities and their planning challenges. Here, the traditional multipurpose batch 
manufacturing system is the main unit of analysis, focusing on the stochastic product launch planning 
problem, including integrated process design and production planning decisions for the clinical 
trials. Figure 1.2 schematically represents the scope of the research work within the context of the 
pharmaceutical product lifecycle. 
 
Figure 1.2 Pharmaceutical product lifecycle and scope of the research project. 
Considering this, three research questions were formulated to guide a sound development of the 
research and meet the defined objectives. The questions are expressed as follows: 
 
RQ 1: How is recent research contributing to overcome the current challenges in 
chemical-pharmaceutical operations management? 
 
RQ 2: What should be the main building blocks of a useful chemical-pharmaceutical 
industry’s decision-making framework? 
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RQ 3: How can pharmaceutical companies enhance their strategic and tactical decision-
making processes through optimization-based approaches, during product launch 
planning and considering its unique complexities and uncertainty environment? 
 
The first research question aims, firstly, to leverage the understanding regarding the current 
developments in the pharmaceutical supply chain management and, secondly, to better comprehend 
how these developments have impacted the industry in what concerns its operational efficiency, and 
what are the main unmet challenges.  
The second research question aims at guiding this research work in developing a new decision-
making reference model capable of accommodating the expected future operating practices and 
business models. The main objective is to clearly identify the main building blocks and respective 
interactions, so as to support the development of future decision-making tools. Following this, the 
third research question focus on the development of an efficient optimization-based decision-making 
tool for strategic and tactical planning, by providing guidance regarding what should be the main 
components and strategies for dealing with the main challenges and complexities of this industry. 
1.3. Research Structure and Methods 
Based on the above considerations, the research work is structured around two stages. The first stage 
is dedicated to a conceptual analysis of the pharmaceutical “Business Context” and its market context 
as a whole, while the second is focused on the “SC Operations” specifically addressing the strategic 
and tactical production planning decisions during the NPD process. A schematic representation of 
the research structure and methods followed in this work is shown in Figure 1.3. 
First, the conceptual analysis, designed to answer RQ1 and RQ2, was performed based on an 
empirical study supported by a thorough literature review and a survey of market reports. From this 
analysis, the prevailing current pharmaceutical business strategies and supply chain operations 
principles are outlined, as perceived by both, practitioners and researchers. Following this, the 
expected new pharmaceutical paradigm is anticipated as well as its impact on the supply chain 
operations and related decision-making processes.   
The following stage in the work aims at answering RQ3, and is focused on the operations planning 
during the NPD process. In this case, the work includes techniques such as Mixed Integer Linear 
Programming (MILP) and Multi-Objective Integer Programming (MOIP) models, for the 
determination of process design (strategic) and production planning (tactical) decisions. To deal 
with uncertainty, Monte Carlo Simulation (MCS) approaches are applied. 
The models were validated using a small industrial case, based on a typical contract manufacturing 
organization (CMO) for Active Pharmaceutical Ingredient (API) production. The problem instances 
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were created with values estimated from the literature and validated by comparing those values with 
the current industrial practice. 
 
Figure 1.3 Research structure and methods. 
1.4. Thesis Outline 
The present thesis is organized following the main research structure presented above and depicted 
in Figure 1.4.  
Therefore, in chapter 2, a thorough conceptual analysis is performed in order to portray the current 
state of the industry and their planning decision-making processes. The main research challenges 
and opportunities for improvement are identified, as well as the current market dynamics, in the 
form of drivers and trends, in order to evaluate their impacts on the global supply chain and envision 
future operations and planning decision-making processes. A general decision-making reference 
framework is then proposed, to provide support and guidance in the decision-making processes, 
taking into account all the complexities associated to the new pharmaceutical paradigm. 
In chapter 3, the stochastic product launch planning problem is presented, with a description of its 
main features, challenges, and relevance for the pharmaceutical industry. 
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A novel approach, combining a MILP model and a Monte Carlo Simulation framework is proposed, to 
efficiently tackle the integrated process design and production planning decisions, under uncertainty 
in product demand and clinical trials outcomes.  The main goal of the developed approach is two-
fold: to assess the impact of several sources of uncertainty on long-term decision-making during the 
NPD process; and to provide a large-range analysis of the uncertainty parameters, by mapping the 
most likely alternative decisions, and thus enabling earlier and better decision-making 
Chapter 4, presents, an extension of the previous model to determine the unique strategic decisions 
under uncertainty. A Multi-objective Integer Programming model, embedded in a unified decision-
making framework, is developed to obtain the final design strategy that “maximizes” productivity, 
while considering the decision-maker preferences. The model is solved by the weighted-sum method, 
and an approximation of the Pareto efficient frontier is determined. In this case, the purpose is to 
determine the unique strategic solution, by balancing the investment costs to develop a new drug 
and the production capacity allocation to accommodate the uncertain future needs. 
Finally, chapter 5 concludes and summarizes the research work developed in this thesis, highlighting 
its main contributions and presenting some recommendations for future research. 
 
Figure 1.4 Thesis outline. 
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1.5. Publications 
The research developed in this doctoral project is supported by several papers that were already 
published or are under review, in international peer reviewed journals. Each chapter is directly 
related to a specific individual publication, as presented below (this may have resulted in some, 
hopefully minor overlapping throughout the different chapters). 
Chapter 2: 
Marques, C. M., Moniz, S., de Sousa, J. P., Barbosa-Póvoa, A. P., & Reklaitis, G. (2019). Decision-making 
in the chemical-pharmaceutical industry: findings and future research directions. Working paper to 
be submitted for publication to an international journal. 
 
Chapter 3: 
Marques, C. M., Moniz, S., de Sousa, J. P., & Barbosa-Póvoa, A. P. (2017). A simulation-optimization 
approach to integrate process design and planning decisions under technical and market 
uncertainties: A case from the chemical-pharmaceutical industry. Computers & Chemical 
Engineering, 106, 796-813. 
 
Chapter 4: 
Marques, C. M., Moniz, S., & de Sousa, J. P. (2018). Strategic decision-making in the pharmaceutical 
industry: A unified decision-making framework. Computers & Chemical Engineering, 119, 171-189. 
 
Conference Proceedings 
Marques, C. M., Moniz, S., de Sousa, J. P., & Barbosa-Póvoa, A. P. (2016). Optimization and Monte Carlo 
Simulation for Product Launch Planning under Uncertainty. In K. Zdravko & B. Miloš (Eds.), Computer 
Aided Chemical Engineering (Vol. Volume 38, pp. 421-426): Elsevier. 
 
Marques, C. M., Moniz, S., de Sousa, J. P., & Barbosa-Póvoa, A. P. (2017). A simulation-optimization 
approach to integrate process design and planning decisions under technical and market 
uncertainties. In Foundations of Computer Aided Process Operations / Chemical Process Control. 
Tucson, Arizona. 
 
  
 
2. Planning decision-making in the 
chemical-pharmaceutical industry  
In this chapter a comprehensive analysis of the current state of the industry and its planning 
decision-making processes is performed and a new general decision-making reference framework is 
proposed to comply with the today’s business context. 
The content of this chapter is based on the working paper currently being prepared for submission 
to a peer reviewed international journal. 
  
 
 
 
  
 
2. Planning decision-making in the chemical-pharmaceutical industry 
13 
 
 Abstract 
The chemical-pharmaceutical business context is facing an unprecedented fast-
changing environment, with new market and technological trends significantly 
impacting the companies’ operational strategies. Managing the pharmaceutical 
supply chain (PSC) operations is, therefore, ever more complex and challenging, 
requiring a multi-perspective approach. 
This work intents to address these issues by, first, presenting a comprehensive 
overview of the current state of the industry and research developments, in order 
to recognise the current and the forthcoming decision problems; and, then, by 
developing a reference framework to provide support and guidelines to structure 
the production systems. This will be achieved through a multi-perspective analysis 
that encompasses strategic and tactical planning decision-making, in the new 
business context of the chemical-pharmaceutical industry. Interesting findings 
reveal a lack of research addressing the most prominent trends currently driving 
the industry, such as the patient centricity or the new technological interventions. 
This may be an important indicator of the disruptive nature of these expected 
changes in a highly conservative industry. This work reveals the main market 
drivers and trends that are putting pressure on the industry, as well as the main 
resulting research challenges. The contributions of this work are twofold. First, the 
main building blocks of the expected new operational paradigm are outlined 
together with their impact on the PSC management. Second, a new decision-
making reference framework is proposed to assist the development of 
optimization-based models. 
2.1. Introduction 
The chemical industry sector is a broad area of the process industry, representing alone (without 
considering pharmaceuticals, food and drink, and pulp and paper) approximately 7% of EU industrial 
production, and 1.1% of EU GDP (EC, 2018). 
Similarly to other industries (such as discrete manufacturing), the typical supply chain in the 
chemical industry includes several entities embedded in a coordinated network, such as: primary 
and secondary manufacturers, suppliers, warehouses, distributors, and customers. Nevertheless, in 
this sector products present some specific features that are not negligible and usually have relevant 
impacts on the supply chain operations and consequently on the decision-making processes. Some 
of those features include: (i) the non-discrete nature of the final products, making it difficult to 
present them as individual and countable units; (ii) impossibility to disassemble the final product 
into their original raw materials, and (iii) huge variety of non-discrete and immiscible materials with 
their own unique characteristics (Naraharisetti et al., 2009). On the other hand, the process plant is 
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composed of a network of units performing various physicochemical operations frequently in batch 
and multi-product/multipurpose operating modes, leading to high flexibility, but also to very low 
material and capital equipment efficiencies (Shah, 2005; Naraharisetti et al., 2009). In addition to 
that, the need for rigorous and expensive cleaning and sterilization operations, as well as 
maintenance procedures, results in long and undesirable lead times (Naraharisetti et al. (2009), Shah 
(2005)). According to Shah (2005), only 0.3-5% of the supply chain cycle time (considered as the 
time between material entering as raw material and leaving as product) involve value-adding 
operations. In that sense, it became clear that there is a great room for improvement and efficiency 
enhancement in chemical industry supply chains. Other key issues, such as the high sensitivity to 
energy prices, environmental and safety regulations, clearly distinguishes this sector from other 
supply chains (Naraharisetti et al., 2009).  
Depending on the characteristics of their final products, the chemical industry is usually grouped into 
different sub-sectors or classes. According to Smith (2005) three major classes can be distinguished: 
bulk chemicals; fine chemicals, and specialty chemicals. Each of these classes has different added 
values to the final product and intrinsic characteristics that influence the representation of the 
production process and consequently the focus of the main management decisions (Smith (2005), 
Srinivasan et al. (2006)). Bulk chemicals are mainly characterized by their undifferentiated character 
and large-scale production. In this case the selling price is the main purchasing driver, and for that 
reason margins tend to be slimmer in order to be competitive. On the other hand, fine chemicals are 
produced in a small scale, and represent high purity products mainly used as intermediaries in other 
industries. Nevertheless, this class of products also presents a strong undifferentiated nature 
(despite some differences that can arise regarding the purity grade between different 
manufacturers), making, once again, selling price as the main driver. Finally, regarding specialty 
chemicals (such as pharmaceuticals, cosmetics, flavourings, and others), these can be highly 
differentiated products, that tend to be purchased based on their function / perceived value, rather 
than price or chemical composition. Furthermore, being highly knowledge-intensive, intellectual 
property plays a critical role in this sector. In that sense, production tends to be in small volumes, but 
with very large margins. The characteristics associated with each of those classes tend to be 
determinant on the main decisions related to supply chain management and production efficiency 
(see Figure 2.1). This has been true for many years, with the individual key challenges being confined 
to the specific industry classes. However, the fast-changing business context experienced in the last 
decades is also shaping the changes occurring in the industry operating mode, bringing new 
paradigms to light. This is particularly the case of the pharmaceutical industry, in which significant 
market and business changes have been observed in recent years, with major impacts on the 
sustainability of this industry. Pharmaceuticals are part of the specialty chemicals in which both, 
product and process development, need to follow rigid frameworks imposed by regulatory agencies 
such as the FDA (Food and Drug Administration) in USA, and the EMA (European Medicines Agency) 
in Europe (Smith, 2005). Therefore, pharmaceutical companies are now being forced to overcome 
the barriers that define the specialty chemicals and incorporate a transverse view of the whole 
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chemical industry (Figure 2.1). In that sense, the main concerns traditionally associated to the bulk 
and fine chemical classes, such as cost reduction and production efficiency, are now also major 
concerns in the pharmaceutical industry which has been highly inefficient.  
According to some authors (Singh et al., 2016)  pharmaceutical companies can benefit greatly by 
learning not only from the operational efficiency of the bulk chemical industry, but also from other 
industrial sectors (automotive, electronics, etc). 
 
Figure 2.1 Key differences between the three main classes of the chemical industry. 
Additionally, new trends are also being observed in recent years across the whole process industry, 
encouraging a shift from a cost-driven development to a sustainable-driven development (Heintz et 
al., 2014). Not only economic goals, but also environmental, safety, and social aspects should be 
simultaneously considered in supply chain management decision-making (Barbosa-Póvoa, 2012; 
Barbosa-Povoa & Pinto, 2018) Over the last years, an important body of research work has been 
published focusing on various sustainability aspects in the process industry, as highlighted in some 
important surveys (Srivastava, 2007; Barbosa-Póvoa, 2009; Nikolopoulou & Ierapetritou, 2012b; 
Eskandarpour et al., 2015; Garcia & You, 2015; Barbosa-Póvoa et al., 2018). The chemical industry 
(including the pharmaceutical sector) plays a critical role in this regard, as its operations are strongly 
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dependent on resources and utilities such as energy and water, thus having a significant 
environmental and social impact.  
Technological breakthroughs, such as continuous manufacturing (Lee et al., 2015) and the advent of 
Industry 4.0 (Branke et al., 2016), are already shaping and transforming the traditional 
pharmaceutical manufacturing landscape.  
The emergence of new markets and new healthcare systems is also expected to have a significant 
impact on the pharmaceutical supply chain operations and business models. 
This highly dynamic context that is already in place is putting pressure on pharmaceutical companies 
to leave their traditional operating strategies and move forward to the path of higher levels of 
efficiency, sustainability, agility and customer value creation. 
Accordingly, it is clear that supply chain management in the pharmaceutical industry has become a 
very complex challenge, with an amalgam of new possible decision-making problems that interact in 
a complex network of agents and their relations, that are not always obvious or easy to understand 
(Varma et al., 2007). Thus, despite the increased effort made by researchers in adopting an ever more 
global and integrated vision of the pharmaceutical supply chain, research works found in the 
literature are still very fragmented in what concerns the enterprise-wide optimization paradigm, and 
are strongly limited  to the traditional operating strategies (Grossmann, 2005; Laínez et al., 2012).  
Moreover, existent taxonomies and frameworks used to classify the decision problems in the context 
of pharmaceutical industry need to be adapted to the current situation. Thus, it becomes clear that a 
new general reference framework, covering the main operations planning problems that arise from 
this new context, is key in this field and brings benefits for both academia and industrial 
practitioners.  
The main goal of this chapter is then twofold. First, it aims at presenting a comprehensive overview 
of the developments made so far to grasp the main operations planning problems in the 
pharmaceutical industry and to bring to light the forthcoming new challenges. Second, it proposes a 
reference model to establish a roadmap for the planning decision-making process in this industry, 
accounting for the new challenges imposed by the current business and technological context. 
2.1.1. Methodology 
To establish the basis for understanding today’s pharmaceutical context and its strategical and 
tactical planning challenges, a comprehensive analysis is performed following a sequence of three 
steps outlined in Figure 2.2. These include: i) pharma context analysis; ii) opportunities for change; 
and iii) new pharma paradigm. 
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Figure 2.2 Main steps adopted. 
 
The first step consists in a conceptual analysis of the current state of the pharmaceutical industry 
operations and business context, as it is perceived by both, practitioners and researchers. The main 
supply chain operational performance indicators are outlined, as well as the corresponding decision-
making processes, showing the industry main weaknesses and opportunities for improvement. 
Additionally, a thorough literature review is performed to assess how the academic community is 
addressing the different pharmaceutical supply chain challenges and identifying the most prevalent 
research gaps. 
The second step (opportunities for change) consists in understanding the market dynamics and the 
technological context behind the main driving forces and enablers, that are currently pressing the 
industry and driving the companies to pursue an unprecedent mind-set change.  
A combined analysis of all the three components – challenges, drivers, and enablers – will provide 
insights regarding the path towards a new operational supply chain and associated decision-making 
processes. 
Finally, in the last step, the main components of the foreseen new pharma paradigm will be identified, 
as a way to enable the definition of the new supply chain operational model as well as the 
characterization of the new planning decisions. The integration of these components will lead to a 
general decision-making reference framework. 
2.2. Analysis of the pharmaceutical industry context 
The pharmaceutical industry is a key asset of the European economy: it is one of Europe’s major high-
technology industrial employers and generates about three to four times more employment 
indirectly (EFPIA, 2016). It plays a critical role in the healthcare structure of each country by 
providing medicines and vaccines with direct impact on population’s quality of life. Along with the 
direct benefits for the population, medicines also contribute to significant cost reductions in the 
expenses of the global healthcare system of each country, by reducing the need for expensive surgery 
and/or long term care in hospitals (Pfizer, 2014). This is very significant and highlights the economic 
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importance of this industry for a country, as it is a key player in guaranteeing the economical 
sustainability of any healthcare system. 
The pharmaceutical industry sector is mainly composed by large R&D multinationals, local 
companies, generic manufacturers, contract manufacturing organizations (CMO) – without their own 
product portfolio, and biotechnological companies mainly focused on research and drug discovery 
(Sousa et al. (2011), Shah (2004)). While the large R&D based multinationals represent by far the 
most economically important sub-sector in terms of sales, generic manufacturers are responsible for 
supplying the vast majority of medicines distributed worldwide in terms of volume. Therefore, 
despite many of the stakeholders involved being the same, their supply chains and drivers (specially 
financial) are significantly different (Association for Accessible Medicines, 2019). In the generic 
drugs’ case, supply chains are mainly characterized by large portfolios of finished products and 
distribution chains, without the highly risky intellectual research and product development 
activities. On the other hand, the R&D based multinationals cover the entire product life-cycle, since 
discovery to commercial distribution, relying largely on a careful balance between the products being 
off-patent and the launch of new drugs under patent protection. Thus, in this case, the supply chains 
tend to be much more complex and difficult to manage, and therefore, also more vulnerable to 
uncertainty and risk. Considering these aspects, this chapter will be mostly focused on the analysis 
of this particular sector. 
Similarly to other products, the general life-cycle of a pharmaceutical product starts with product 
development, followed by market launch of the successful products, a growth phase in sales, a 
maturity phase and finally it reaches the end of life with a decline phase (Figure 2.3) (Laínez et al., 
2012). 
 
Figure 2.3 Pharmaceutical product life-cycle (adapted from (Laínez et al., 2012)). 
However, in the pharmaceutical industry, each of these stages has some specific features, that are 
different from other industries, and that create some significant and unique management challenges. 
In order to better understand these challenges, three main sub-topics are proposed here as the most 
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relevant in these supply chains, regarding their strategic and tactical planning problems and 
decision-making processes. These topics are: i) product development and market launch, due to their 
fundamental role in product innovation and in the economic sustainability of pharmaceutical 
companies; ii) supply chain and logistics, which are typically global, with complex drug delivery 
systems that are difficult to manage; and iii) decision-making challenges, emerging from planning 
problems that have been addressed in this industry and how they have been handled. 
With this classification scheme, we attempt to capture the major problems, trends and challenges, in 
the strategic and tactical process planning optimization. 
2.2.1. Product development and market launch in the pharmaceutical 
industry 
In the innovative product sector of the pharmaceutical industry the product development phase is 
particularly challenging essentially due to the well-known high expenditures, low success rates, and 
long development cycles.  
Typically, a new product development (NPD) phase involves four main activities: discovery, pre-
clinical tests, clinical trials on humans, and approval and product launch (including pharmacovigilance 
after launch). The time laps between discovery and market launch can take an average of 15 years 
(Federsel (2009), Laínez et al. (2012)) with a total cost per approved new compound of $ 2,558 
million in 2013 dollars, as recently estimated by DiMasi et al. (2016) and indicating an increase from 
the authors previous estimates. Also, in the recent outlook report (Pharma, 2017) the total R&D 
spending is expected to reach US$181 billion in 2022, corresponding to a grow at a rate of 2.4% per 
year. The allocation of this investment cost in product development is outlined in Figure 2.4, with 
clinical trials alone representing almost 50% of the total investment (EFPIA, 2016). 
 
Figure 2.4 Allocation of R&D investment by main activity (EFPIA, 2016). 
In the discovery activities thousands of chemical compounds are tested until a promising new 
molecule (Active Pharmaceutical Ingredient – API) is found. The new API is then subjected to 
extensive tests (pre-clinical tests) conducted in animals to determine the toxicity and safety levels for 
human testing in the following clinical trials stage. Clinical trials are not only the most expensive 
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activity during product development (see Figure 2.4), but also the most time consuming, taking about 
5 to 6 years to complete all the three consecutive phases (I, II, and III) (Colvin & Maravelias, 2008). 
Each of these phases requires an increased amount of the new drug to perform the set of rigorous 
tests imposed by the regulatory agencies. In phase I, the new molecule is tested in humans for the 
first time, mainly for safety and dosage determination. In phase II, tests are performed on a medium 
scale for efficacy assessment, and finally, in phase III, tests are conducted on a large-scale to compare 
the performance of the new therapeutic compound with other existing treatments, and assess its 
long-term effects (Colvin & Maravelias (2008), Varma et al. (2008a), Levis & Papageorgiou (2004)). 
Only after successful completion of all the clinical trials phases a New Drug Application (NDA) is 
submitted for approval and market launch. According to DiMasi et al. (2016), the overall probability 
of a new drug that enters clinical trials to be approved was estimated to be 11.83% compared to 
21.50% estimated by the same authors in previous studies. Thus, not only the investment in R&D is 
increasing, but also the success rates in clinical development are decreasing (Bunnage, 2011; 
Pammolli et al., 2011b; Wang et al., 2015).  
Additionally, after a new drug is commercially launched, market success is not guaranteed. This may 
happen due to the lack of differentiation or perceived therapeutic value not only by the end-users, 
but particularly by the healthcare payers, who are more concerned with the cost/benefit impact of 
the new drug on their patient population, when compared to existing treatments.  
Simultaneously with the product development described above, many other activities related to the 
production process need also to be undertaken, since not only the product, but also the production 
process needs to be approved by the regulatory agencies. Furthermore, in order to assure availability 
of commercial scale production capacity as soon as the new drug is approved, the investment in new 
production facilities for the API production should be made around 5 years before market launch 
(Stonebraker, 2002; Hansen & Grunow, 2015a), and this is well before the completion of clinical trials 
and FDA approval is known. These decisions, although highly risky, are essential to prevent delays in 
the market launch, and consequent revenue losses resulted from the reduction of the patent effective 
life.    
Finally, after regulatory approval of both product and process, the new drug is launched under patent 
protection into the market, through a network of manufacturing and distribution agents embedded 
in a coordinated supply chain Figure 2.3. 
Overall, the product development process in the pharmaceutical industry is still highly inefficient, 
with very low levels of productivity, making it a fruitful area for improvement (Paul et al., 2010a; 
Pammolli et al., 2011b). The main challenges that pharmaceutical companies are facing today can be 
summarized in three major categories:  
1. minimize the development lead time (reduced time-to-market);  
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2. maximize the product pipeline value, by guaranteeing a good balance between the number 
of products in the pipeline and their technical quality (safety, efficacy, and market 
differentiation);  
3. minimize development costs. 
2.2.2. Pharmaceutical industry supply chain and logistics 
After the market launch, the process enters a growth phase in which companies try to capture and 
establish a market share as large as possible. As innovators, companies usually witness a sustainable 
growth in sales in a relatively easy way, while also trying to build customer confidence, until they 
reach the maturity phase (Figure 2.3).  
Although the maturity phase can provide the highest returns from the product, this phase is 
particularly challenging for the innovator manufacturers. As the drug patent life approaches the end, 
generic manufacturers become active in preparing their prompt entry immediately after the 
expiration date. Usually, the first generics enter the market with prices as low as 25% of the original 
brand. These prices continue to decline over time as new generics also enter the market, competing 
with each other solely by price (Petrova, 2014). This factor introduces new dynamics in the supply 
chains of both innovators and generic drugs manufacturers. While in the first case the original brand 
starts losing market share relatively fast without a significant decrease in price, in the second case 
the drug price drops considerably, but with an important growth in volume and market share. 
According to Petrova (2014), in the USA, approximately 74% of all new (brand) drug sales occurs in 
the exclusivity period after drug approval. In this way, companies should be able to ensure adequate 
production and capacity management, as well as effective supply distribution in order to be 
responsive and sustain the required service levels during this short time window.  
This is a challenging endeavour given that the pharmaceutical industry is inherently global, and 
consequently supply chains are usually large and complex, comprising a network of product (primary 
and secondary) manufacturers, packaging facilities, regional distribution centres (wholesalers), and 
final healthcare providers such as hospitals, pharmacies, etc. Due to globalization and Mergers and 
Acquisitions (M&A) strategies, all these agents (including the product manufacturers) can be in 
several different locations around the world, forcing companies to deal with different regional 
policies, cultures and taxes structures. Adding to this already complex network (raw material 
suppliers, contract manufacturers, and third-party logistics providers), a high level of coordination 
is required between all these agents, government bodies, and regulators. However, each of these 
agents tends to function independently, pursuing their own operational efficiencies and goals, often 
with some lack of transparency or visibility. This leads to disconnected systems, with the occurrence 
of disruptions and inefficiencies that propagate throughout the supply chain network (Privett & 
Gonsalvez, 2014; Srai et al., 2015b). 
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At the core of this disconnected system is the pharmaceutical drug manufacturing process, which 
typically occurs in two autonomous stages – the primary and the secondary production, adding 
additional complexity to the SC and significant operational inefficiencies.   
The primary production consists of the conversion of starting materials into Active Pharmaceutical 
Ingredients (API). This is performed through several chemical and separation processes that can 
involve long processing times (Sousa et al., 2011). Usually, the chemical-pharmaceutical plants 
process low production volumes with high product variability using the still predominant batch and 
multipurpose operating modes, in which different products are produced by sharing all the available 
resources (Floudas & Lin, 2004). In batch processes there is a well-defined start-up step, as well as 
the follow-up and final steps that are defined by product recipes (Kallrath, 2002). This allows a clear 
identification of the intermediaries and products being produced and ensures lot traceability, a 
critical aspect in the pharmaceutical industry. Thus, the batch operating mode can lead to higher 
flexibility and economical savings, due to the spread of capital across multiple products. However, 
the inherent gain in flexibility is achieved at the price of additional complexity of the production 
system. This complexity is translated into long changeovers and cleaning tasks required by the “stop-
and-start” steps and the regulatory requirements, to provide assurance that there is no possibility of 
cross contamination between API.  
Moreover, since high customer service level is a key focus of this industry, inventories tend to be high 
to guarantee an acceptable level of responsiveness. Therefore, batch plants for primary production 
can be the bottleneck of the entire supply chain, being characterized by some poor performance 
measures, such as (Shah, 2004; Laínez et al., 2012; Singh et al., 2016): (i) long production cycle-times; 
(ii) lack of responsiveness (inflexibility to sudden changes); (iii) many unproductive tasks 
(changeovers, Cleaning-in-Place (CIP) and Sterilization-in-Place (SIP)) – contributing to long setup 
times (in the order of weeks or higher) and also to an increase of energy and water utilization; (iv) 
high levels of inventory to compensate for slow responsiveness to market dynamics; (v) high levels 
of expired final product due to the excess of inventory; (vi) inefficient materials utilization mainly 
due to low production yields; and (vii) low equipment utilization.  
Despite the clear great opportunity for operational improvement and production optimization, only 
recently have industry practitioners and researchers started looking at these issues as critical factors 
impeding industry sustainability (Laínez et al. (2012), Moniz et al. (2015a)). Continuous 
manufacturing presents new opportunities in this regard as has already been demonstrated by its 
successful adoption in several manufacturing sectors such as food & beverage, oil & gas, 
petrochemicals and polymers (Bieringer et al., 2013; Harrington et al., 2014). In the pharmaceutical 
industry, however, despite the recent advances in continuous manufacturing capabilities and the 
increasing awareness of its advantages (Klutz et al., 2015; Rogers & Ierapetritou, 2015; Ierapetritou 
et al., 2016), as well as the encouragement by regulators such as FDA (Lee et al., 2015), the adoption 
has fallen far short of the desirable, and the traditional batch operating mode still prevails in the 
primary manufacturing stage.  
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On the other hand, secondary production is responsible to transform the API, produced in the primary 
stage, into a suitable form for commercialization. It usually involves further processing of the API and 
packaging into discrete final products, which are typically presented as solid dosage forms (such as 
tablets or capsules), semi-solid (such as ointments or gels) or liquid dosage forms (such as 
injectables) (Gad, 2008). Depending on the specific product characteristics or final dosage form, the 
(secondary) manufacturing process and its associated distribution network imply different costs and 
lead to several interesting challenges. These differences are mainly associated to the production of 
complex solid forms (such as bilayer tablets or extended release formulations) and sterile 
preparations (such as injectables), requiring more rigorous and expensive manufacturing processes. 
Moreover, biologics entail significant challenges associated to temperature sensitivity and control, 
requiring the need for complex and expensive cold chain distributions. 
Nevertheless, traditional solid dosage forms are still the most common, representing about 60% of 
all drug products (Wright, 2015; Ierapetritou et al., 2016), and comparatively less expensive 
formulations. The associated manufacturing processes are well established, making this stage more 
responsive and closer to local markets, usually operating on a “pull” basis in contrast with the 
traditional “push” operating mode that characterizes the primary production stage.  
Secondary production is both physically and organisationally separated from primary production 
and consists of several manufacturers geographically spread and responsible to satisfy local markets 
(Sousa et al., 2011). Moreover, the construction of additional capacity for secondary production may 
take only about 3 months, making capacity decisions much more informed and less risky when 
compared to primary production (Hansen & Grunow, 2015a).  
The finished drug products are then shipped to packaging facilities and from these to final consumers 
mainly through wholesalers that play a critical role in this industry. The current (batch operating 
mode) pharmaceutical supply chain is depicted in Figure 2.5.  
The pharmaceutical supply chain has been inefficient over the years and across its different levels. 
Companies have been slow to react to market changes, and scale-ups (or scale-downs) are difficult 
to perform, costly, and ineffective in absorbing the demand dynamic. Also, the functional “silos” 
(Garnier, 2008; Srai et al., 2015a) over the entire supply chain network hinder an end-to-end 
visibility leading to operational inefficiencies, and quality and safety concerns.  According to Privett 
& Gonsalvez (2014) the lack of coordination (together with fragmentation and a “silos” based system) 
is, for industry practitioners, at the top of the main supply chain issues, followed by the inventory 
management issue. 
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Figure 2.5 Current supply chain structure based on the traditional batch production mode. 
 
In order to provide a comprehensive characterization of the pharmaceutical industry supply chain 
and logistics, we first present a general view of the challenges and opportunities for improvement, 
along with a set of associated performance measures. From the analysed literature it seems there are 
two main levels of opportunities for improvement: the manufacturing level and the supply chain 
level.  
At the manufacturing level, the main challenges include the minimization of production lead times 
and costs, more effective capacity utilization, the improvement of resource and energy efficiency, the 
improvement of production yields, the reduction of inventory levels and waste production, and an 
enhanced production flexibility and agility.  
On the other hand, at the supply chain level, the most critical challenges include: the reduction of the 
supply chain complexity, the development of agile and more responsive supply chains, the 
minimization of production and distribution costs, the improvement of end-to-end visibility across 
the entire SC, fostering a seamless integration and coordination across the SC network, the inventory 
reduction in every node of the SC, and the integration of sustainability aspects. 
Considering the three main pharmaceutical functional groups, analysed above, all challenges 
identified are summarized in Table 2.1. 
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Table 2.1 Challenges/opportunities for improvement, and current performance measures 
Pharmaceutical 
function 
Challenges Acronym Performance measures 
R&D / Product 
Development 
minimize time-to-market TM  15 years1 
maximize the product pipeline value PPV 
- high phase III discontinuation 
- high commercial failures 
- drug beneﬁts are not deemed to 
outweigh risks 
minimize development costs DC > $2,5 million per approved drug2 
Manufacturing 
minimize production lead times LT 30 – 90 days3 
minimize production costs PC 27-30% of sales4 
improve quality levels (excessive 
rework and discarded product) 
Q 
costs of rejected batches and rework 
estimated on 25% of revenue5 
minimize inventory levels I 40-60 days6 
improve capacity utilization (OEE) CU OEE: 30%7 
improve resource and energy 
efficiency (improve production yields) 
RU/Y material efficiency: 1-10%8 
minimize waste production WP 
E-factor (API production):    from 25 to 
higher than 1009  
(kg waste/kg product) 
improve production flexibility and 
agility 
F low responsiveness 
Supply Chain 
 
 
minimize the supply chain complexity SCC 
large manufacturing footprint / complex 
supply network 
minimize SC/distribution costs DC 25% of pharma costs10 
development of agile and more 
responsive supply chains 
R 1000-8000 h11 
                                                                    
 
 
1 Development cycle time considered since discovery to market launch Federsel, H.-J. (2009). "Chemical process research 
and development in the 21st century: challenges, strategies, and solutions from a pharmaceutical industry perspective." Acc. 
Chem. Res 42(5): 671-680. 
2 DiMasi, J. A., H. G. Grabowski and R. W. Hansen (2016). "Innovation in the pharmaceutical industry: new estimates of R&D 
costs." Journal of health economics 47: 20-33. 
3 Singh, M. P. (2005). The pharmaceutical supply chain: A diagnosis of the state-of-the-art, Massachusetts Institute of 
Technology. 
4 Basu, P., G. Joglekar, S. Rai, P. Suresh and J. Vernon (2008). "Analysis of manufacturing costs in pharmaceutical companies." 
Journal of Pharmaceutical Innovation 3(1): 30-40. 
5 Harrington, T. S., L. Alinaghian and J. S. Srai (2014). Making the business case for continuous manufacturing in the 
Pharmaceutical Industry. Proceedings of the 25th Annual Production and Operations Management Society (POMS) 
Conference, Atlanta GA, May. 
6 Singh, M. P. (2005). The pharmaceutical supply chain: A diagnosis of the state-of-the-art, Massachusetts Institute of 
Technology. 
7 According to Vervaet, C. and J. P. Remon (2005). "Continuous granulation in the pharmaceutical industry." Chemical 
Engineering Science 60(14): 3949-3957. 30% is the typical value in pharmaceutical industry, reaching a value of 74% in 
good manufacturing processes, and 92% in ‘best-in-class’ pharmaceutical production lines. 
8 Material efficiency considered as the amount of product produced per unit amount of materials used Shah, N. (2004). 
"Pharmaceutical supply chains: key issues and strategies for optimisation." Computers & chemical engineering 28(6): 929-
941. 
9 According to Dunn, P. J., A. Wells and M. T. Williams (2010). Green chemistry in the pharmaceutical industry, John Wiley & 
Sons., the E factor (kg waste/kg product) for the pharmaceutical industry range from 25 to higher than 100, being 
organic solvents the major contributor for the waste generated.  
10 Thomas, E., K. George, E. Larsen, K. Shah and D. Ungerman (2013). Building New Strengths in the Healthcare Supply Chain. 
Pharmaceuticals and Medical Products Operations. Mckinsey&Company, Mckinsey&Company. 
11 Supply chain cycle time considered as the elapsed time between material entering as raw material and leaving as product 
according to Shah, N. (2004). "Pharmaceutical supply chains: key issues and strategies for optimisation." Computers & 
chemical engineering 28(6): 929-941.25 
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Pharmaceutical 
function 
Challenges Acronym Performance measures 
improve end-to-end visibility across 
the entire SC 
V independent silos of activities 
seamless integration and coordination 
across the SC network 
SI independent silos of activities 
minimize inventory levels in every 
node of the supply chain 
I 
4-24 weeks’ worth of finished good12 
70 weeks E2E inventory13 
integration of sustainability aspects 
across the entire SC. 
SSC 
mainly economically issues (profit 
maximization or cost minimization) 
2.2.3. Planning decision-making processes 
2.2.3.1. Reference frameworks 
The decision-making processes (regardless of the industrial sector) span across different levels and 
problems to solve. These processes are highly dependent on how the problems themselves are constructed 
and on the specificities of the decisions involved. Problem construction, in one hand, will largely depend 
on a clear definition of the object of study, including the scope and the system boundaries, and on its formal 
conceptualization. Decisions may be more or less strategic, depending mainly on the impact that they will 
have on the company, on the time span needed for their implementation, and on the level of investment 
required. In this context, the way in which the supply chain runs and the way in which the analyst/modeller 
understands it are two inseparable attributes in the decision-making process. In short, to support an efficient 
planning of the supply chain operations, having a full understanding of the decision-making process is key. 
Due to the complexity of supply chains, these decisions are usually grouped into different categories or 
taxonomies, embedded in matrices and frameworks that help researchers and practitioners to frame their 
decision problems. One of the widely accepted frameworks that have been developed is the well-known 
supply chain planning matrix proposed by Meyr et al. (2008) (see Figure 2.6(a)) that has been followed by 
researchers and practitioners to accommodate the majority of the decision problems arising in this context. 
This matrix summarizes three decision levels based on the length of the planning horizon, such as long-
term decisions, medium-term decisions, and short-term decisions. 
The long-term or strategic decisions encompass the design and structure of the supply chain, and 
typically involve large investments and long-term effects. The mid-term or tactical decisions are 
related to production planning with the main goal of meeting the targets established at the strategic 
level. The short-term or operational decisions specifically address individual activities/operations 
and their sequencing, in order to meet the production requirements defined at the tactical level. 
                                                                    
 
 
12 Ibid. 
13 Harrington, T. S., L. Alinaghian and J. S. Srai (2014). Making the business case for continuous manufacturing in the 
Pharmaceutical Industry. Proceedings of the 25th Annual Production and Operations Management Society (POMS) 
Conference, Atlanta GA, May. 
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Moreover, the hierarchical automation pyramid representation (ISA-S95 standard) is widely used as 
a reference to categorize the decisions involved in the supply chain management problems. 
 
(a) 
 
(b) 
Figure 2.6 (a) Supply chain planning framework (Meyr et al., 2008); and (b) Hierarchical automation pyramid 
(ISA-S95 standard) (Harjunkoski et al., 2014) 
 
In a way similar to the Meyr et al. (2008) matrix, decisions are grouped into three enterprise levels, 
namely: the business management (long-term decisions), the production management (mid-term 
decisions) and production process (short-term decisions), see Figure 2.6(b). This hierarchical 
vertical perspective is the most widely used to accommodate the decision problems arising in the 
process industry, and has been the basis for many other adapted versions that have  emerged over 
the years. Grossmann & Guillén-Gosálbez (2010) adapted this pyramid conceptualization to the 
hierarchical levels treated in PSE applications, considering single- and multi-site settings, and 
highlighted the role of an enterprise-wide optimization (EWO) perspective (Figure A.1 in Appendix 
A). Garcia & You (2015) presented a comprehensive overview of the main technical challenges and 
opportunities for supply chain design and optimization and presented a hierarchical pyramid similar 
to the previous authors (Grossmann & Guillén-Gosálbez, 2010) including at the top level the supply 
chain dimension (Figure A.2(a) in appendix A). The authors outline three major technical challenges 
in the supply chain design problem: multi-scale challenges, multi-objective and sustainability 
challenges, and multi-player challenges. However, these challenges are not explicitly reflected in the 
conceptualization depicted in Figure A.2(a). Moreover, Chu & You (2015) presented an interesting 
review of the progresses in integrated control and operations. The authors recognize the limitations 
of the ISA-S95 model (Figure 2.6 (b)) to characterize the decision levels, and categorized the current 
integrated methods based on modelling and optimization. In that sense, a more specific hierarchical 
structure was developed to accommodate the decision problems commonly investigated in 
integrated methods (Figure A.2(b) in Appendix A). Similarly to the model presented by Garcia & You 
(2015) at the top level, the authors included supply chain management. 
All these models are based on a vertical hierarchical structure to accommodate the different decision 
levels. However, these levels are too broad to capture and categorize the current mix of complex 
decision problems and their integration, that currently dominate the pharmaceutical industry. 
Additionally, these representations tend to put the research focus into single and isolated problems 
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of the hierarchical model, that are solved sequentially in order to reduce complexity (Chu & You, 
2015).  
However, these approaches tend to lead to sub-optimal solutions or even infeasibilities because the 
interactions among all decision levels are neglected. In this regard Heintz et al. (2014) developed a 
more complete and interesting framework dedicated to the sustainable chemical product design 
activity, in order to enable the collaborative work across the chemical enterprise stakeholders at the 
different decision levels (Figure A.3 in Appendix A). The framework displays the vertical alignment 
of decisions with the enterprise layers and the three pillars of sustainability. In the following year, 
Moniz et al. (2015a) identified the critical factors that drive the planning and scheduling functions in 
the pharmaceutical industry and presented a conceptual representation (the Delivery Trade-offs 
Matrix) to support the management of the trade-offs occurring from the drug development process 
to commercial production (Figure A.4 in Appendix A). 
A more recent perspective is presented by Harjunkoski (2017), assessing the impact of the recent 
"Internet of Things" developments on the traditional automation pyramid. According to 
(Harjunkoski, 2017) the different decision-levels will become more integrated and collaborative, 
blurring the traditional structural separation of the different hierarchical levels (Figure A.5 in 
Appendix A). 
It is clear that these decision-level frameworks and conceptualizations are evolving over the years in 
an attempt to match the real challenges of the process industry, while giving shape and structure to 
the individual problems and their interactions. The current complexity in the pharmaceutical 
context, however, is still far from being captured by these models, that are too broad and 
disconnected from the functional enterprise organization and supply chain operational structure. 
The evolution in the company’s organizational systems must be accompanied by the same level of 
development in the decision-making reference frameworks, and these should be able to efficiently 
accommodate the specificities of this sector. 
2.2.3.2. Decision-making in the pharmaceutical industry 
The The problems addressed in the pharmaceutical industry span across all decision-levels 
according to the more traditional vertical pyramid conceptualization described above, however with 
still very limited interaction between the levels and focusing on specific functional areas. In a recent 
work, Settanni et al. (2017) evaluate reconfiguration opportunities in pharmaceutical supply chains 
by critically mapping and categorizing the current pharmaceutical supply chain models. The authors 
acknowledge that the current definitions of the pharmaceutical supply chain are mainly based on a 
“product-centric perspective and linear sequence of stages across the manufacture and physical 
distribution of medicines”. In addition, the analysis of the several reviews specifically dedicated to the 
pharmaceutical industry (Shah, 2004; Verderame et al., 2010; Laínez et al., 2012; Narayana et al., 
2012; Narayana et al., 2014; Moniz et al., 2015c; Singh et al., 2016), reveals that research in this area 
has been covering several problems along the drug product life cycle (see Figure 2.3) without clearly 
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defining what has been, in fact, the main research focus of the academic community. A more 
comprehensive analysis of the literature is then required for a clear understanding of the planning 
problems structure in this sector.  
Figure 2.7 depicts the distribution of the main published works across the pharmaceutical product 
life cycle. It contains full research works selected from the Scopus database, specifically addressing 
strategic, tactical and operational decision-making problems in the pharmaceutical industry. In order 
to provide a systematic characterization, works from the different perspectives (process system 
engineering, operations research, and supply chain management communities) are included. This 
search was done in May 2018 employing the following Boolean combination of keywords: “planning” 
OR “scheduling” OR “decision-making” OR “supply chain”) AND pharma. The search was complemented 
by the analysis of several, selected review papers. A total of 113 papers were included in this analysis, 
after excluding duplicates, review papers, conference papers (some exceptions were admitted for 
works considered relevant for the analysis) and works exclusively related to management problems 
at the hospital/pharmacy level. The complete set of the selected publications is depicted in Table B.1 
of Appendix B.  
Analysing Figure 2.7 it is interesting to note that in the context of the pharmaceutical industry, the 
two extreme ends of the product life cycle have been the focus of the academic research, namely the 
R&D / New Product Development (NPD) phase, and the commercial production/distribution phase. 
Regarding the former, the most active sub-problems are the portfolio selection and scheduling of 
testing tasks, either individually or considered simultaneously. These problems have been mostly 
formulated as stochastic versions of the well-known Resource-Constrained Project Scheduling 
Problem (RCPSP), in which each product under development is considered a project with several 
tasks (product design and clinical trials) to be planned or scheduled. Recent works, however, include 
more sophisticated features such as task interdependency, outsourcing decisions, and risk 
management (Blau et al., 2004a; Colvin & Maravelias, 2011). Here, uncertainty has been modelled 
mainly by using stochastic programming, but other approaches can also be found, namely real option 
analysis (Rogers et al., 2002; Gupta & Maranas, 2004), robust optimization (Hassanzadeh et al., 
2014), dynamic programming (Choi et al., 2004), or the emerging area of simulation-optimization 
based approaches (Blau et al., 2000; Subramanian et al., 2000; Subramanian et al., 2001; 
Subramanian et al., 2003; Blau et al., 2004a). 
On the other hand, in Production/Distribution operations, the most addressed sub-problems are 
production planning and scheduling. In this case, the majority of the approaches employ MILP model 
formulations considering both, discrete- and continuous-time representations. The notably few 
works related to "global supply chain network design / capacity planning" are expected to consider 
the increasingly large-scale problems that typically arise from global pharmaceutical supply chains.  
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Figure 2.7 Main problems addressed in the literature. 
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Regarding uncertainty, a great discrepancy is observed between the NPD related work and the 
remaining studies (see Figure 2.7). This is mostly due to the high relevance of the technical 
uncertainty associated with the outcomes of the clinical trials during the development process. On 
the other hand, consideration of uncertainty in the commercial production/distribution level leads 
to greater complexity, particularly when dealing with multi-site, and/or multi-echelon settings. It is 
important to note that some major differences exist between innovators and generic manufacturers, 
regarding uncertainty. In the case of innovators, not only the obvious product development process 
is highly risky, but also the market in the commercial stage is highly uncertain. After product launch, 
the market needs first to grow, and then establish itself in a sustained way to face generic entrants in 
the near future. On the other hand, in the case of generic manufacturers, uncertainty plays a very 
different role in the sense that regulatory approval is much less risky and the market is already 
developed and well-established. 
Nevertheless, the majority of the works dealing with uncertainty are still related to the innovators 
supply chain problems (Figure 2.7), with just a few exceptions explicitly dealing with planning 
problems associated to generic manufacturers (Stefansson et al., 2006; Stefansson et al., 2009; Jia & 
Zhao, 2017). Despite the major differences between these two supply chains, selected works show 
that the uncertainty issues related to generic supply chains are still very poorly explored or not 
explicitly addressed. 
Concerning sustainability, from the total selected works there are only a few notable exceptions that 
explicitly integrate sustainability considerations into the developed framework, covering supply 
chains with reverse flows (Amaro & Barbosa-Póvoa, 2008; Amaro & Barbosa-Póvoa, 2009; Weraikat 
et al., 2016), efficient water and energy utilization (Halim & Srinivasan, 2011), waste management 
(Linninger et al., 2000; Linninger & Chakraborty, 2001), optimization of carbon emissions (Su et al., 
2017; Zahiri et al., 2017), and socially responsible supply chains (Nematollahi et al., 2017; 
Nematollahi et al., 2018). All of these works, however, are only focused on the 
Production/Distribution operations. In the NPD phase, only modest considerations can be found in 
the form of penalty costs associated to waste generation due to the limited product lifetime or to the 
unused final product at the end of each trial (Fleischhacker & Zhao, 2011; Chen et al., 2012a; Chen et 
al., 2012b; Marques et al., 2017b). 
Another interesting observation is that despite the increased interest in continuous manufacturing, 
very few works included in this analysis explicitly address planning problems in alternative 
technological settings or technology related decisions. Exceptions include the works of 
Sundaramoorthy et al. (2012) in which a capacity planning model for new product introductions is 
developed considering an integrated end-to-end continuous manufacturing scheme, Seifert et al. 
(2015) in which a real option framework for capacity expansion is developed and applied to the 
design of a continuous multiproduct plant, and Farid et al. (2005) in which a decision-support tool is 
developed for technology selection between a stainless steel pilot plant and disposable equipment 
for the production of clinical trial material.  
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This could be an indicator that research in continuous manufacturing is still very focused on “proof-
of-concept” analysis, rather than in real practical applications (see Schaber et al. (2011), Srai et al. 
(2015b), Ierapetritou et al. (2016)), and reflecting also some caution in addressing this matter, due 
to the uncertainty that still exists associated to the supply chain implications of going continuous.  
Additionally, this literature analysis also shows that the overall interest is mainly focused on 
efficiency improvement almost exclusively based on profit (NPV) maximization or cost minimization. 
Alternative performance metrics are seldom considered in the literature , as also noticed by 
Narayana et al. (2014). 
Regarding multi-level, and cross-functional integration, only limited attention has been given over 
the years to these aspects. Despite the huge potential for value creation, also noticed by Varma et al. 
(2007) the published literature on integration of decision-making across the different decision-levels 
and enterprise functions is still very scarce. 
The areas where decision-level integration is found are mainly in production planning and 
scheduling of the production/distribution functions (Berning et al., 2002; Stefansson et al., 2006; 
Amaro & Barbosa-Póvoa, 2008; Stefansson et al., 2009; Moniz et al., 2014a; Meiler et al., 2015; Vieira 
et al., 2016), and portfolio selection and scheduling of testing tasks/resource allocation in the product 
development functions (Blau et al., 2000; Subramanian et al., 2000; Blau et al., 2004a; Gupta & 
Maranas, 2004; George & Farid, 2008; Varma et al., 2008a; Perez-Escobedo et al., 2012; Zeng & 
Cremaschi, 2017).  
Concerning cross-functional integration, the works explicitly addressing planning problems 
considering an enterprise-wide perspective are scarce and limited in scope. Even so, some 
noteworthy studies include the work of Maravelias & Grossmann (2001) in which an integrated 
approach is presented for the simultaneous planning of new product development and batch 
manufacturing facilities. The proposed model not only addresses the portfolio selection, resource 
allocation for the testing tasks, and the associated sequencing of the tests, but also the investment in 
new plants or the expansion of the existing ones to accommodate the commercial distribution of the 
new products, and the production plans for both, the new and existing products. Susarla & Karimi 
(2012a) developed an MILP model for enterprise-wide planning, considering the seamless 
coordination of several functional areas, such as procurement, production, distribution, and financial 
considerations (tax regulations). Moreover, Sousa et al. (2011) developed a model that optimizes the 
global supply chain planning of a pharmaceutical company, considering the coordination of primary 
and secondary production, distribution, and tax rates. Due to the large scale of the problem two 
decomposition approaches were proposed by the authors. Nevertheless, despite the relevant 
contributions of these works, none of them fully covers the complete enterprise-wide perspective, 
and only the work of Maravelias & Grossmann (2001) explicitly accounts for uncertainty. 
Given this state of the literature, it is clear that many challenges still remain as open research 
opportunities needing to be addressed in this sector. In summary, these include: (i) greater attention 
 
2. Planning decision-making in the chemical-pharmaceutical industry 
33 
 
to integrated clinical trial supply chain operations management, and process development; (ii) 
improved approaches to assess and analyse the impacts of new product introductions in existing 
plants, covering global capacity and production planning decisions; (iii) development of effective 
approaches to tackle large-scale real industrial problems; (iv) development of systematic approaches 
for multi-level, multi-echelon, and cross-functional integration; (v) better exploitation and models of 
uncertainty in global supply chain operations; (vi) incorporation of sustainability issues such as 
environmental assessment and waste management, including over-supply related problems (such as 
the disposal of unused drugs and/or drugs past their expiry date), and social responsibility metrics 
across all functional areas and decision-levels; (vii) exploitation of different technological settings 
and incorporation of technological related decisions; (viii) introduction of alternative performance 
measures with relevance for the industry, including productivity, flexibility, and resiliency related 
metrics; (ix) development of powerful computational tools and solution methods to efficiently tackle 
all the above issues; and finally (x) the increasing availability of data with data acquisition and 
storage issues, and the development of new data-driven optimization approaches. 
Tackling these research gaps, however, is becoming increasingly challenging as complexity grows 
fast, and the current decision-making reference frameworks have clear limitations to provide a 
systematic characterization of new problem structures. 
2.3. Opportunities for change: driving forces and key enablers 
For decades the pharmaceutical industry has benefited from a straightforward business model based 
on the discovery and development of high successful drugs (blockbuster drugs) with high profit 
margins. A good portion of these profits was then reinvested in R&D for financing the discovery of 
new drugs. Competition was almost entirely based on product innovation and new product 
introductions. At that point, production costs were considered as a small enough part of the 
companies’ economic structure (compared for instance with the R&D costs), and operational or 
supply chain efficiency was not a priority for the decision-makers (Schaber et al., 2011; Berk et al., 
2013). Consequently, the supply operations have been unchanged for decades, making both, the R&D 
and the manufacturing system, inefficient and unimproved for many years. However, the market 
conditions for pharmaceutical companies have significantly changed  with the future trends 
suggesting fewer blockbusters, more specialty and personalized drug products, more stringent 
quality control, increased competition from generics, and more global and geographically dispersed 
markets (Srai et al., 2015a). The healthcare operating landscape is in clear transformation, and the 
new context has been shaped by many critical factors that were already pointed out by several 
authors (Shah, 2004; Laínez et al., 2012; Moniz et al., 2015c; Rogers & Ierapetritou, 2015; Srai et al., 
2015a; Settanni et al., 2017). Not only have market and political factors provided driving forces for 
change, but also scientific and technological breakthroughs have served as enablers, defining new 
paths for the pharmaceutical industry and challenging its traditional business model. In the next 
sections these main drivers and enablers will be identified and described in detail. 
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2.3.1. Driving forces 
Following the previous literature review, complemented by the analysis of several market reports 
(Berk et al., 2013; Jamie Cattell, 2013; Thomas et al., 2013; Alicke; et al., 2014;  Little, 2016; Deloitte, 
2016a; Deloitte, 2016b; EFPIA, 2017; Evaluate, 2017; Pharma, 2017; Deloitte, 2018; Dhankhar et al., 
2018; Marwaha et al., 2018), nine driving forces were identified to have a significant impact on 
pharmaceutical supply chain operations. These forces will be classified according to two broad 
categories: external drivers, i.e., those which cannot be controlled by companies; and internal drivers, 
those that may be influenced to a certain extent by companies. As external drivers, the following were 
considered: (i) increasingly regulatory burden; (ii) pricing (and cost) pressures; (iii) growing 
personalized medicines; (iv) growth of emerging markets; (v) sustainability concerns; and (vi) 
increased uncertainty and risk. On the other hand, the following internal drivers were considered: 
(vii) declining R&D productivity; (viii) decreasing of effective patent life; and (ix) growing supply 
chain complexity. These driving forces will be presented in detail in the following sections. 
2.3.1.1. External drivers 
(i) Increasingly regulatory burden 
The pharmaceutical industry is characterized by its robust and complex regulatory context, with 
patient safety as the central concern. Due to the potential of adverse effects on patient’s health, new 
drugs are subject to very stringent regulations and clinical requirements, for both product and 
process development. Regulators, such as FDA and EMA, are putting a greater focus on pre-approval 
safety and efficacy evaluations, imposing more demanding protocols and quality criteria before 
market approval. Moreover, due to the higher complexity of the target diseases and new molecular 
entities, some extended trials to prove efficacy and long-term safety are now required, as well as 
post-approval mechanisms to monitor safety parameters (Kaitin, 2010; Khanna, 2012). Concerns are 
also present in logistics, with stricter regulations for storage areas with temperature and relative 
humidity monitoring. In addition, regional markets also have their own compulsory regulations and 
protocols to enable local commercialization, thus adding more complexity and further constraints to 
these already difficult processes. 
Therefore, the entire regulatory framework has become very slow, expensive, and considered by the 
companies as one important factor for the lack of active innovation in the sector (Federsel, 2010).  
However, despite these stringent regulations, regulators such as FDA or EMA are strongly committed 
in creating favourable conditions for innovation in both clinical trials and manufacturing processes. 
According to Lee et al. (2015) the vision for FDA’s pharmaceutical quality for the 21st century is to 
promote a pharmaceutical sector with maximum efficiency, agility and flexibility, in producing high-
quality drugs without extensive regulatory oversight. In this regard, the efforts of regulators to 
streamline the approval process by expedited review programs, have resulted for instance in the 
record number of 59 approved new drugs in 2018 (PMC, 2018; Mullard, 2019). 
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Even so, the current regulatory context and the corresponding demanding quality requirements are 
forcing companies to adapt and develop strategies to effectively meet these requirements, while 
improving productivity and operational efficiency. 
(ii) Pricing (and resulting cost) pressures 
The pharmaceutical industry has been under great pressure to reduce medicine prices, not only by 
the typical competition between pharmaceutical brands, but especially due to generics competition, 
government pressures and public health policies. Generic competition has become increasingly 
stronger, stimulated in part by legislation issued in 1984 that provided a pathway for competition 
once drug patents expired. as well as due to the increasing pressures for price reduction from 
national governments. (Grabowski & Vernon, 2000). Under present conditions, soon as the patent 
protection for a drug that has achieved a large enough market expires, generic manufacturers seek 
to enter the market. Without the associated costs of drug development, the generic companies are 
able to launch into the market bioequivalent drugs, with a lower  price compared to the branded 
counterparts (Grabowski & Vernon, 2000). 
The price of medicines has a significant impact on each country’s economy. The high drug prices 
clearly increase the burden of government public expenditures in developed countries, and the 
affordability of medicines and its accessibility to the lower income populations play a critical role for 
the development of sustainable health care systems in emerging economies (Chen et al., 2018). 
Accordingly, governments and citizens are constantly pressing pharmaceutical companies for price 
reduction and developing strategies, such as price cap regulations and reference prices to control 
and limit the pharmaceuticals expenditure (Chen et al., 2018). Each country’s government defines 
and fixes the distribution margins at wholesalers, which can differ significantly from country to 
country depending on their domestic economy (EFPIA, 2017). 
In that sense, pharmaceutical companies need, more than ever, to demonstrate real “value-for-
money” through cost-effectiveness analysis when applying for market authorization in a specific 
country. The new drug must significantly improve current therapeutic practices or otherwise 
significantly reduce the therapeutic costs (Kaitin, 2010). In this way, many pricing strategies are 
already being “value-based” (or “outcome-based”) with the price of medicines being directly linked 
not only to their economic value, but also to their demonstrated therapeutic value (Hulshof, 2014). 
This is not without controversy, as shown with several recent cases where the price of a new and 
highly effective drug was set on the basis of the savings in the costs achieved by less effective 
conventional therapies. 
Especially in the case of generics, with much tighter profit margins, cost-effectiveness analysis is 
driving companies to develop strategies for cost reduction over the entire supply chain. Instead of 
the traditional product-centric perspective, companies are now starting to learn from other 
industrial sectors (both, in the chemical industrial sector and in other industries) that are highly 
focused on cost reduction and production efficiency.  
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In this regard the academic community and, in particular, the process systems engineering 
community has been playing a key role on the development of strategies and decision-making 
support tools focused on cost-reduction and overall operational efficiency. Works can be found 
specifically addressing a great variety of decision problems arising in the pharmaceutical industry, 
such as: (i) product portfolio and capacity management (Maravelias & Grossmann, 2001; 
Papageorgiou et al., 2001; Subramanian et al., 2001; Gatica et al., 2003b; Subramanian et al., 2003; 
Levis & Papageorgiou, 2004; Maravelias & Grossmann, 2004; Colvin & Maravelias, 2008; Colvin & 
Maravelias, 2009; Chen et al., 2012a; Perez-Escobedo et al., 2012); (ii) planning for new product 
introductions (Papageorgiou et al., 2001; Sundaramoorthy & Karimi, 2004; Hansen & Grunow, 
2015b); (iii) Planning and scheduling (Lakhdar et al., 2006; Stefansson et al., 2006; Kopanos et al., 
2010; Stefansson et al., 2011; Moniz et al., 2014a; Moniz et al., 2014c; Moniz et al., 2015c; Vieira et 
al., 2016); (iv) global supply chain network design and planning (Sousa et al., 2008; Sousa et al., 2011; 
Susarla & Karimi, 2012a); (v) supply chain with reverse flows (Amaro & Barbosa-Póvoa, 2008; 
Amaro & Barbosa-Póvoa, 2009); and (vi) incorporation of financial components in planning 
problems (Blau et al., 2004a; Guillén et al., 2006). Even though all the developments made so far, an 
effective modelling approaches to address real world large-scale problems still remain as an open 
challenge, together with cross-functional and decision-level integration (see section 2.2.3.2). 
(iii) Growing Personalized medicines 
Personalized medicine refers to medicines tailored to the genomic of each individual, contradicting 
the “one-size-fits-all” perspective and moving the traditional focus of reactive treatment of a disease 
to a proactive healthcare management concentrated on prevention and early treatment (Abrahams 
et al., 2005; Hamburg & Collins, 2010).  
This type of approach has been a major trend in recent years, with the number of personalized 
medicines increasing steadily since 2008 (PMC, 2017).  According to PMC (2018), the Personalized 
Medicine Coalition (PMC) classified 25 of the 59 new molecular entities approved by the FDA in 2018 
(Mullard, 2019), as personalized medicines. This value accounts for about 42% of all new approvals 
in 2018, representing an increase from the 34% registered in 2017. 
These trends are mainly due to the several benefits arising not only for patients with improved 
therapies, reduction of adverse reactions, and increased patient adherence to treatments, but also 
for the overall health care system with the potential overall cost reduction. 
This paradigm change will obviously have a substantial impact on the current business model of 
innovators and on how the associated supply chains are designed and operated. Beyond the scientific 
and technological challenges, determining how to effectively and efficiently deliver this highly 
innovative medicines to patients in a large-scale perspective, i.e. how to move from mass production 
to mass customization, will be crucial to dictate which companies will succeed or fail in the future. 
Moreover, the traditional distribution network, with the wholesalers playing a central role, will 
inevitably suffer a shift to more direct distribution models (beginning and ending with the patient) 
as personalization increases.  
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At the quality level, an increase of quality data is expected, demanding for the development of better 
“track-and-trace” and on-line monitoring capabilities. 
Despite the great challenges ahead, the benefits are very promising, particularly for the R&D and 
product development activities, in which a game-changing is expected to occur. Personalization will 
lower the risk and costs during clinical trials research, by steering research in the right direction with 
the selection of patients based on genetic characteristics instead of on the traditional "random" 
process (Abrahams et al., 2005; Davis et al., 2009). This can reduce the clinical trials size and 
complexity with a direct impact on the development costs and time-to-market, and at the same time, 
it can improve the probability of technical success and regulatory approval by avoiding patients 
susceptible to adverse reactions. 
Nevertheless, despite the significant advancements in the development of personalized medicines 
and companion diagnostics, according to IQVIA (2019) the routine personalized treatment will not 
be expected within the next ten years. In fact, there are still some major challenges in terms of 
scientific and technological developments, regulatory policies, investment incentives, and 
reimbursement strategies.    
(iv) Growth of emerging markets   
The rapid economic growth of developing countries is also gradually improving their health care 
systems and shifting the growth opportunities for the medical drug market. In this environment, 
pharmaceutical companies are forced to rethink their manufacturing strategies and business models 
as their supply chains become even more global (Garnier, 2008; Ierapetritou et al., 2016). This 
expected increase on product demand will contribute to the retrofit of existing plants and optimized 
production processes, with increased process yields and assets utilization. 
Emerging markets will also demand for new strategies to achieve affordable drug prices for the less-
advantaged population, and to understand the specific needs of those patients, forcing companies to 
re-examine their supply models and distribution networks (Chen et al., 2018). This market expansion 
will also contribute to increase the risk of counterfeit drugs  (Alicke; et al., 2014), demanding for 
greater transparency with an “end-to-end” supply chain monitoring and control.  
In addition to these changes, academia will also need to adapt and shift from a research highly 
focused on operational efficiency improvement in developed economies, to embrace these new 
challenges imposed by the emerging markets.   
(v) Sustainability concerns 
Companies in all industrial sectors are increasingly aware of their economic, environmental and 
social responsibility, and their importance in achieving increased value and global success, far 
beyond the traditional financial dimension.  
The process industry, and the pharmaceutical industry in particular, plays a significant role regarding 
sustainability issues, since it relies mainly on resource-intensive operations, typically with large 
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amounts of water, solvents and energy consumption. According to the 2030 agenda for sustainable 
development (UN, 2015), a substantial increase in resource-utilization efficiency should be achieved 
by 2030, as well as the implementation of actions to combat climate changes and their impacts. In 
that sense, companies are currently still facing great pressures to reduce their environmental impact, 
particularly regarding resources utilization and waste generation. 
According to (Ott et al., 2014; Chaturvedi et al., 2017), the environmental impacts of the 
pharmaceutical industry are significant, with an E factor many times higher than that for oil refining 
and for bulk chemical industries. Furthermore, within pharmaceuticals also significant differences 
exist. Typically, biologics present E factors significantly higher than small molecule-based products, 
making the former environmentally more critical and, therefore, a priority from a sustainability 
perspective (Ramasamy et al., 2015; Budzinski et al., 2019). 
The role of the Process System Engineering community has been crucial in this regard, by developing 
efficient decision-making tools and strategies covering different sustainability aspects and supply 
chain configurations (Bakshi & Fiksel, 2003). Its importance can be stressed by the amount of 
research work published over the years, and highlighted in several important reviews (Srivastava, 
2007; Barbosa-Póvoa, 2009; Grossmann & Guillén-Gosálbez, 2010; Nikolopoulou & Ierapetritou, 
2012b; Eskandarpour et al., 2015; Garcia & You, 2015; Barbosa-Póvoa et al., 2018). 
Moreover, the increase of unused and expired drug products is pressing the pharmaceutical 
manufacturers to redesign their supply chains in order to adopt new eco-friendly technologies and 
to accommodate new activities, such as the collection, reintegration, and disposal of these products. 
Concepts such as “life cycle assessment” (Wernet et al., 2010; Ott et al., 2014), “reverse logistics” and 
“closed loop supply chains” (Amaro & Barbosa-Póvoa, 2008; Amaro & Barbosa-Póvoa, 2009; Kumar 
et al., 2009; Weraikat et al., 2016), particularly for the management of the growing problem of unused 
and/or expired drugs, are deserving a growing attention among the pharmaceutical community. 
The rise of emerging economies will also generate new, important socio-economic challenges (Mani 
et al., 2018), putting the pharmaceutical industry in a privileged position to foster the adoption of 
business strategies that enable an efficient interaction between industry, society and ecosystems, 
leading to an end-to-end supply chain redesign. 
(vi) Increased uncertainty and risk 
Today’s highly dynamic business context, with rapid political and socio-economic fast-changes, is 
raising uncertainty (or its perception) about the future among practitioners of all industrial sectors. 
Standing as an important concern for decision-makers, uncertainty is present in almost every 
practical problem across all decision-levels.  
Particularly for the pharmaceutical industry, uncertainty is being increased by some break-out 
events with direct impact on the business context. The second patent cliff era between 2017 and 
2022 as predicted in Pharma (2017), the rise of emerging markets, and the new digital based 
technologies are transforming this industry. Additionally, the prevalence of more complex molecular 
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entities and increased complexity of clinical trials, together with the rise of personalized therapies 
will contribute to increased uncertainty regarding the product portfolios of the future, and how the 
regulatory landscape will evolve to cope with product innovation. Moreover, not only the uncertainty 
associated with product development and the clinical trials outcomes, but also the uncertainty of 
market success after launch are factors making business decisions very challenging. 
Several sources of uncertainty are arising, and a full understanding of these sources will be critical 
for effectively integrating uncertainty in decision-making processes. According to Garcia & You 
(2015), uncertainties can be viewed as strategic (associated to changes in the socio-political context, 
unpredictable events, climate effects, etc)  and as operational (associated to changes in supply chain 
operations or execution strategies). In a similar way, Laínez et al. (2012) classifies uncertainties as 
external or internal. A different classification is presented by Jonsbråten (1998), based on the way 
uncertainty is resolved: exogenous uncertainty, in which realizations occur independently of process 
decisions; and endogenous uncertainty, in which realizations are dependent on process decisions. 
Regardless of the classification used, efficient identification and management of all relevant sources 
of uncertainty is still a great challenge for practitioners and researchers. In particular, researchers 
have devoted increased attention to this issue over the years, with notable developments across the 
different decision-levels. Comprehensive reviews specifically devoted to optimization under 
uncertainty can be found in Powell (2018), Grossmann (2012), Grossmann et al. (2016b), Verderame 
et al. (2010), Li & Ierapetritou (2008) and Sahinidis (2004).  
In a “big data” world, the ability to collect and access data efficiently will contribute to a better 
modeling of uncertainty, leveraging the development of new stochastic programming approaches. 
However, dealing with uncertainty is still an open research challenge, particularly in the context of 
real-world large-scale problems, clearly demanding for innovative approaches (Grossmann et al., 
2016b; Powell, 2018).  
2.3.1.2. Internal drivers 
(vii) Declining of R&D productivity 
In order to stay competitive and maintain revenue in stable levels, R&D should guarantee a 
continuous flow of new drugs to replace older drugs whose  patents are expiring (Garnier, 2008; Paul 
et al., 2010a). According to Garnier (2008), the decline in R&D productivity is the central issue 
regarding pharmaceutical sustainability and competitiveness.  
After a sharp decrease of 50% in drug approvals in the US in 2016 (from 56 in 2015 to 27 in 2016) 
(Pharma, 2017), a recover was observed in 2017, with 46 approved new drugs (Mullard, 2018) and 
a record number of 59 in 2018 (Mullard, 2019). However, according to (Mullard, 2019) the 
commercial potential of the 2018 approvals falls short of expectations, with the combined projected 
peak sales of the newly approved drugs being in decline. 
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The high investments in R&D, combined with the decrease in success rates during clinical 
development and the downfall in the recovery of investments, contribute to the low levels of 
productivity that have been experienced by the industry.  
Together, the longer clinical trials, due to their increasingly complexity and dimension, the stringent 
regulatory requirements, the difficulty in addressing ever more challenging diseases, and the poor 
focus on target selection by the industry, have dramatically  lowered the number of approved new 
drugs in recent years, standing at the basis of this productivity crisis  (Garnier, 2008; Paul et al., 
2010a; Bunnage, 2011; Pammolli et al., 2011b; DiMasi et al., 2016). Although scientific breakthroughs 
have raised the level of understanding of disease’s mechanisms and improved the current analytical 
techniques, the significant variability across individuals and their behaviour towards diseases are 
still unsolved challenges that contribute to the persistent complexity of the drug innovation process 
(Gittelman, 2016). 
The decline in R&D productivity has major consequences not only regarding the revenue and profit 
potential that is obviously compromised, but also regarding capacity management issues. 
Considering that the current installed infrastructure is sized for blockbuster volumes, the difference 
between new drug introductions and off patent drugs will result in an excess of production capacity 
of innovators. In that sense, efficient decision-making regarding the portfolio investment strategy is 
critical and should include market opportunity analysis, and regulatory and development aspects 
(Kaitin & DiMasi, 2011).  
Companies should also become more focused, putting more effort towards larger unmet needs and 
smaller patients’ populations, as it is the case of rare diseases. Recent estimates suggest that the 
orphan drug market (medicines aimed to target rare diseases) is expected to almost double during 
the 2016/2022 period (Evaluate, 2017). In addition, strategies such as the use of Contract 
Manufacturer Organizations (CMO) are raising among innovators, as they allow the introduction of 
new capacity as needed. In this way, the capacity management is shifted to the CMO, that is able to 
better balance capacity utilization by making products for multiple innovators.  However, despite the 
importance of this issue for the pharmaceutical community, little attention has been given by 
researchers to the development of efficient decision-making tools for addressing product 
development and portfolio management, considering productivity as a central performance measure.  
Some relevant works, can be found in the literature addressing different problems regarding new 
product development and pipeline management (Maravelias & Grossmann, 2001; Papageorgiou et 
al., 2001; Gatica et al., 2003b; Subramanian et al., 2003; Levis & Papageorgiou, 2004; Colvin & 
Maravelias, 2008; Chen et al., 2012a; Chen et al., 2012b), however, essentially focusing on total cost 
minimization or profit maximization. 
(viii) Decreasing of effective patent life 
Effective patent life can be measured as the time between regulatory approval and patent expiration 
(Grabowski & Vernon, 2000), and it represents the period of commercialization under patent 
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protection. The pharmaceutical industry is one of the most dependent on patent effective life, since 
it is during this period that the majority of the companies recover their investments. However, the 
long development cycles and the increasingly regulatory burden are delaying the time-to-market of 
new drugs, thus reducing the opportunity for companies to recover their investments under market 
exclusivity. 
Time-to-market has been acknowledged by several authors (Shah, 2004; Moniz et al., 2015a) as the 
most critical issue in the pharmaceutical industry. Therefore, the current NPD model strictly focused 
on product innovation should also incorporate strategies to improve operational efficiency (such as 
the adoption of continuous manufacturing) in order to reduce not only the costs, but also the 
development cycle times. Currently, research addressing the product development process is mainly 
focused on cost reduction and portfolio management, with little attention being given to the 
reduction of the development cycle time. 
(ix) Growing in SC complexity 
The advent of globalization, the growth of emerging economies, and the increasing adoption of 
strategies such as mergers and acquisitions, outsourcing and licencing, have paved the way to larger, 
costly, and more complex global supply chains. It is common for big pharmaceuticals to have APIs 
being produced in several different countries that need to be transported to other facilities to 
formulate the final product, from there to packaging organizations, and finally to regional 
distribution centres and final customers. 
The number of mergers and acquisitions (M&A) has increased substantially since the beginning of 
the twenty-first century and has been still rising in recent years (Blass, 2015; Wang et al., 2015). This 
strategy has been widely implemented by large pharmaceutical companies to face crises in R&D 
productivity. Particularly when approaching patent expirations of a major product, mergers become 
attractive in the sense that they can boost product portfolios, achieving capacity consolidation and 
exploiting economies of scale (Kaitin, 2010; Wang et al., 2015). Moreover, mergers and strategic 
alliances also contribute to develop new core competences, to expand the company’s presence in 
emerging markets, as well as to gain market share in other sectors, such as generics and others (Tso 
& Jacob, 2012). 
However, despite these potential benefits, M&A also contribute to a significant, uncontrolled increase 
in the organization’s network, originating larger and more complex supply and distribution chains. 
This type of consolidation tends to result in redundant manufacturing facilities and capabilities, with 
lack of integration and a consolidate management (Tso & Jacob, 2012). Some studies suggest (Danzon 
et al., 2007; LaMattina, 2011; Sousa et al., 2011), that in the long-term mergers are unsuccessful in 
creating a positive pipeline value and in improving R&D productivity. Moreover, Sousa et al. (2011) 
advocates that the only way to improve profit margins, is by changing the relationship between 
volume and costs through productivity gains in the supply chain. 
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Other related strategies, such as outsourcing and alliances, as opposed to a fully integrated 
pharmaceutical company model, have been defended by some authors (Kaitin, 2010). According to 
Kaitin (2010), despite the increased complexity in supply chain management and coordination, these 
strategies can lead to a significant enhancement of production efficiency and speed to market. 
In addition, more diverse markets, possibly resulting from the economic growth of emerging 
economies, will also increase complexity, leading to the emergence of new business models and 
strategies. 
Due to this increasing complexity, not only the companies are struggling to efficiently manage all SC 
operations, but also researchers are being challenged to develop efficient decision-making tools 
covering the global SC management problems. In fact, the inherent large-scale of real problems tends 
to limit the number of published works addressing the entire pharmaceutical SC. Nevertheless, some 
interesting examples of these works can be found in (Timpe & Kallrath, 2000; Sundaramoorthy et al., 
2006; Sousa et al., 2008; Sousa et al., 2011; Susarla & Karimi, 2012b). 
2.3.2. Industry key enablers 
Together with the above driving forces, technology breakthroughs are critical as key enablers of the 
inevitable changes towards a new paradigm. 
If, on the one hand, these driving forces are pressing the industry to make a turnaround to stay 
competitive in the business environment in which it operates, on the other hand, technological 
developments are providing the necessary means to foster this change. Technology developments 
with direct impact on the pharmaceutical supply chain operations can be divided in three key areas: 
product, process, and decision-making.  
The technology associated to the product is mainly related to the enhancement of new cell and 
genetic therapies that are enabling the personalization of medicines in an effort to match treatments 
to individual patients or small population niches with specific genome characteristics. Scientists are 
putting great focus on diagnostic tests based on genetics, to better predict patients’ responses to 
target therapies (Hamburg & Collins, 2010). In this way, they are leveraging the medicines 
therapeutic value, as well as engaging more strategically with customers and fostering a patient-
centric perspective. Personalized medicine is a current major trend and a rising market that will have 
also a significant impact at the supply operational level (see the “driving forces”, section 2.3.1). 
Nevertheless, some challenges still need to be addressed at a scientific level, with greater 
understanding of the relation between genetic markers and clinical significance, and at an 
economical and operational level, as there is a poor alignment between the different stakeholders 
and the evidence of economic value (Davis et al., 2009). Moreover, at a regulatory level, there are 
interesting open issues on the definition and establishment of regulations and protocols capable of 
guaranteeing quality and patients safety, without compromising the necessary innovation character 
(Hamburg & Collins, 2010). Regulators such as FDA and EMA are strongly encouraging the 
development of personalized therapies, and they are truly engaged in creating the conditions and the 
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necessary regulatory landscape to help companies approach small niche therapeutic markets. For 
instance, the European agency EMA, through the program PRIME (PRIority MEdicines) launched in 
March 2016, aims at optimizing the development process and accelerate the market launch of 
innovative medicines that address unmet needs for very specific groups of patients, as it is the case 
of rare diseases (EMA, 2016).  
At the process-related technologies, the most significant developments are in continuous 
manufacturing, and in the rising of digitalization with the Industry 4.0 revolution (including IoT, big 
data analytics, AI, cloud computing, and other related technologies).  
The current state-of-the-art manufacturing technology for primary production in the 
pharmaceutical/biopharmaceutical industry is based on large scale batch stainless steel equipment. 
However, due to the already described low performance operational indicators, such as lack of agility, 
long lead times or high operational costs, together with the current market trends (see the “driving 
forces”, section 2.3.1), the interest in implementing continuous manufacturing technologies has 
significantly raised in recent years. 
Continuous manufacturing relies on the seamless flow of material between unit operations, 
undergoing different chemical/biological or physical processes, forming the final product in a 
continuous way. Thus, manufacturing is controlled by its production rate instead of its production 
volume (Nepveux et al., 2015). The most obvious effect is the elimination of the holding times 
between the “stop-and-start” steps involved in the batch production mode, with benefits not only on 
the production lead time and costs, but also on quality and safety aspects. A higher level of 
automation decreases the risk of human errors and enhances the quality and process control, with 
real-time monitoring of process parameters, and reduced variability between batches. Since, in this 
case, production does not depend on discrete sizes of processing units, higher flexibility is achieved 
for both, product and volume mix. This is particularly interesting to rapidly accommodate not only 
demand changes, but also innovative products such as personalized medicines or orphan drugs that 
will inevitably lead to high product variability, with very low volumes (niche markets).  
Moreover, the intermediary stocks needed between each individual operation are eliminated in this 
case, thus reducing significantly the inventory level across the entire manufacturing process. The 
continuous flow of materials also enables higher throughputs, improved yields and purity, resulting 
in better resource and energy utilization. At the R&D level, continuous manufacturing will have a very 
significant impact by avoiding the need for complex, time consuming and costly scale-ups across the 
development cycle, as well as the ramp-up for commercialization. On the other hand, the 
manufacturing footprint is reduced, thus contributing to smaller and simpler supply chains.  
These benefits have been widely recognized not only by the scientific community in some interesting 
recent works (Schaber et al., 2011; Klutz et al., 2015; Rogers & Ierapetritou, 2015; Adamo et al., 2016; 
Ierapetritou et al., 2016), but also by the regulatory entities that are strongly encouraging the 
adoption of continuous manufacturing, advocating for instance that it is strongly aligned with the 
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current Quality by Design (QbD) paradigm (Food & Administration, 2004; Lee et al., 2015) and that 
it can dramatically shorten the scale up time of newly approved drugs (National Academies of 
Sciences, 2019). 
Together with continuous manufacturing technologies, single-use equipment has also attracted some 
attention by the scientific community, both separately or integrated with continuous manufacturing 
(Novais et al., 2001; Farid et al., 2005; Shukla & Gottschalk, 2013; Klutz et al., 2015).  
Nevertheless, the lack of initiative by companies in adopting these technologies is well known, with 
adoption rates around 5%, basically related to pilot scale operations (Harrington et al., 2017). This 
low value has been mainly attributed to the regulatory burden, quality concerns, and to some major 
challenges, such as  (Poechlauer et al., 2012; Lee et al., 2015; Nepveux et al., 2015): the higher level 
of process design (including on-line measurement systems) and process knowledge (including 
material characteristics, and knowledge of kinetic information regarding the unit operations) to 
guarantee the required product quality; the high initial investment needed; and the current available 
inventory of batch facilities that, according  to Srai et al. (2015a) are currently sized for blockbuster 
supply in most of the big pharma companies.  
Moreover, according to (National Academies of Sciences, 2019), the continuous manufacturing 
technology is gradually entering in the small molecule space, but still very far behind regarding 
biologics. The main reasons stand on the fact that, in the first case, the chemical reactions are well-
defined and the critical quality attributes well-characterized. On the other hand, regarding biologics 
the biochemical processes involved are not so well-understood and the production processes are 
difficult to control.  
Overall, continuous technologies for the secondary production have been much well accepted and 
developed, with significant progresses on the solid oral dosage forms of small molecules 
(Ierapetritou et al., 2016; Burcham et al., 2018; National Academies of Sciences, 2019). The few FDA 
approvals regarding continuous manufactured drugs are related to the secondary production of this 
type of products (Burcham et al., 2018). 
In what concerns generic manufacturers, it is interesting to note that little attention has been given 
so far to the development of continuous manufacturing, even if its importance in delivering accessible 
drugs world-wide may be considered critical. The main features of this technology are summarized 
in Table C.1 - Appendix C. 
Along with the industry trend of moving from batch operations to continuous operations, the industry 
4.0 revolution is also starting to emerge in the process industry. Industry 4.0 envisions a 
decentralized self-organising and reconfigurable factory in which goods and machines are connected 
to each other in cyber-physical systems (CPS), communicating, exchanging data, triggering actions, 
and ultimately coordinating all manufacturing and supply chain operations by making decisions 
autonomously and intelligently (Kagermann et al., 2013). The benefits are huge and with great 
potential to help companies to cope with their current biggest challenges regarding operational 
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efficiency in an era of personalization and increased value. A comprehensive overview of the main 
benefits and challenges of this trend in the biopharmaceutical supply chains is made by Branke et al. 
(2016). Some of the main benefits include (see Table C.1 – Appendix C): real-time monitoring, 
enabling a better process control and adaptability to sources of variability; enhanced process safety 
and predictive maintenance, with self-aware production lines constantly monitoring themselves and 
reporting on their own condition; democratization of information and real-time flow of data (patient 
data, product data, process data, and supply chain operations data), a critical factor for the 
development of personalized therapies;  enhanced track-and-trace capabilities; end-to-end supply 
chain visibility; and seamless coordination across all functional groups. All these benefits will 
contribute to a more flexible and responsive SC with greater operational efficiency, decentralized 
decision-making processes, new patient-oriented product-service solutions (linking diagnostics, 
devices, and drugs), and improved security and anti-counterfeiting systems (e.g. by the development 
of “smart” packaging).  
According to some recent market studies (PwC, 2016; Deloitte, 2018; Marwaha et al., 2018) 
digitalization in the chemical and pharma industry is inevitable, and this will have an important role 
in the transition towards increased industrialisation (Branke et al., 2016).  
However, the adoption of industry 4.0 capabilities in process industries is not as straightforward as 
it is for instance in discrete industries (such as the automotive), and there is still a long way to go for 
the chemical and pharmaceutical sector. In order to fully embrace these new competencies and be 
part of the industry 4.0 revolution, pharma companies need to undertake a complete change in their 
operating model and old manufacturing practices (such as batch processes) with an end-to-end 
redesign (Marwaha et al., 2018). Moreover, the lack of automation and virtual manufacturing 
technologies in this industry stand out as some of the most important adoption barriers (Marwaha 
et al., 2018). Thus, very few research projects have been published in the area so far, with the most 
relevant works starting to emerge in the chemical and petrochemical industry, particularly for fault 
detection/diagnosis applications (Li, 2016; Shu et al., 2016; Onel et al., 2018). Even so, some 
companies are already developing promising projects in this area. This is the case of BASF which, 
according to Deloitte (2016a), is already implementing these capabilities in a smart pilot plant in 
Kaiserslautern, through the mass customization of liquid soaps production without human 
involvement. 
Finally, decision-making capabilities will form the link between all the above technologies in which 
modelling, optimization, and simulation together, with high performance computing, will stand as 
the basis for the decision-making processes. Even though IT tools, such as Enterprise Resource 
Planning (ERP) software, stand as paramount regarding an effective integration of information, they 
do not provide optimization capabilities for an effective decision-making (Grossmann, 2014; Moniz 
et al., 2014c). 
Optimization based approaches in process system engineering rely largely on deterministic or 
stochastic Mixed Integer Linear and Non-linear Programming (MILP and MINLP) formulations and 
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decomposition techniques, such as Lagrangean or Benders decomposition, bi-level decomposition, 
and rolling horizon techniques (Grossmann, 2012). Several reviews on the developments in 
optimization models in the process industry have been published over the years. considering 
different modeling settings (Sahinidis, 2004; Méndez et al., 2006; Li & Ierapetritou, 2008; Verderame 
et al., 2010; Grossmann, 2012; Maravelias, 2012; Grossmann, 2014; Grossmann et al., 2016b).  
Nevertheless, further improvements regarding optimization and mathematical programming 
applications still need to be made, in order to develop comprehensive decision-making support tools 
with real relevance for practitioners. Some current major challenges include (Grossmann, 2014; 
Garcia & You, 2015): (i) the effective integration and coordination across the company functional 
activities, and across several spatial (physical network of organizations) and temporal (SC decision-
making levels) scales; (ii) appropriate modelling and integration of uncertainty; (iii) effective 
incorporation of sustainability and novel multi-objective approaches; (iv) new solution methods to 
solve large-scale complex problems; and finally (v) more powerful computational tools and 
decomposition techniques. With the increasing availability of data (big data), novel modelling 
frameworks, computational algorithms, and data-driven optimization approaches are also emerging. 
Machine learning is one of the most growing technics, lying at the core of artificial intelligence and 
data science (Jordan & Mitchell, 2015), and has been also a major trend in process systems 
engineering (Lee et al., 2017). As a consequence, recent works have been published proposing 
decision-making frameworks that integrate machine learning and data science methods with 
optimization approaches, particularly to address uncertainty (Jiang & Guan, 2016; Ning & You, 2017; 
Ning & You, 2018). 
Moreover, the virtualization of plants, supported by simulation, will play an important role not only 
to improve the overall SC operational performance, but also for training purposes, including the 
simulation of scale-up processes before their implementation, the exploitation of alternative reaction 
routes or operational processes, or even to assess process safety opportunities. Thus, on-line 
optimization and simulation-optimization models will be vital for the digitalization process. Many 
hybrid simulation-optimization approaches have been proposed in recent years, and several 
combinations between these two techniques are possible today as recently acknowledged by 
Figueira & Almada-Lobo (2014). Simulation-optimization based models in the chemical-
pharmaceutical have been used to address different supply chain management problems  (Jung et al., 
2004; Nikolopoulou & Ierapetritou, 2012a; Chu et al., 2015b), clinical trials supply chain and capacity 
management (Chen et al., 2012a; Marques et al., 2017b; Marques et al., 2017a) or R&D pipeline 
management (Blau et al., 2000; Subramanian et al., 2001; Subramanian et al., 2003; Blau et al., 
2004a).  
To summarize, we may say that, as new paradigms emerge in the pharmaceutical business model and 
supply chain, new and more sophisticated modelling and optimization approaches are being 
developed to accurately capture all the materials and information flows across different time and 
geographical scales.  
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These three technological domains (product, process and decision-making) are evolving 
independently from each other, and may be considered, in some cases, as disruptive innovations. 
However, they need to be integrated in a fully collaborative way, in order to create real value in the 
pharmaceutical supply chain. Still, the development and application of innovative planning and 
scheduling tools to the current batch operations may introduce significant gains and achieve part of 
the benefits offered by continuous manufacturing.  
2.3.3. Challenges, drivers and enablers impact Matrix 
In order to systematize the great variety of issues to address, an impact matrix has been designed. In 
this matrix, both, drivers and enablers, are correlated with the industry challenges (Figure 2.8). The 
correlation is constructed considering 3 levels of impact on the industry challenges, namely positive, 
negative, and not relevant. The positive impact is considered when the driver/enabler has a positive effect 
towards the improvement of the challenge, and the negative impact is applied when it leads to a worse 
performance of the challenge. 
An immediate observation is that the impacts of the uncertainty, and the price/cost pressures drivers 
are common to all functional areas, with the former contributing to a poor performance of the 
challenges, and the later with a generalized positive impact. 
The uncertainty drivers may be viewed as disturbances to the system that cannot be controlled by 
the industry, but that must be anticipated and carefully managed. The current high level of 
uncertainty is a strong driver for a paradigm shift in the pharmaceutical industry, which has been 
poorly prepared to deal with risk (Dhankhar et al., 2018). In this way companies and researchers 
should invest in robust risk analysis and advanced risk management approaches to cope with the 
current uncertain environment. Regarding the price/cost pressures, these are market context drivers 
that are forcing companies to focus on efficiency across all functional areas. 
From Figure 2.8 we can deduce that, for the R&D / Product Development functional group, the drivers 
price/cost pressures, growing personalized medicines, declining R&D productivity, and decreasing of 
effective patent life, put a mainly positive pressure in all the three challenge goals, while the drivers 
increasing regulatory burden, and uncertainty contribute to a poor performance of these challenges. 
In what concerns the positive pressure drivers, the market context drivers are forcing the product 
development process to be both, cost-effective and product-effective, by developing target-specific 
medicines and covering unmet needs. In this way, the product development process is expected to evolve 
towards higher productivity levels, generating more value with less money.  The last two drivers are 
internal, and they result from the poor performance that the current pharmaceutical industry faces. In that 
sense, they are industry self-motivated drivers in which improving the R&D / product development 
performance will inevitably lead to their decrease.
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Figure 2.8 Impact matrix – Drivers, Challenges and Enablers. 
◊   ○ (ix) Growing in global SC complexity ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ − − − − − − −
+ Pos itive Impact in chal lenges     (viii) Decreasing of effective patent l ife + + + ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○
− Negative Impact in chal lenges     (vii) Declining R&D productivity + + + ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○
○ Not relevant Impact in chal lenges     (vi) Uncertainty − − − − − − − − − − − − − − − − − −
 Strong relation    ◊ (v) Sustainability ○ ○ ○ ○ + ○ + + + + ○ + + + ○ ○ + +
◊ Week relation    ○ (iv) Growing of emerging markets ○ ○ ○ + + − − ○ ○ ○ + − − + − − − +
○ No relation ◊    (iii) Growing personalized medicines + + + − − + + − − + ○ − − + + + + ○
   ◊ (ii) Price/cost pressures + + + + + − + + + + + + + + ○ + + ○
◊    (i) Increasing Regulatory Burden − − − − − + ○ ○ ○ ○ − − − − ○ ○ ○ ○
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On the other hand, regarding the negative impact drivers, like uncertainty also the increasing regulatory 
burden driver can be seen as an external disturbance that must be carefully managed, in order to efficiently 
balance the compulsory requirements and their associated costs. 
Concerning the production and supply chain functions, the drivers with the most significant impact on the 
industry challenges, in addition to the uncertainty and the price/cost pressures already mentioned, we have 
the sustainability, the growing of personalized medicines and the growing of emerging markets, with a mix 
of positive and negative impacts, depending on the challenge. The sustainability driver will have not only 
a direct positive impact on challenges such as the minimization of waste production, the improvement of 
resource and energy efficiency, and the integration of several sustainability aspects across the entire SC, 
but it may also contribute indirectly to the reduction of inventory levels in all SC nodes, and to the 
improvement of the capacity utilization of the processing units. 
Growing of personalized medicines, on the other hand, is in some cases expected to impact more negatively, 
in the sense that it will disrupt the current production and supply chain paradigm, forcing a change from 
mass production to customized (low volume and high product mix) production. Regarding growing of 
emerging markets, the impact is also mostly negative due to the need to exploit new markets geographically 
dispersed. This will contribute to an increase of the SC complexity and of the distribution costs, and in the 
proliferation of counterfeit drugs. Nevertheless, a positive impact should be expected in the minimization 
of production costs due to pressures to increase affordability of new medicines in the emerging economies.  
Finally, at the supply chain level, the growing in SC complexity driver will have a negative impact on all 
the identified challenges, as expected.  
In what concerns the key technological enablers, all of them have a positive impact on the challenges, thus 
contributing to a generalized improvement of the performance indicators. The only exception is the cell 
and genetic therapy technology whose impact practically only affects the R&D / Product Development 
functional area. 
This analysis allowed us to identify, in a systematic and structured way, the gaps that exist between 
the traditional operating modes still prevailing in the industry and the requirements and needs of 
the current market context. Filling these gaps is mandatory today, and accordingly companies should 
take advantage of the several technological breakthroughs as enablers to the construction of new 
operational strategies. 
2.4. New paradigm in the Pharmaceutical Industry 
The analysis of the impact matrix shows that the industry challenges, drivers, and enablers are 
forcing pharmaceutical companies to evolve from their traditional product-centric and margin-driven 
perspective to an enterprise-wide perspective in which cost reduction, resource efficiency, flexibility, 
speed to market, and sustainability issues are now considered as central concerns. Successful 
approaches that are already in place in the chemical industry, as well as in other manufacturing 
settings (e.g. discrete manufacturing), are now also being explored and implemented in the 
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pharmaceutical industry, as a way to benefit from strategies based on economies of scale and 
operational efficiency. Although this clear change in the direction of greater efficiency is already on 
the way, to precisely define what may be the future new operational paradigm seems to be a difficult 
or even impossible task. The expected operational changes can be challenging for a highly traditional 
industry, in which process innovation was almost inexistent for several years (Smith, 2005). As 
stated by Kaitin (2010) the big challenge for this industry will depend on its ability to develop new 
strategies and change an obsolete business model and an outdated R&D paradigm. Both functions, 
operations management and business strategy, will have to be perfectly aligned to be successful. 
Nevertheless, we need to clearly identify the fundamental building components of the expected new 
paradigm, as well as its main impacts on the supply chain operations. Figure 2.9 depicts these 
components (6) viewed here as the main factors of this paradigm shift. Each of these factors has a 
very specific guiding focus, namely: outcome, efficiency, increased value, flexibility, market 
expansion, and overall welfare. Therefore, in line with these concerns, the new paradigm is expected 
to include the following models / strategic approaches (Figure 2.9): a patient-centric model, cost-
driven operations, a targeted approach (as opposed to “blockbuster” drugs), outsourcing strategies, 
emphasis on emerging economies, and a sustainable mindset.  
 
Figure 2.9 Paradigm shift and its impact on the pharmaceutical supply chain. 
 
Regarding the patient-centric model, with the increased attention on outcomes instead of products, 
along with the emergence of “outcome-based” pricing models (see section 2.3.1.1) and Real-World-
Evidence (RWE), the customer-experience is starting to arise as the centrepiece of the pharma 
business strategy. Accordingly, companies will need to engage more strategically with patients, 
fostering further understanding of their needs, expectations and fears in order to continuously revise 
and update their value propositions. New product-service solutions are expected by the exploitation 
of innovative technological breakthroughs (such as digital capabilities), and new distribution and 
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information channels will have to be created to increase patient’s proximity and to build a trustful 
partnership with him. Extraordinary amounts of data will be available, and advanced analytics tools 
will be used to generate meaningful information and knowledge.   
In what concerns the cost-driven approach, it is clear that operational efficiency is already catching 
the attention of pharmaceutical companies, that recognize the competitive advantage of capturing 
value from the supply chain. Advanced decision-making tools, together with innovative cost-efficient 
process technologies (such as continuous manufacturing), stand as key capabilities to achieve higher 
levels of cost-effectiveness. The ability to adopt innovative technologies and integrate those 
technologies with decision-making frameworks will surely dictate the company’s operational 
success. 
Moreover, the traditional primary care “blockbuster” model, which is highly risky today due to the 
lack of R&D productivity and its inability to replace the lost revenue from patent drops, is already 
changing. Companies are putting increased attention in value creation by a targeted approach 
essentially based on market segmentation and personalization. However, in order to effectively 
leverage product value, and even before the beginning of product development, companies should 
focus on two co-related endeavours. First they should identify the market specific unmet needs and 
the associated outcomes that are more valued by patients (both, in terms of therapeutic value and 
treatment comfort). Those needs should then be translated into product requirements to be 
incorporated in the final drug. Second, the company should focus on the patient’s genome 
characteristics and, by exploring the universe of patients, identify those with greater potential for 
benefiting from the new drug.  
In this way, the target-driven approach leverages the company’s ability for differentiation from the 
competition by targeting both, the market unmet needs and personalized care. 
Another shift from the “business as usual” that has also been observed in recent years is the rise of 
outsourcing and joint ventures strategies, moving from single to extended collaborative supply 
chains. Contract Manufacturing Organizations (CMOs) play a key role in this regard by providing 
faster and less expensive access to increased manufacturing capacity, and by making new 
technological capabilities available. In this way, pharmaceutical companies have more flexibility in 
reacting to market dynamics, and enhance their ability to manage risks more efficiently. Moreover, 
outsourcing strategies will also be crucial in providing local access to new markets. With emerging 
markets driving the most significant growth in the pharmaceutical industry, the business is clearly 
becoming more global and geographically spread. To cope with this increased complexity, companies 
will need to fully understand the cultures and the ways of doing business of the new markets, and 
will have to redesign their supply chains accordingly. Market segmentation and multiple distribution 
channels will be critical strategies for companies to secure drugs’ access in remote places. And higher 
levels of transparency and “end-to-end” visibility will be required for an effective management and 
monitoring of the SC operations. 
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Finally, the last main component of the new pharma paradigm concerns the main responsibility of 
this industry in providing overall welfare, considering its environmental and social impacts.   
Strategic decision-making should embrace environmental challenges and include eco-friendly 
strategies to reduce waste, minimize water and energy consumption, improve resource utilization, 
and achieve overall operational efficiency. Companies should also focus on innovative decision-
making frameworks to responsibly address social issues such as affordability, availability, safety 
concerns, and generalized access to medicines (both physical and timely access). 
All these strategic orientations, along with many other guidelines, are expected to arise in a 
shortcoming future as a result of the advent of the emerging industry 4.0  (Branke et al., 2016), 
providing companies with new capabilities in core business dimensions.  
The precise way in which all these contributions will be integrated and work together is obviously 
difficult to predict. However, it is clear that companies consistently adopting these principles will 
have an undeniable competitive advantage. 
2.4.1. The future of supply chain operations 
Based on this new paradigm, we made a thorough reflection on the impacts of these principles and 
tried to anticipate the structure and features of the future pharmaceutical supply chain. 
According to Gautam & Pan (2016), the big pharma model is already changing to more lean and 
focused companies, with the specialty products and emerging markets growing as key revenue 
streams. The new pharmaceutical supply chain is then expected to be highly focused on patient and 
value deliver (Figure 2.9). Each individual patient will be expected to have an active role in every 
function of the company (marketing & sales, NPD, and operations) boosted by the growing adoption 
of a real-time flow of information on the patient needs and on the treatment outcomes. As depicted 
in Figure 2.10, the patient is understood here as the beginning and end of the entire supply chain, 
covering all enterprise-wide functions, as he is an active determinant in the identification of unmet 
needs, in the development of new drugs, and in the after launch long-term effect assessment. 
The new supply chains should be designed based on market segmentation and on a “fit-for-purpose” 
strategy in which multiple distribution channels can be used according to each market segment. Both, 
primary care products for large populations and personalized care targeting small population niches, 
will exist in the global healthcare panorama, and companies need to be prepared, through resilient 
SC, to deal with these two scenarios simultaneously (see Figure 2.10).  
Production will need to be more agile, flexible, and driven by efficiency and cost-reduction. A shift 
from exclusively based batch operations to continuous or semi-continuous operations is inevitable 
to improve efficiency and enable the accommodation of the required product/volume mix. Moreover, 
outsourcing strategies based on the establishment of trustful partnerships will be critical to achieve 
greater flexibility and attain the needed risk management competences. 
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Figure 2.10 Schematic representation of the main components of the future pharmaceutical supply chain. 
Improved “end-to-end” visibility and extended supply chain coordination will be paramount and 
achieved through the use of innovative technologies and digital capabilities responsible to generate, 
translate, and manage data from multiple sources (product, patient, enterprise). 
Not only all the company functional activities, such as finance, marketing and sales, R&D and product 
development, and supply chain operations should communicate in an efficient and seamless way, but 
also the manufacturers, suppliers, wholesalers and other stakeholders should integrate collaborative 
networks as opposed to the strict supplier/customer relationship. 
In this way, the new supply chains are expected to be more capable to deal with globalised, 
geographically dispersed manufacturing networks, hopefully depending on fewer and more efficient 
intermediates.  
Finally, instead of the traditional linear sequence of stages, a circular approach is presented here, 
simultaneously fostering a sustainable perspective, with the reverse flows of materials, and a patient-
centric perspective, with a real-time continuous flow of information (Figure 2.10). 
All these characteristics are depicted in Figure 2.10, which is not intended to be a finished 
representation of the future pharmaceutical supply chain, but rather a schematic representation of 
the most relevant components to be considered, as opposed to the current supply chain depicted in 
Figure 2.5. 
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Together, the adoption of more cost-efficient technologies (such as continuous manufacturing), the 
incorporation of digital capabilities, and the exploitation of new distribution strategies less 
dependent on wholesalers (such as direct to patient distribution models), will be critical in reducing 
the manufacturing footprint, breaking out the silo-based perspective, and building up a sustainable 
operational mindset. 
This future vision depicted in Figure 2.10 is already being pursued by several companies with several 
projects, showing this new path has very promising outcomes. In 2016, Johnson & Johnson received 
the first regulatory approval from FDA to switch from batch to continuous processing for the 
production of its HIV treatment Prevista (Hayek, 2017). Other companies are also investing in 
continuous manufacturing technologies at both laboratory and pilot-scale levels, such as Eli Lilly, 
GSK, Novartis, Pfizer, and others (Srai et al., 2015b). 
2.4.2. Decision-making reference framework 
The industrial standard hierarchical structure in which decisions span across three main levels 
(strategic, tactical, and operational) is no longer enough to deal with the multidimensionality of the 
problems faced today by the chemical-pharmaceutical industry. Strategic decisions (or long-term 
decisions) are not anymore exclusive of global supply chain management or of the plant design level, 
as presented in some existing conceptualizations (see Appendix I), but instead they cross all 
functional activities and echelons of the company (such as R&D, NPD, marketing, etc). Likewise, 
medium- and short-term decisions are also no longer exclusive of production planning and 
scheduling functions, but encompass a much wider scope. Moreover, the integration of the different 
decision levels is today an inevitable requirement to achieve a closer adherence to real-world 
problems. As also stated by Harjunkoski (2017), the structural separation of the hierarchical levels 
is becoming increasingly tenuous and questionable, as new digital technological breakthroughs 
emerge.  
The current decision structure of a company is therefore much wider and complex, encompassing 
not only different time scales, but also different enterprise/business functions and activities, 
different scopes and impacts, different physical networks, and finally several technological settings. 
The new reference model is, therefore, expected to be able to capture not only the main 
activities/processes, and entities/actors, but also their interdependencies and global context.  
In that sense, we propose a novel conceptualization that seeks to deconstruct the hierarchical vertical 
perspective of decisions to give rise to a novel patient-centric layered approach, in which each layer 
corresponds to a specific dimension of the problem being addressed (Figure 2.11). 
Grounded on the previous findings regarding the drivers and enablers impacting the industry 
challenges, and the lessons learned from the other industrial sectors, five building blocks were 
identified as being the foundations of the new reference model. 
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Figure 2.11 Decision-making reference model. 
With the patient needs as the core of the decision-making process, each building block corresponds 
to a specific decision layer, through which problems will be defined, and optimization-based models 
developed. These building blocks are briefly described now: 
 
0. Patient needs 
In line with the expected new patient-centric business strategy, the proposed decision-making 
reference framework should be built around the patient needs and expectations. Being at the 
beginning and end of the supply chain network ( 
Figure 2.10), the patient will be the future main driver, not only in the definition of the 
product/service specifications, but also in setting some relevant operational performance metrics.  
With an increasingly active role in the pharmaceutical SC, the patient is becoming more and more 
involved in the decision-making processes regarding his own health. Companies need, therefore, to 
incorporate his “voice” in the process, thus improving the customer experience, since the discovery 
process to the final delivery. 
In this way, decision-making models will efficiently deal with issues such as higher product/volume 
mix, patient-centric distribution networks, more precise service levels, and real-time assessment of 
the overall customer-experience in closed-loops information channels.  
1. Business layer 
At the business layer, the description of the main functional areas of the company and the explicit 
representation of their interactions is highlighted. Within this layer we expect to position the 
problem being addressed within the main activities of the company, and explicitly consider the 
critical links between all the relevant activities and their interdependencies. 
These activities are grouped here in three main functional areas as depicted in Figure 2.11, namely: 
Marketing, Sales and Finance; R&D and New Product Development; and Supply Chain Operations.  
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Each of these functional areas depends on its specific technological context and capabilities to 
achieve their goals, as explicitly addressed by the next layer.  
2. Technological layer 
The technological layer aims to describe all the company’s established technological capabilities and 
to force researchers to incorporate those capabilities in their models in order to enhance the 
decision-making value. 
The complete characterization of the technological capabilities inside the organization is vital to 
allow the different actors to jointly define the best optimization strategies. In this way, not only the 
batch/continuous operation modes need to be defined, but also the data acquisition systems and 
monitoring and control competencies should be rigorously characterized for a sound model 
development. 
Moreover, considerations regarding the most relevant future capabilities (such as digital 
technologies) and technological-related decisions (such as technology selection) should be taken into 
account whenever possible, as a way to assess cost-effective and/or eco-friendly alternatives. 
With the technological setting fully specified, the physical entities/facilities that host those 
technologies need to be carefully defined and characterized in terms of their spatial structure. 
3. Physical layer 
This layer describes the possible physical configurations of all supply chain entities and frames the 
decision problem in respect to the echelons considered in the analysis. 
Decisions under the physical dimension may span from an individual “process” at the plant level to a 
geographically spread multi-echelon problem. The multiplicity of network configurations of 
processes within a manufacturing facility (single-site) and facilities in the same or different SC 
echelons (multi-site) is large and complex. 
Whatever the network or sub-network configuration is, it needs to be optimized considering 
decisions that may span across all different temporal levels. For instance, at the strategic level, 
decisions can vary between network design in a multi-site configuration and technology selection if 
dealing with a single plant configuration. Likewise, at the operational level, decisions may span from 
routing plans (in a multi-site configuration) to production scheduling (at the plant level). 
Significant modeling challenges may arise when dealing with large-scale networks in order to fully 
capture their complexities, particularly the interactions between the different SC echelons. 
4. Temporal layer 
The temporal layer describes decisions hierarchically, in terms of time, and for a given planning 
horizon. In this way, decisions can range from real-time (real-time monitoring and control) to several 
years (long-term strategic decisions). As depicted in Figure 2.11, this is the last layer in the problem 
definition and consequent model development. While the previous layers have as the most 
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prominent purpose the definition of the problem scope and its boundaries, in this case the most 
valuable outcome is a clear definition of the problem objective and its main constraints, considering 
all the previous assumptions.  
Here, the external disturbances will have a significant impact that need to be explicitly accounted as 
described below.  
5. External disturbances 
Several external disturbances can affect the supply chain, with direct impact on its operational 
performance. In the proposed reference framework (Figure 2.11) four external factors are 
highlighted as the most relevant, namely: uncertainty (including external and internal uncertainty 
aspects); sustainability issues; regulatory framework; and market dynamics. 
These factors have already been described in detail, and in particular they should be taken into 
account during system implementation. Nevertheless, despite their inherent complexity, they cannot 
be disregarded during model development, as they are always present and may significantly affect 
the system performance. 
 
6. Seamless coordination 
Finally, in the proposed reference framework (see Figure 2.11), “seamless coordination” is intended 
to reflect the major goal of achieving a fully integrated system, with global optimized operations 
across each dimension (layer) of the decision problem. In this way, optimization-based decision-
making models should incorporate not only the more traditional cross-functional (business layer) 
and multi-level integration (temporal layer), but also a multi-echelon coordination (physical layer) 
and technology integration (technological layer). Additionally, with the rise of personalization, the 
patient will be closer to the production and distribution activities, leading to a growing 
approximation between product development operations and supply chain operations, hopefully 
towards a deeper, seamless integration.   
Typically, integrated problems are currently solved by resorting to sequential methods, that seldom 
capture the links and interdependencies between the different levels, leading to sub-optimal or even 
inconsistent solutions (Chu & You, 2015). However, there are significant complexities even in each 
of these separate problem dimensions with its own scopes, scales and goals, and a single approach 
with such a high level of integration is yet to be developed.  
At the business layer, data integration and real-time information sharing, across all company levels, 
is one of the main challenges when trying to achieve a higher level of collaboration (Dias & 
Ierapetritou, 2017). At the physical layer, the high dimensionality of the multi-echelon integration 
may be pointed as the main modelling challenge. Regarding multi-level (temporal) integration, it is 
clear that the different hierarchical decision-levels, although spanning across a wide time-scale, are 
highly interdependent. In this case, the major hurdle is possibly the way how the different temporal 
scales will be conjugated and modelled.  
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Full integration is still a great unsolved challenge, requiring the design of new sophisticated models 
and computational algorithms, and the implementation of enhanced decomposition techniques 
(Garcia & You, 2015; Dias & Ierapetritou, 2017). 
2.4.3. Improvement assessment 
Considering the expected evolution of the pharmaceutical supply chain and the proposed decision-
making reference framework is possible to foresee the overall forthcoming gains at the several 
business levels (NPD, Manufacturing, and Supply Chain), as presented in Table 2.2. 
The drug development process is expected to be more effective, with smaller and simpler trials, 
targeting specific patient characteristics and relying in evidence-based techniques (such as real-
world evidence (RWE)) to support decision-making. Personalization will also reduce the risk of 
failure during trials, boosting faster product launches (thus reducing time-to-market) and 
contributing to decrease development costs.  
The effective coordination between R&D and marketing in an effort to match drug development to 
market needs, will raise the likelihood of future commercial success and consequently increase the 
product pipeline value. Additionally, the adoption of continuous production modes will have a direct 
impact on the scale-up operations during development and on the ramp-ups after product launch, 
which will become considerably faster and simpler.  
At the manufacturing level, we can anticipate a reduction of production costs, of production lead 
times, and of inventories, as a direct consequence of the adoption of more cost-efficient technologies 
(i.e. continuous manufacturing), and of the development of innovative decision-support tools, based 
on advanced optimization and simulation methods. Additionally, higher capacity utilizations are 
expected with improvements regarding energy and resource efficiency, as well as higher flexibility 
with improved responsiveness to market changes.  
Finally, in what concerns the supply chain, the reduced footprint and complexity depicted in Figure 
2.10 will definitely lead to a reduction in the distribution costs, inventory levels, and cycle times 
across the entire SC. Moreover, the new digital capabilities will contribute to enhanced end-to-end 
visibility and seamless coordination between all SC nodes and business functions. In this way, higher 
levels of operational efficiency will be achieved, and a greater quality control will be ensured. 
Additionally, the adoption of market segmentation strategies and innovative distribution channels 
(e.g. directly to the patient) will contribute to avoid wholesalers’ margins, reduce the overall 
distribution costs, improve patients' experience, and build patients' trust in the industry. 
Table 2.2 shows the expected improvements in each of the industry challenges (as identified in 
section 2.2), based on several research works.  
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Table 2.2 Challenges/opportunities for improvement, current performance measures and expected 
improvements 
Pharmaceutical 
function 
Challenges Acronym Performance measures Future expectation 
R&D / Product 
Development 
minimize time-to-
market 
TM  15 years14 <10 years15 
maximize the product 
pipeline value 
PPV 
- High phase III 
discontinuation 
- High commercial failures 
- Drug beneﬁts are not 
deemed to outweigh risks 
- Reduced clinical trial 
failures 
- Increased probability 
of market success 
- Increased patient 
minimize 
development costs 
DC 
> $2,5 million per approved 
drug16 
 10% reduction17 
Manufacturing 
minimize production 
lead times  
LT 30 – 90 days18 60-80% reduction19 
minimize production 
costs  
PC 27-30% of sales20 15-30% cost reduction21 
Improve quality levels 
(Excessive rework and 
discarded product) 
Q 
costs of rejected batches and 
rework estimated on 25% of 
revenue22 
50% reduction in 
product deviations23 
minimize inventory 
levels 
I 40-60 days24 Up to 50% reduction25 
improve capacity 
utilization (OEE) 
CU OEE: 30%26 
move from 30% to more 
than 75%27 
improve resource and 
energy efficiency 
RU/Y material efficiency: 1-10%28 
yield improvement of 
10%29/ 
                                                                    
 
 
14 Development cycle time considered since discovery to market launch Federsel, H.-J. (2009). "Chemical process research 
and development in the 21st century: challenges, strategies, and solutions from a pharmaceutical industry perspective." Acc. 
Chem. Res 42(5): 671-680. 
15 Ibid. 
16 DiMasi, J. A., H. G. Grabowski and R. W. Hansen (2016). "Innovation in the pharmaceutical industry: new estimates of R&D 
costs." Journal of health economics 47: 20-33. 
17 Harrington, T. S., L. Alinaghian and J. S. Srai (2014). Making the business case for continuous manufacturing in the 
Pharmaceutical Industry. Proceedings of the 25th Annual Production and Operations Management Society (POMS) 
Conference, Atlanta GA, May. 
18 Singh, M. P. (2005). The pharmaceutical supply chain: A diagnosis of the state-of-the-art, Massachusetts Institute of 
Technology. 
19 Hayek, M. (2017). "Continuous manufacturing: The clock is ticking. Is pharma ready?" ACCENTURE LIFE SCIENCES BLOG 
https://www.accenture.com/us-en/blogs/blogs-continuous-manufacturing-pharma-ready Accessed July, 2018 2018. 
20 Basu, P., G. Joglekar, S. Rai, P. Suresh and J. Vernon (2008). "Analysis of manufacturing costs in pharmaceutical companies." 
Journal of Pharmaceutical Innovation 3(1): 30-40. 
21 Harrington, T. S., L. Alinaghian and J. S. Srai (2014). Making the business case for continuous manufacturing in the 
Pharmaceutical Industry. Proceedings of the 25th Annual Production and Operations Management Society (POMS) 
Conference, Atlanta GA, May, Hayek, M. (2017). "Continuous manufacturing: The clock is ticking. Is pharma ready?" 
ACCENTURE LIFE SCIENCES BLOG https://www.accenture.com/us-en/blogs/blogs-continuous-manufacturing-pharma-
ready Accessed July, 2018 2018. 
22 Harrington, T. S., L. Alinaghian and J. S. Srai (2014). Making the business case for continuous manufacturing in the 
Pharmaceutical Industry. Proceedings of the 25th Annual Production and Operations Management Society (POMS) 
Conference, Atlanta GA, May. 
23 Hayek, M. (2017). "Continuous manufacturing: The clock is ticking. Is pharma ready?" ACCENTURE LIFE SCIENCES BLOG 
https://www.accenture.com/us-en/blogs/blogs-continuous-manufacturing-pharma-ready Accessed July, 2018 2018. 
24 Singh, M. P. (2005). The pharmaceutical supply chain: A diagnosis of the state-of-the-art, Massachusetts Institute of 
Technology. 
25 Srai, J. S., C. Badman, M. Krumme, M. Futran and C. Johnston (2015a). "Future Supply Chains Enabled by Continuous 
Processing—Opportunities Challenges May 20–21 2014 Continuous Manufacturing Symposium." Journal of Pharmaceutical 
Sciences 104(3): 840-849. 
26 According to Vervaet, C. and J. P. Remon (2005). "Continuous granulation in the pharmaceutical industry." Chemical 
Engineering Science 60(14): 3949-3957. 30% is the typical value in pharmaceutical industry, reaching a value of 74% in 
good manufacturing processes, and 92% in ‘best-in-class’ pharmaceutical production lines. 
27 Hayek, M. (2017). "Continuous manufacturing: The clock is ticking. Is pharma ready?" ACCENTURE LIFE SCIENCES BLOG 
https://www.accenture.com/us-en/blogs/blogs-continuous-manufacturing-pharma-ready Accessed July, 2018 2018. 
28 Material efficiency considered as the amount of product produced per unit amount of materials used Shah, N. (2004). 
"Pharmaceutical supply chains: key issues and strategies for optimisation." Computers & chemical engineering 28(6): 929-
941. 
29 Harrington, T. S., L. Alinaghian and J. S. Srai (2014). Making the business case for continuous manufacturing in the 
Pharmaceutical Industry. Proceedings of the 25th Annual Production and Operations Management Society (POMS) 
Conference, Atlanta GA, May. 
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Pharmaceutical 
function 
Challenges Acronym Performance measures Future expectation 
(improve production 
yields) 
40% reduction in power 
consumption30 
and CO2 savings of 50% 
minimize waste 
production 
WP 
E-factor (API production):  
from 25 to higher than 10031  
(kg waste/kg product) 
waste reductions highly 
dependent on the 
produced API32 
improve production 
flexibility and agility 
F low responsiveness  
faster scale-ups and/or 
scale-downs in response 
to market disturbances 
Supply Chain 
minimize the supply 
chain complexity 
SCC 
large manufacturing footprint 
/ Complex supply network 
50-70% reduction in 
physical footprint33/ 
fewer SC actors more 
geographical dispersed 
minimize Supply 
Chain/Distribution 
costs 
DC 25% of pharma costs34 15 – 20% 35 reduction 
development of agile 
and more responsive 
supply chains 
R 1000-8000 h36 
50-70% reduction in 
physical footprint37 
improve end-to-end 
visibility across the 
entire SC 
V independent silos of activities 
seamless flow of 
information and cross-
functional integration 
seamless integration 
and coordination 
across the SC network  
SI independent silos of activities 
seamless flow of 
information and cross-
functional integration 
minimize inventory 
levels in every node of 
the supply chain (E2E) 
I 
4-24 weeks’ worth of finished 
good38 
70 weeks E2E inventory39  
up to 50% reduction40 
Integration of 
sustainability aspects 
across the entire SC. 
SSC 
mainly economically issues 
(profit maximization or cost 
minimization) 
Integration of 
environmental and 
social indicators 
                                                                    
 
 
30 Hayek, M. (2017). "Continuous manufacturing: The clock is ticking. Is pharma ready?" ACCENTURE LIFE SCIENCES BLOG 
https://www.accenture.com/us-en/blogs/blogs-continuous-manufacturing-pharma-ready Accessed July, 2018 2018. 
31 According to Dunn, P. J., A. Wells and M. T. Williams (2010). Green chemistry in the pharmaceutical industry, John Wiley & 
Sons., the E factor (kg waste/kg product) for the pharmaceutical industry range from 25 to higher than 100 with organic 
solvents being  the major contributor for the waste generated.  
32 Several studies have demonstrated the potential of continuous manufacturing in reducing the waste generated in API 
production. According to Gerogiorgis, D. I. and P. I. Barton (2009). Steady-state optimization of a continuous pharmaceutical 
process. Computer Aided Chemical Engineering, Elsevier. 27: 927-932. one order of magnitude lower in waste generated 
was observed in the production of an innovative API when compared to the corresponding batch process. Also, Jolliffe, H. G. 
and D. I. Gerogiorgis (2016). "Process modelling and simulation for continuous pharmaceutical manufacturing of 
artemisinin." Chemical Engineering Research and Design 112: 310-325. determined on average  66% less waste  in the 
production of antimalarial substance artemisinin. In another study the same authors Jolliffe, H. G. and D. I. Gerogiorgis 
(2015). "Process modelling and simulation for continuous pharmaceutical manufacturing of ibuprofen." Chemical 
Engineering Research and Design 97: 175-191. determined the E-factor value of 25.4  for the continuous production of 
ibuprofen, which is considerably low compared to many pharmaceutical processes. 
33 Hayek, M. (2017). "Continuous manufacturing: The clock is ticking. Is pharma ready?" ACCENTURE LIFE SCIENCES BLOG 
https://www.accenture.com/us-en/blogs/blogs-continuous-manufacturing-pharma-ready Accessed July, 2018 2018. 
34 Thomas, E., K. George, E. Larsen, K. Shah and D. Ungerman (2013). Building New Strengths in the Healthcare Supply Chain. 
Pharmaceuticals and Medical Products Operations. Mckinsey&Company, Mckinsey&Company. 
35 According to Deloitte (2016b). Innovative Routes to Market-Rethinking the Life Sciences Distribution Model. Innovative 
Routes to Market, Deloitte. a reduction in distribution costs of 15 - 20% is expected for the adoption of innovative routes to 
market, such as direct to patient distribution models. 
36 Supply chain cycle time considered as the elapsed time between material entering as raw material and leaving as product 
according to Shah, N. (2004). "Pharmaceutical supply chains: key issues and strategies for optimisation." Computers & 
chemical engineering 28(6): 929-941. 
37 Hayek, M. (2017). "Continuous manufacturing: The clock is ticking. Is pharma ready?" ACCENTURE LIFE SCIENCES BLOG 
https://www.accenture.com/us-en/blogs/blogs-continuous-manufacturing-pharma-ready Accessed July, 2018 2018. 
38 Shah, N. (2004). "Pharmaceutical supply chains: key issues and strategies for optimisation." Computers & chemical 
engineering 28(6): 929-941. 
39 Harrington, T. S., L. Alinaghian and J. S. Srai (2014). Making the business case for continuous manufacturing in the 
Pharmaceutical Industry. Proceedings of the 25th Annual Production and Operations Management Society (POMS) 
Conference, Atlanta GA, May. 
40 Srai, J. S., C. Badman, M. Krumme, M. Futran and C. Johnston (2015a). "Future Supply Chains Enabled by Continuous 
Processing—Opportunities Challenges May 20–21 2014 Continuous Manufacturing Symposium." Journal of Pharmaceutical 
Sciences 104(3): 840-849. 
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2.5. Conclusion 
This work presents a detailed analysis of the pharmaceutical industry’s business environment, its 
supply chain operations, and related decision-making processes.  
Within the industry’s characterization, three main areas were identified as the most relevant, 
considering their impact on the industry’s operational performance, namely: (i) product 
development and market launch; (ii) supply chain and logistics; and (iii) decision-making processes. 
In each of these areas, some research gaps and the key opportunities for improvement were 
identified, and then correlated with the most prevalent market drivers and technological enablers, in 
order to anticipate the industry’s evolutive path to a new organizational paradigm. Following this, a 
new general decision-making reference framework, based on a patient-centric layered approach, is 
proposed, to give support to researchers and practitioners in structuring problems while considering 
all the current complexities of the industry, 
The present study highlights the unprecedent changes currently faced by the pharmaceutical 
industry caused by today's business and market landscape. Conjunctural factors such as scientific 
and technological breakthroughs, increased societal pressures, stringent regulations, and a fast-
changing market and competition environment, are considerably impacting the pharmaceutical 
supply chain operations and creating new, unexpected management challenges. In this context, the 
typical poor performance metrics of the industry are no longer acceptable, and new business 
strategies for its overall improvement seem inevitable. 
It is clear that the industry is struggling to stay economically competitive, while maintaining the 
necessary levels of innovation needed to ensure R&D productivity.  
Moreover, given the industry’s fragilities and bottlenecks, the product development phase stands out 
as the most critical stage in the pharmaceutical product life-cycle, especially due to its essential role 
in providing new drugs to the market. Yet productivity metrics are seriously compromised with the 
increasing development costs and declining product pipeline value. At the manufacturing and supply 
chain level, significant opportunities for improvement were identified, and not taking advantage of 
those opportunities is greatly decreasing companies’ ability to respond to market dynamics and 
securing their competitive positions.  
Over the years, researchers and practitioners have been developing several positive approaches for 
the referred problems, thus contributing to higher levels of operational efficiency in the 
pharmaceutical industry. The amount of published papers addressing e.g. product portfolio 
management and production planning and scheduling during commercial manufacturing, shows 
already a certain level of maturity in the research interests around the pharmaceutical industry. 
However, our comprehensive literature survey also reveals that some pharmaceutical management 
issues are not yet duly covered, and that the current research is in general misaligned with the recent 
main trends driving the industry.  
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It seems, in fact, that little attention has been given to the patient-centric view and to new 
technological solutions, as part of alternative supply chains. Likewise, the increased importance of 
emerging markets does not seem to be accompanied by the academic community, typically focusing 
on the design of planning problems in developed economies. Moreover, the consideration of 
sustainability aspects beyond the purely economic dimension is still very poorly explored. This is 
particularly critical regarding social issues. As one of today’s biggest challenges for the 
pharmaceutical companies is to broaden access and affordability of medicines by disadvantaged 
population, a social perspective is critical. 
Moreover, the surveyed studies suggest a high influence of the traditional hierarchical vertical 
structure paradigm, with a little effort for the development of decision-making models and solution 
methods, in the case of the pharmaceutical industry. There is a clear lack of decision-level integration 
and functional coordination across the literature, and a deficit of attention to specific industry 
features such as lot traceability or process development considerations. 
Therefore, and despite the difficulty in accurately predicting the future strategic path for the 
pharmaceutical industry, it is possible to foresee that a deep change in operations and decision-
making processes will occur soon. 
In this line, the decision-making reference framework proposed in this work aims at filling the 
existing gaps, by providing guidance for the "construction" of the relevant decision problems along 
their multiple dimensions. This new framework is able to capture all major aspects of the industry’s 
behaviour and its supply chains, assisting managers and researchers in structuring problems and in 
focusing on the patient and his needs. In future research, we intend to incorporate some often 
neglected specific features of the pharmaceutical industry, such as its highly regulated nature, 
sustainability issues, complex uncertainty environments, resources and operational limitations, or 
technological settings.    
In this way, the following chapters try to explore these new capabilities through the development of 
a decision-making tool applied to the NPD process, due to its importance in ensuring an efficient and 
timely product launch. Moreover, as depicted in Figure 2.7, planning for the clinical trials has been 
neglected over the years, thus evidencing a clear need for further development.  
 
  
 
3. Stochastic product launch planning 
problem: A simulation-optimization 
approach 
This chapter describes a new simulation-optimization based approach to tackle the pharmaceutical 
product launch planning problem under technical and market uncertainty. 
The content of this chapter is based on the work published in an international peer reviewed journal 
and presented in two international conferences as follows: 
  
Journal publication 
 
Marques, C. M., Moniz, S., de Sousa, J. P., & Barbosa-Póvoa, A. P. (2017). A simulation optimization 
approach to integrate process design and planning decisions under technical and market uncertainties: 
A case from the chemical-pharmaceutical industry. Computers & Chemical Engineering, 106, 796-813. 
 
Conference Proceedings 
 
Marques, C. M., Moniz, S., de Sousa, J. P., & Barbosa-Póvoa, A. P. (2016). Optimization and Monte Carlo 
Simulation for Product Launch Planning under Uncertainty. In K. Zdravko & B. Miloš (Eds.), Computer 
Aided Chemical Engineering (Vol. Volume 38, pp. 421-426): Elsevier. 
 
Marques, C. M., Moniz, S., de Sousa, J. P., & Barbosa-Póvoa, A. P. (2017). A simulation-optimization 
approach to integrate process design and planning decisions under technical and market uncertainties. 
In Foundations of Computer Aided Process Operations / Chemical Process Control. Tucson, Arizona. 
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Abstract 
This chapter addresses the product-launch planning problem in the chemical-
pharmaceutical industry under technical and market uncertainties and 
considering resource limitations associated to the need of processing in the same 
plant products under development and products in commercialization. A novel 
approach is developed by combining a mixed integer linear programming (MILP) 
model and a Monte Carlo simulation (MCS) procedure, to deal with the integrated 
process design and production planning decisions during the New Product 
Development (NPD) phase. The Monte Carlo simulation framework was 
designed as a two-step sampling procedure based on Bernoulli and Normal 
distributions. Results show the unquestionable influence of the uncertainty 
parameters on the decision variables and objective function, thus highlighting 
the inherent risks associated to the deterministic models. Process designs and 
scale-ups that maximize expected profit were determined, providing a valuable 
knowledge frame to support the long-term decision-making process, and 
enabling earlier and better decisions during NPD. 
3.1. Introduction 
3.1.1. Motivation 
As acknowledge in the previous chapter, the pharmaceutical industry operates in a very dynamic, 
highly regulated and competitive business context, being one of the most important manufacturing 
sectors in Europe (EFPIA, 2016). The specificities of this industry are well known in the Process 
System Engineering (PSE) community. The heavy regulatory burden, high investment in R&D with 
very low success rates, and long periods for new product launch, clearly differentiate this industry 
from other sectors and impose significant managing challenges (Laínez et al., 2012). Furthermore, 
the liberalization of the global pharmaceutical market and the pressures of the regulatory agencies 
for a price reduction in medical drugs has paved the way to generic competition (Federsel, 2006). 
Considering the fact that the costs of imitation are extremely low when compared to the costs of 
innovation in pharmaceuticals, generic competition is becoming increasingly fierce, particularly 
regarding economic issues (Grabowski & Vernon, 2000). In that sense, this industry is now highly 
dependent on patent effective life, being forced to deliver medical drugs faster and more efficiently. 
As stated by Shah (2004)  and more recently by (Moniz et al., 2015c),  it is clear that time-to-market 
is the most critical issue in this industry, and that any delay associated with the product launch 
process entails a significant loss in future profits. This demanding business context has encouraged 
companies to invest in production capacity and to make process design decisions as early as possible, 
even before knowing if the products will ever reach the market (Kaminsky & Yuen, 2014). Those 
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decisions are thus highly risky, involving several sources of uncertainty that must be considered 
during the decision-making process (Moniz et al., 2015b). 
In addition to the economic dimension of these decisions, sustainability concerns are also one main 
motivation of this work. In recent years a paradigm shift has been observed, with sustainability 
aspects being considered simultaneously with economic goals (Bakshi & Fiksel, 2003; Barbosa-
Póvoa, 2012) Efficient resource utilization is becoming a global challenge, clearly reflected in the 
recent SPIRE (Sustainable Process Industry through Resource and Energy Efficiency) initiative, 
where the main goals towards improved efficiency and competitiveness are fully aligned with the 
European Horizon 2020 agenda (EC, 2013). The fine chemical and pharmaceutical industry plays an 
important role in this regard due to their high dependence on resources such as: water, raw materials 
and energy (Halim & Srinivasan, 2008; Wernet et al., 2010; Halim & Srinivasan, 2011). Thus, 
implementing efficient production planning decisions will definitely contribute to better resource 
utilization and waste minimization. More than ever, the need to achieve higher efficiency and cost 
savings in resource utilization, combined with the urgency in reducing the time-to-market of under 
development pharmaceutical products, clearly justifies further research in more advanced and 
reliable methods to solve real world planning optimization problems under uncertainty. 
Accordingly, the work presented in this chapter addresses the product-launch planning problem, 
considering uncertainty on product demand and on the pass/fail outcomes of clinical trials. This 
work integrates process design and planning decisions, considering the resource limitations in 
processing, in the same plant, products under development and products already in 
commercialization. In practice, this approach provides contributions to enhance decision-making 
processes, with four overall goals: (i) maximize the profit of companies; (ii) minimize investments; 
(iii) minimize future changes in the production process; and (iv) to improve processes efficiency, 
particularly in what concerns resource utilization and waste reduction.  
Therefore, improving the balance between available resources and product demand, while achieving 
interesting and sustainable results, is one of the main goals of the decision-making framework 
proposed here. The majority of currently available approaches are supported by deterministic 
models based on the maximization of expected values, without considering the highly stochastic 
nature of the problems (Li & Ierapetritou, 2008; Verderame et al., 2010). In this work, we have 
developed a MILP model for optimal product-launch planning, combined with a two-step MCS 
framework to tackle simultaneously different types of uncertainty. 
3.1.2. Pharmaceutical Product Launch 
3.1.2.1. New Product Development (NPD) 
The development of new drugs is an expensive and time-consuming process that comprises several 
consecutive steps, already described in the previous chapter (see section 2.2.1), namely: discovery, 
pre-clinical tests, clinical trials, regulatory approval and market launch. Figure 3.1 depicts the 
pharmaceutical product lifecycle, since discovery to manufacturing and distribution, highlighting the 
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moments of scale-up decisions. According to Laínez et al. (2012), the time from discovery to market 
launch can take up to 15 years, and the average cost of a new drug is about US$ 2 billion and 
increasing, with about 50% representing clinical trial costs. 
Clinical trials involve a series of very rigorous tests conducted on human beings, to assess the safety, 
efficacy and dosage levels of the new compound. These trials comprise three successive phases (I, II 
and III). In phase I, the new molecular entity is tested in 20/100 healthy volunteers, for safety 
assessment. In phase II, 100/500 volunteer patients are tested, to ensure the efficacy of the 
compound. Phase III usually involves thousands of volunteer patients, with the main purpose of 
comparing the performance of the new treatment with other existing treatments, and assessing its 
long-term effects (Levis & Papageorgiou, 2004; Colvin & Maravelias, 2008). The clinical trials process 
may take approximately 5 to 6 years (Colvin & Maravelias, 2008) and only after its successful 
completion and the FDA approval, the new compound is able to be commercially launched. In that 
sense, decisions such as “how much to produce?”, “when to produce?” and “with what resources?” 
during the new product development process, are critical, and will have a significant impact on the 
company’s sustainability. As failing a trial dosage can seriously compromise the time-to-market of 
the new drug, all the necessary resources need to be available as soon as they are needed (Levis & 
Papageorgiou, 2004). These decisions are, therefore, taken under significant levels of uncertainty, 
particularly regarding product demand. The high variability of product demand during clinical trials 
results mainly from the uncertainty of the pass/fail outcomes of clinical trials and is partially due to 
patient drop out during the progress of treatments (Chen et al., 2012a). On the other hand, if the 
compound fails at any clinical trial phase, the whole investment made until then is considered lost. 
This makes the NPD (New Product Development) stage one of the most critical in the whole product 
life cycle.  
 
Figure 3.1 Pharmaceutical product lifecycle, highlighting the main scale-up decision moments. 
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3.1.2.2. Process Design 
Along with the product development, also the production process for the new drug needs to be 
developed, in order to get the final approval by the regulatory agencies. Moreover, the company itself 
must also guarantee that it will be able to routinely manufacture reproducible batches of the new 
drug (Colvin & Maravelias, 2008). Traditionally, the pharmaceutical industry operates in batch and 
multipurpose production systems, simultaneously processing campaign and short-term modes 
(Moniz et al., 2014a) . In these plants, products already in commercialization and products under 
development compete for the same resources. In that sense, providing the right amount of resources, 
at the right moment, to each trial, represents a key management challenge, with the development of 
the production process playing a very critical role (Moniz et al., 2015b). The company starts by 
providing small amounts of the new product to the early stages of the clinical trials. Then it up-scales 
the process as needed to fulfill the last stages of product development and, finally, it has to guarantee 
the satisfaction of commercial demand, in terms of quantity and quality (Stonebraker, 2002). Process 
design and capacity decisions are therefore of paramount importance, and late-stage process 
changes will inevitably compromise the market launch of the new drug (Federsel, 2003).  
Since changing the process after this being approved is very costly and complex, any poor decision 
taken during the early stages will have a huge impact in the commercialization phase. According to 
Federsel (2003), the process should be frozen no later than clinical trial phase II, in order to 
guarantee a drug production of good quality for long-term toxicology and stability testing. Therefore, 
in practice, these decisions are made with two conflicting objectives: (i) they should be sound and 
based on a considerable amount of information; and (ii) they should be made early enough to prevent 
any delays in the completion of the trials. According to Stonebraker (2002), the capital investments 
for the production facility usually occur around five years before the market launch of the new drug. 
As late decisions could significantly jeopardize the future incomes of the company, process design 
and capacity decisions, such as the assignment of processes to units, scale-up, and the acquisition of 
production units, have to be made under a significant uncertainty context. 
3.2. Background 
 
New product development management in the pharmaceutical industry has been one of the major 
concerns of the process system engineering community in recent years. In this area, the great 
majority of published works focus on product portfolio selection, on capacity planning, and on supply 
chain management during clinical trials (Laínez et al., 2012).  
Typically, planning decisions are formulated as deterministic optimization problems in which all the 
parameters are assumed to be known. However, the importance of incorporating uncertainty into 
planning and scheduling models is increasingly recognized by the academic community (see some 
interesting, recent review articles such as Li & Ierapetritou (2008); Sahinidis (2004); Verderame et 
al. (2010) ). Verderame et al. (2010) present a comprehensive overview of the main contributions in 
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planning and scheduling optimization under uncertainty, across multiple industrial sectors The most 
commonly used approach for planning under uncertainty is two-stage Stochastic Programming (SP) 
(Steimel & Engell, 2015). Planning decisions are typically taken in two stages, where strategic 
decisions (“here and now”) are made in the first stage under significant uncertainty, and operational 
decisions (“wait and see”) are made in a second stage after the resolution of the uncertainty. Usually, 
uncertainties are modelled as a set of discrete scenarios, as a way to account for all possible future 
outcomes, and each scenario is solved as a deterministic problem. 
Rotstein et al. (1999) was one of the first papers addressing capacity planning under uncertainty in 
the outcomes of clinical trials. They developed a two-stage SP approach, with the first stage dealing 
with decisions such as product selection, initial capacity investment, and initial allocation of 
manufacturing resources to products. In a second stage, decisions are made after the completion of 
the clinical trials, and they include: additional capacity investments, re-allocation of manufacturing 
resources to products, and production plans. Papageorgiou et al. (2001) developed a MILP model to 
simultaneously address the selection of a product development and introduction strategy, and a long-
term capacity planning and investment strategy, at multiple sites. However, this work does not 
account for the uncertainty associated to product demand or the outcomes of clinical trials. At the 
same time, Maravelias & Grossmann (2001) addressed the problem of simultaneously planning the 
new product development and the design of batch manufacturing facilities. The authors proposed a 
multi-period MILP model that maximizes the expected net present value of multiple projects 
(products under development). A two-stage stochastic optimization approach is adopted to account 
for the uncertainty in the outcome of the trials.  
Gupta & Maranas (2000) also propose a two-stage SP approach, to address the multisite midterm 
supply-chain planning problem under demand uncertainty. The production decisions are made 
“here-and-now”, and the supply chain (inventory and distribution) decisions are postponed as “wait-
and-see”. Later, the same authors (Rogers et al., 2002) presented a real-options strategy to determine 
the optimal product selection decisions in the pharmaceutical R&D portfolio management.  
Gatica et al. (2003b) presented a multistage programming formulation for capacity planning with 
uncertainty associated to the outcomes of clinical trials. A scenario analysis was performed, and these 
uncertainty issues were modelled via a tree of scenarios. However, in this work only the outcomes of 
the last phase of clinical trials were considered, and this may obviously lead to suboptimal solutions. 
The same authors later presented (Gatica et al., 2003a) a scenario aggregation–disaggregation 
approach, with scenarios being grouped into predetermined clusters, based on a mapping procedure 
between products and the outcomes of clinical trials. Cheng et al. (2003) addressed the problem of 
designing and planning under market and technological uncertainty. The decision process explicitly 
incorporates both the upper-level investment decisions and the lower-level production decisions, as 
a two-stage optimization problem, with a multi-objective Markov chain. Later, Levis & Papageorgiou 
(2004) also proposed a two-stage, multi-scenario MILP model, to determine the product portfolio 
and to perform the multi-site capacity planning, considering uncertainty in the outcomes of clinical 
 
3. Stochastic product launch planning problem: A simulation-optimization approach 
70 
 
trials. In the same year (Sundaramoorthy & Karimi, 2004) presented a multi-period, continuous-time 
MILP model to address the supply chain management problem in a pharmaceutical plant considering 
new product introductions (active ingredients or intermediates) and outsourcing. The model 
determines the production and inventory levels, and the level of outsourcing for existing 
intermediates to maximize gross profit. However, this work does not account for uncertainty, and it 
is assumed that the scale-up procedures are completed before the new product enters the facility for 
commercial production. A scenario-based multi-stage Stochastic Programming model was developed 
by Colvin & Maravelias (2008) for planning the clinical trials in the pharmaceutical R&D pipeline. The 
model determines which trials should be performed in each planning period, taking into account the 
uncertainty in the outcomes of the clinical trials. The authors use a reduced set of scenarios to limit 
the size of the problem. Later, they extend their work (Colvin & Maravelias, 2009) to simultaneously 
address the scheduling of clinical trials and resource planning. More recently, the same authors 
(Colvin & Maravelias, 2011) developed a multi-stage SP framework for R&D pipeline management, 
accounting for interdependencies between projects and tasks, and incorporating risk management 
considerations (both value-at-risk and conditional value-at-risk novel formulations). The main goal 
of this approach is to determine the schedule of tasks and make the resource planning decisions that 
maximize the Expected Net Present Value. 
Lakhdar et al. (2006) presented another two-stage SP, by developing a MILP model based on Chance 
Constrained Programming (CCP), for medium-term planning of biopharmaceutical manufacturing 
with uncertainty on the fermentation titers. Later, Lakhdar & Papageorgiou (2008) presented a two-
stage, multi-scenario MILP model for optimizing production plans in a biopharmaceutical 
manufacturing facility, addressing the same technical uncertainty. And more recently, 
Sundaramoorthy et al. (2012), developed a framework for capacity planning, ensuring the 
availability of enough resources for the foreseen product demand (a multi-scenario, multi-period 
MILP formulation, that takes into account uncertainty in the outcomes of clinical trials). 
Although two stage stochastic programming approaches are still the most widely used, with some 
interesting results having been achieved in recent works, these procedures have important 
drawbacks that limit their full application. The need to generate a large number of scenarios 
significantly increases the model size, leading to formulations that are computationally intractable. 
Moreover, decisions such as how many scenarios to generate and which scenarios to generate are 
neither simple nor obvious, and the analysis of each scenario can be a very complex and time-
consuming task. The inevitable increase in the number of scenarios, with the number of products and 
outcomes of the clinical trials, makes in fact this methodology less attractive to tackle many real 
problems. 
Nevertheless, an interesting body of literature dedicated to simulation-optimization based 
approaches has emerged in the past years, to tackle some of the problems arising in new product 
development management. Subramanian et al. (2001) developed an approach (the “SIM-OPT” 
architecture) to address the R&D pipeline management problem. The approach combines 
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mathematical programming and discrete event system simulation, to tackle uncertainty and control 
the underlying risk. The concept of time lines is introduced to accommodate various stochastic 
realizations present in the R&D pipeline. Later, the same authors (Subramanian et al., 2003) extend 
their previous work to include methods for improvement of the stochastic optimization problem 
solution. (Jung et al., 2004) adopted part of the “SIM-OPT” architecture previously developed 
(Subramanian et al., 2001) to determine the safety stock levels under demand uncertainty in a 
chemical process industry supply chain. They have later extended their work to determine the safety 
stock levels in a multi-stage supply chain (Jung et al., 2008). Blau et al. (2004b) also addressed the 
product portfolio selection in the pharmaceutical industry, considering project uncertainties and 
dependencies. The developed approach combines a discrete event simulation with a genetic 
algorithm to select the optimal sequence of projects that maximizes the expected economic returns. 
(Choi et al., 2004) addressed the stochastic Resource-Constrained Project Scheduling Problem 
(RCPSP) using a discrete-time Markov chain for modeling uncertainties in task duration, cost and 
task results. A dynamic programing formulation, in a heuristically confined state space, was 
developed to solve the problem. (Rajapakse et al., 2005) developed a decision-making tool based on 
discrete event simulation to predict process and business outcomes of the biopharmaceutical drug 
development process. Wan et al. (2006a) developed a simulation based optimization approach to 
address multi-stage capacity expansion problems for risk management in the pharmaceutical 
product pipeline. (Varma et al., 2008a) also developed a computational framework (SIM-OPT), based 
on a combination of discrete event simulation and mixed integer programming, to address the joint 
optimization of scheduling and resource allocation decisions in the context of pharmaceutical R&D 
pipelines. More recently, Perez-Escobedo et al. (2012) developed a simulation-optimization 
approach combining a multi-objective Genetic Algorithm optimization framework coupled with a 
discrete event simulator to address the portfolio management and scheduling of new drugs in the 
pharmaceutical industry. In the same year, Chen et al. (2012a) addressed the clinical trial supply 
chain management problem, with a simulation-optimization framework that combines patient 
demand simulation, stochastic demand forecasting, a mathematical programming to optimize the 
production and distribution cost, and discrete event simulation to capture uncertainties. 
Notwithstanding the important contributions of the above papers, most of the simulation-
optimization approaches have been developed to address the R&D pipeline management and 
resource allocation (including portfolio selection and task scheduling decisions) and not the process 
design and production planning decisions at facility level (as addressed in this work). Moreover, the 
effect of resource sharing due to processing in the same plant products under development and 
products in commercialization, as well as the long-term capacity investment decisions (including 
scale-up analysis), are seldom considered in these works. 
It seems clear that there is an evident scarcity of research in sound alternatives to the two-stage SP 
for simultaneously addressing process design and planning decisions, under market and technical 
uncertainties. 
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An alternative seems to be MCS (as proposed in this work), used to determine the impact of the 
uncertainty parameters, through the estimation of their probability distributions. Bassett et al. 
(1997) developed a framework for including uncertainty parameters into a general aggregate 
production planning procedure, or resource constrained scheduling problems, using MCS. The 
framework does not determine a specific schedule, but instead it determines robust operating 
policies that support the decision-making process. Farid et al. (2005) also used MCS to model 
technical and market uncertainties of biopharmaceutical batch manufacturing processes, based on a 
hierarchical framework. More recently, Eberle et al. (2014) proposed a framework for measuring and 
improving the production lead time of pharmaceutical processes, with MCS being applied to predict 
future total lead time based on probabilistic distributions. At the same time, Kaminsky & Yuen (2014) 
developed a model to address the problem of capacity investments during clinical trials, using a 
Bernoulli process with unknown rate. Through this model, the company re-evaluates its capacity 
investment strategy, as information about the potential success of the product is continually updated 
via the results of the clinical trials. 
In the current work, an innovative approach to solve the product-launch planning problem in the 
pharmaceutical industry, under technical and market uncertainty is proposed. A mixed integer linear 
programming (MILP) model, incorporating Monte Carlo simulation (MCS), is developed for 
optimizing the process design decisions (process-unit allocation, scale-ups, and capacity planning) 
and for production planning. The proposed framework allows a deep investigation of a large number 
of possible values for the uncertainty parameters (instead of just scenarios) and provides a 
comprehensive analysis and assessment of the risks associated with these parameters.  
3.3. Problem Statement 
In order to increase economies, pharmaceutical production plants typically operate in batch and 
multi-purpose production systems, simultaneously processing, in the same plant, commercial and 
pilot scale (under development) products. In this production mode, a great variety of products can 
be produced by sharing all available resources (including processing units, raw materials, 
intermediaries, and utilities) with the same or different sequences of operations (Floudas & Lin 
(2004), Barbosa-Póvoa (2007)). Even if continuous manufacturing is currently a developing and 
promising area in the pharmaceutical industry, batch operating modes still prevail in this industrial 
sector (see Lee et al. (2015)). 
We will therefore assume that, to adequately meet the demand requirements, plant resources are 
shared between these two types of products, with capacity expansions expected to accommodate this 
simultaneous production. Nevertheless, capacity expansions for the products in commercialization 
are, in general, highly undesirable. Not only because of the high costs involved in changing a 
production process that has already gained regulatory approval, but also because of the time 
consuming procedure of revalidating the process, whenever a modification is made. Therefore, the 
 
3. Stochastic product launch planning problem: A simulation-optimization approach 
73 
 
model developed in this work will only allow capacity increases associated to the products under 
development.  
The product development process considered here encompasses the three clinical trials phases and 
ends with the regulatory approval (of both product and production process) and the product launch. 
In a typical pharmaceutical company, the development phase comprises a portfolio of products that 
are in different stages of development (different clinical trial phases), at any given time. Although the 
proposed model could be easily adapted for this situation, for the sake of clearness we will assume 
that a known set of products reaches phase I of the clinical trials at the same time, and that the 
optimal production plan is determined considering the probabilities of success of each product, at 
each phase of the clinical trials.  
To accommodate all phases of the clinical trials, a planning horizon with several years is divided into 
equal time intervals (𝑡 ∈ 𝐇). Due to the long time horizon imposed by clinical trials, demand 
uncertainty is considered for both types of products. For the products under development, 
uncertainty arises from two main sources: (i) outcomes of the clinical trials (pass/fail outcomes); and 
(ii) demand variability mainly due to patient drop out during the trials progress. 
Moreover, lot traceability is also modelled in this work, due to its importance for the pharmaceutical 
industry. Nevertheless, a distinction should be made between lots and task-batches. According to 
Moniz et al. (2013a), the term “lot” refers to the total amount (quantity) of stable intermediary or 
final product that is produced following the known recipe (that includes the set of tasks, processing 
units, and materials). On the other hand, “task-batches” are limited by the capacity of the processing 
units and correspond to the amount of material produced by each task (tasks are elements of the 
production process of a lot). Thus, in order to ensure lot traceability, lots are associated to all 
materials, including raw materials, intermediaries and final products. In this work, lots are defined 
by the starting raw materials, with the availability of these materials being limited by predetermined 
lot-sizes. The model will select some of these lot-sizes in order to achieve the best trade-off between 
those sizes and the operational costs associated to the capacities of the processing units needed to 
process them.  
In terms of storage policies, it is assumed that in each period, storage is only allowed for the final 
products in order to accommodate the demand variability. For the products under development, the 
excess of final product at the end of each clinical trial phase must be considered as wastage and 
discarded, since it cannot be reused. Thus, a critical balance between the amounts required for the 
trial and the additional costs associated with the leftovers at the end of each clinical trial, should be 
achieved by the model. 
Regarding the production yields, a distinction between the two types of products is also made. For 
those under development, lower levels of production yields are considered due to their still 
premature manufacturing process when compared with the products already in commercialization. 
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The main goal of this planning process is to determine the “optimal” production plan, the process 
design, and production scale-ups for a set of products (𝑝 ∈ 𝑃), ensuring that all demand requirements 
are fulfilled. Because failures in the deliveries to the trials seriously compromise the time-to-market 
and the payback of the investments, we assume that all the demand requirements will be fulfilled for 
the under development products. Therefore, the problem addressed in this work is formally defined 
as follows. 
Given:  
(i) a fixed time horizon, discretized into several time periods of equal duration (𝑡 ∈ 𝐇); 
(ii) a set of under development products entering clinical trials (p ∈ 𝐏U);  
(iii) a set of products already in commercialization (𝑝 ∈ 𝐏C); 
(iv) the recipes of each final product (𝑝 ∈ 𝐏); 
(v) the lot sizes available for the raw materials of each product (𝑚 ∈ 𝐖𝑝);  
(vi) the set of processing units initially installed in the plant (𝑒 ∈ 𝐄); 
(vii) the maximum and minimum capacities of each processing unit; 
(viii) the task suitability for every processing unit and the respective processing times; 
(ix) the probabilistic distributions of the product demand; 
(x) the probabilities of success of the under development products in each clinical trial 
phase; 
(xi) all the operational and investment costs associated to each task and processing unit, as 
well as the sales prices of each product; 
the key decisions for the product launch production planning problem are:  
(i) best set of processing unit types for each process; 
(ii) size and timings of scale-ups; 
(iii) amount (quantity) to produce in each time period; 
(iv) how much to store in each time period; 
(v) capacity extension requirements for the under development products; 
in order to maximize the Net Present Value (NPV) of the company operations related to these 
projects. 
In light of the general decision-making reference framework proposed in the previous chapter, the 
problem being addressed can be positioned in the framework as depicted in Figure 3.2. 
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Figure 3.2 Problem positioning whithin the general refernce framework. 
3.4. Proposed Method 
3.4.1. A two-step MCS framework 
The conceptual framework developed in this work integrates a MILP model with a two-step MCS. The 
MCS component randomly samples a large number of instances of product demand and outcomes of 
the clinical trials, until a stopping criterion is met. For each of these instances, the MILP model is 
solved and an optimal solution is obtained. The uncertainty parameters are randomly sampled from 
their given probabilistic distributions. Since normal distributions have been often used to capture 
the essential characteristics of product demand uncertainty (Wellons & Reklaitis (1989), Petkov & 
Maranas (1997), Gupta & Maranas (2003)), the normality assumption is also considered in this work. 
On the other hand, to model the uncertainty associated with the outcomes of the clinical trials, the 
probability of success of each product, at the end of the trial phases, is given by Bernoulli 
distributions, since there are only two possible results of the clinical tests: “success” or “failure”.  
For the products already in commercialization, only the demand is randomly sampled, but for those 
under development both uncertainty parameters (product demand and clinical trial outcomes) are 
randomly generated, in a two-step procedure performed for each clinical trial phase (see Figure 3.3). 
The random sampling for the product demand (step 1) is performed for each time period, while the 
sampling for the outcomes of the clinical trials (step 2) is performed only at the end of each clinical 
trial phase, as illustrated in the detailed diagram of Figure 3.4 (note that the procedure starts with 
the definition of the number of iterations to be performed). 
In step 2, if the outcome of the clinical trial test is “pass”, step 1 is performed again with the random 
generation of a value for the product demand for the next clinical trial phase, and so on. However, if 
the outcome is “fail”, the two-step procedure stops (step 1 of the next trial phase will not be 
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performed) and the MILP model will be run considering that the demand for that product is zero for 
the following periods (this meaning that the development of this product will be abandoned). This 
procedure is executed for all products in each MCS iteration, and the MILP model is run considering 
the product demands obtained by this procedure. 
At the end of the MCS procedure, we get the probability density function for the objective function, 
and the results for the probabilistic occurrence of the decision variables can be derived. These results 
are then analysed to support decision-making concerning the process design configuration, as well 
as the capacity and planning decisions during product development.    
 
Figure 3.3 Schematic representation of the two-step MCS framework. 
 
 
Figure 3.4 The two-step MCS procedure. 
3.5. MILP Model 
The optimal plan will be determined considering that resources are shared among the production of 
products under development and the production of products already in commercialization, over a 
planning horizon of several years. Thus, detailed time and task-sequencing constraints will not be 
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considered in this model. All material requirements, as well as all storage levels and production 
yields, will be precisely defined through the model parameters and decision variables.  
The process design configuration and planning decisions are represented by the following decision 
variables: 
• the process/unit assignment binary variables 𝑌𝑝𝑙𝑒𝑡 , that are equal to 1 if product p of lot l is 
assigned to processing unit e in period t; 
• the task batch-size decisions are associated to continuous variables 𝐵𝑘𝑙𝑡 , denoting the amount 
to be produced by each task k and lot l at period t; 
• the number of instances of each task k of lot l are defined through the integer variables 𝑁𝑘𝑙𝑡  
for each period t; 
• the lot-size decisions are modelled by integer variables 𝐿𝑚𝑙𝑡 , that define the number of lots of 
each lot-size l from a set of pre-determined lot sizes, for the starting raw material 𝑚 ∈ 𝐖𝑝 at 
each period t; 
• the excess resource continuous variables 𝑅𝑚𝑙𝑡 , that define the total amount available of 
material m of lot l at each period t; 
• the final product waste continuous variables 𝑊𝑚𝑙|𝑡=𝑡𝑖
𝐹, that denote the leftovers of the under 
development final products m (m  PU) at the end of each clinical trial i (the final product 
that was not used during the clinical trial i and must be destroyed since it cannot be reused); 
• deliveries are given by the continuous variables 𝐷𝑚𝑙𝑡 , denoting the total amount of material 
m (final product) of lot l delivered at period t; 
• the unused capacity continuous variables 𝐹𝑒, that define the amount of capacity not used by 
product p (products in commercialization) in processing unit e, and that will be available for 
the production of under development products; 
• the capacity extension integer variables 𝐴𝑒𝑡 , that define the number of additional processing 
units e to be added to the plant at period t. 
The complete formulation encompasses constraints (3.1) to (3.15) and the objective function (3.16), 
as presented in the next section. 
3.5.1. Mathematical formulation 
NOTATION 
Indices 
e Processing unit 
i Clinical trial phase 
k Processing task 
l Lot 
m Material (may be a raw material, an intermediary or a final product) 
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p Final product 
t Period 
Sets 
E Processing units 
Ep Processing units associated with product p 
Em Processing units associated with raw material 𝑚 ∈ 𝐖 
H Planning horizon 
Hi Time interval of the clinical trial phase i: Hi = {tiinitial, …, tiFinal}  
I Clinical trial phases 
K Processing tasks 
Km Processing tasks associated with material m 
𝐊𝑒
𝑪
 
Processing tasks of products in commercialization associated with processing unit 
e 
𝐊𝑒
𝑼
 Processing tasks of products under development associated with processing unit e 
L Lots 
Lm Lots associated with raw material 𝑚 ∈ 𝐖  
M Materials including raw materials, intermediaries and final products 
P Final products 
PC Final products in commercialization 
PU Final products under development 
W Raw materials 
Wp Raw materials of final product p  
Parameters 
𝑘𝑚 
Production rate (positive value for production, and negative value for consumption) 
of each task k and material m 
𝜏 Length of each period  
𝜏?̅?𝑒
𝑣𝑎𝑟 Time required per unit of processed material 
𝜏𝑐ℎ𝑔  Changeover time 
?̂?𝑒  Installation and commissioning time of each processing unit e added to the plant 
𝛽𝑘𝑒
𝑚𝑎𝑥/ 
𝛽𝑘𝑒
𝑚𝑖𝑛 
Maximum and minimum capacity for task k in processing unit e 
𝜇𝑚
𝑚𝑎𝑥  Maximum availability of material m 
𝜇𝑚
𝑖𝑛𝑖𝑡𝑖𝑎𝑙  Initial availability of material m 
𝜎𝑚𝑙  Lot size of lot l associated to raw material 𝑚 ∈ 𝐖  
𝜔𝑚𝑡  Product demand for material m at period t 
𝜃𝑖
𝐼 /𝜃𝑖
𝐹  Initial and final times for clinical trial phase i 
𝛾𝑚𝑡  Maximum number of lots for raw material  𝑚 ∈ 𝐖  at period t 
𝛿𝑒
𝑖𝑛𝑖𝑡  Number of processing units e initially available 
𝜋𝑚 Sales price for materials m  P  
𝛼𝑘
𝑜𝑝𝑒𝑟.
 Operational cost of each processing task k 
𝛼𝑚
𝑠𝑡𝑜𝑟. Storage cost for each material m 
𝛼𝑚
𝑤𝑎𝑠𝑡𝑒  Cost of disposing each unit of material m 
𝛼𝑒
𝑐ℎ𝑔
 Changeover costs associated to each processing unit e 
𝛼𝑚𝑙
𝑙𝑜𝑡 𝑠𝑖𝑧𝑒  Cost associated with the lot size l for raw material 𝑚 ∈ 𝐖 
𝛼𝑒
𝑖𝑛𝑣𝑒𝑠𝑡. Investment costs for each new additional processing unit e  
Continuous variables 
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𝐵𝑘𝑙𝑡  Batch size of task k of lot l at period t, expressed in kg  
𝐷𝑚𝑙𝑡  Amount delivered of each material m of lot l at period t, expressed in kg 
𝑅𝑚𝑙𝑡  Excess resource for each material m of lot l at each period t, expressed in kg 
𝑊𝑚𝑙|𝑡=𝑡𝑖
𝐹  
Excess amount of final product under development (m  PU) of lot l considered 
waste at the end of each clinical trial i (𝑡 = 𝑡𝑖
𝐹), expressed in kg 
𝐹𝑒 Capacity unused for each processing unit e, expressed in hours 
Binary variables 
𝑌𝑝𝑙𝑒𝑡  =1 if product p is assigned to processing unit e and lot l, at period t 
Integer variables 
𝑁𝑘𝑙𝑡  Number of instances of task k of lot l at period t  
𝐴𝑒𝑡  Number of additional processing units e to add to the plant at period t 
𝐿𝑚𝑙𝑡  Number of lots l of raw material 𝑚 ∈ 𝐖  at period t 
𝑍𝑝𝑒𝑙𝑡  
Process design variable for each product p of lot l assigned to processing unit e at 
period t 
 
3.5.1.1. Constraints 
 
𝜎𝑚𝑙𝐿𝑚𝑙𝑡  = − ∑ 𝑘𝑚𝐵𝑘𝑙𝑡  
𝑘∈𝐊𝑚
     ∀𝑝 ∈ 𝐏, 𝑚 ∈ 𝐖𝑝, 𝑙 ∈ 𝐋𝑚, 𝑡 ∈ 𝐇 
 
(3.1) 
∑ 𝑌𝑝𝑙𝑒𝑡
𝑒∈𝐄𝑚
≤ 𝐿𝑚𝑙𝑡  ≤  𝛾𝑚𝑡 ∑ 𝑌𝑝𝑙𝑒𝑡
𝑒∈𝐄𝑚
       ∀𝑝 ∈ 𝐏, 𝑚 ∈ 𝐖𝑝, 𝑙 ∈ 𝐋, 𝑡 ∈ 𝐇 (3.2) 
 
𝑌𝑝𝑙𝑒𝑡 + 𝑌𝑝𝑙′𝑒𝑡′ ≤ 1    ∀𝑝 ∈ 𝐏, 𝑒 ∈ 𝐄𝑝, 𝑙, 𝑙
′ ∈ 𝐋𝑚 ∶ 𝑙
′ > 𝑙, 𝑡 ∈ 𝐇, 𝑡′ = {0 … 𝑡} 
 
(3.3) 
 
𝑅𝑚𝑙𝑡 = (𝜇𝑚
𝑖𝑛𝑖𝑡𝑖𝑎𝑙|𝑡=0 ,   𝑅𝑚,𝑡−1|𝑡>0) + (𝜎𝑚𝑙𝐿𝑚𝑙𝑡)|𝑚 ∈ 𝐖 + ∑ 𝑘𝑚𝐵𝑘𝑙𝑡
𝑘∈𝐊𝑚
− 𝐷𝑚𝑙𝑡|𝑚 ∈ 𝐏
− 𝑊𝑚𝑙𝑡|𝑚 ∈ 𝐏𝐔,𝑡=𝜃𝑖
𝐹    ∀𝑚 ∈ 𝐌 , 𝑙 ∈ 𝐋, 𝑖 ∈ 𝐈, 𝑡 ∈ 𝐇 
(3.4) 
 
0 ≤ ∑ 𝑅𝑚𝑙𝑡
𝑙∈𝐋
≤ 𝜇𝑚
𝑚𝑎𝑥       ∀𝑚 ∈ 𝐌, 𝑡 ∈ 𝐇 
 
(3.5) 
 
𝑅𝑚𝑙|𝑡=𝜃𝑖
𝐹 = 0      ∀𝑚 ∈ 𝐏𝐔, 𝑙 ∈ 𝐋, 𝑖 ∈ 𝐈, 𝑡 ∈ 𝐇 
 
(3.6) 
 
∑ 𝐷𝑚𝑙𝑡
𝑙∈𝐋
= 𝜔𝑚𝑡       ∀𝑚 ∈ 𝐏, 𝑡 ∈ 𝐇 
 
(3.7) 
 
𝐷𝑚𝑙𝑡 = 0      ∀𝑚 ∈ 𝐌\𝐏, 𝑙 ∈ 𝐋, 𝑡 ∈ 𝐇 
 
(3.8) 
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𝛽𝑘𝑒
𝑚𝑖𝑛𝑁𝑘𝑙𝑡 ≤ 𝐵𝑘𝑙𝑡 ≤ 𝛽𝑘𝑒
𝑚𝑎𝑥𝑁𝑘𝑙𝑡       ∀𝑒 ∈ 𝐄, 𝑘 ∈ 𝐊𝑒 , 𝑙 ∈ 𝐋, 𝑡 ∈ 𝐇 
 
(3.9) 
𝑌𝑝𝑙𝑒𝑡 ≤ 𝐵𝑘𝑙𝑡 ≤ 𝑏𝑖𝑔𝑀𝑌𝑝𝑙𝑒𝑡      ∀𝑝 ∈ 𝐏, 𝑒 ∈ 𝐄, 𝑘 ∈ 𝐊𝑒 , 𝑙 ∈ 𝐋, 𝑡 ∈ 𝐇 
 
(3.10) 
∑ ∑ 𝐵𝑘𝑙𝑡
𝑘∈𝐊𝒆
𝑪
𝜏?̅?𝑒
𝑣𝑎𝑟
𝑙∈𝐋
+ ∑ ∑ 𝑌𝑝𝑙𝑒𝑡
𝑝∈𝐏𝐶
𝜏𝑐ℎ𝑔
𝑙∈𝐋
− 𝜏𝑐ℎ𝑔 + 𝐹𝑒 ≤ 𝛿𝑒
𝑖𝑛𝑖𝑡  𝜏      ∀ 𝑒 ∈ 𝐄, 𝑡 ∈ 𝐇  
(3.11) 
∑ ∑ 𝐵𝑘𝑙𝑡
𝑘∈𝐊𝒆
𝑼
𝜏?̅?𝑒
𝑣𝑎𝑟
𝑙∈𝐋
+ ∑ ∑ 𝑌𝑝𝑙𝑒𝑡
𝑝∈𝐏𝑈
𝜏𝑐ℎ𝑔
𝑙∈𝐋
− 𝜏𝑐ℎ𝑔 ≤  𝐹𝑒 + ∑ 𝐴𝑒𝑡′𝜏 
𝑡−1
𝑡′=0
+ 𝐴𝑒𝑡(𝜏 − ?̂?𝑒)      ∀ 𝑒 ∈ 𝐄, 𝑡 ∈ 𝐇 (3.12) 
𝑍𝑝𝑙𝑒𝑡 ≥  𝑌𝑝𝑙𝑒𝑡 −  𝑌𝑝𝑙𝑒,𝑡−1     ∀𝑒 ∈ 𝐄, 𝑝 ∈ 𝐏𝑒 , 𝑙 ∈ 𝐋, 𝑡 ∈ 𝐇 (3.13) 
∑ 𝑍𝑝𝑙𝑒𝑡
𝑡∈𝐇
≤ 1      ∀𝑒 ∈ 𝐄, 𝑝 ∈ 𝐏𝑒 , 𝑙 ∈ 𝐋, 𝑡 ∈  𝐇 (3.14) 
𝑅𝑚𝑙𝑡 ∈ ℝ+         ∀𝑚 ∈ 𝐌, 𝑡 ∈ 𝐇 
𝐵𝑘𝑙𝑡 ∈ ℝ+         ∀𝑘 ∈ 𝐊, 𝑡 ∈ 𝐇 
𝑊𝑚𝑙𝑡 ∈ ℝ+         ∀𝑚 ∈ 𝐏
𝐔, 𝑡 ∈ 𝐇 
𝐷𝑚𝑙𝑡 ∈ ℝ+         ∀𝑚 ∈ 𝐏, 𝑡 ∈ 𝐇 
𝐹𝑒 ∈ ℝ+         ∀𝑝 ∈ 𝐏
𝐂, 𝑒 ∈ 𝐄 
𝑁𝑘𝑙𝑡 ∈ ℤ+         ∀ 𝑘 ∈ 𝐊, 𝑡 ∈ 𝐇 
𝐿𝑚𝑙𝑡 ∈ ℤ+         ∀ 𝑚 ∈ 𝐖, 𝑙 ∈ 𝐋𝑤 , 𝑡 ∈ 𝐇 
𝑌𝑝𝑙𝑒𝑡 ∈ {0, 1}         ∀𝑝 ∈ 𝐏, 𝑒 ∈ 𝐄, 𝑡 ∈ 𝐇 
𝐴𝑒𝑡 ∈ ℤ+          ∀𝑒 ∈ 𝐄, 𝑡 ∈ 𝐇 
𝑍𝑝𝑙𝑒𝑡 ∈ ℤ+          ∀ 𝑝 ∈ 𝐏, 𝑒 ∈ 𝐄, 𝑡 ∈ 𝐇 
(3.15) 
 
Constraints (3.1) to (3.3) are used to model the lot-size and scale-up decisions based on the starting 
raw material of each final product p. Constraint (3.1) guarantees that the total amount available of 
raw material  𝑚 ∈ 𝐖 of lot l at each time period is equal to the total amount consumed by the 
respective tasks 𝑘 ∈ 𝐾𝑚  of lot l. The parameters 𝜎𝑚𝑙  on the left hand side of this constraint represent 
the lot-sizes of lot l for each raw material 𝑚 ∈ 𝐖, and the 𝑘𝑚 parameters on the right hand side take 
a negative value corresponding to the consumption rate of each task k and raw material m. 
Constraints (3.2) bound the number of lots of each lot-size l (𝐿𝑚𝑙𝑡) to a given maximum value (𝛾𝑚𝑡) 
for each starting raw material m associated with final product p (𝑚 ∈ 𝐖𝑝) and period t. These 
constraints also guarantee that the number of lots will be zero if no product p of lot l is assigned to 
processing unit e, at period t (i.e. 𝑌𝑝𝑙𝑒𝑡 = 0). Finally, constraints (3.3) model the scale-up decisions, 
by ensuring that the size of the lots never decreases during the planning horizon.  
The excess resource balances are defined by constraints (3.4) in which the continuous variables 𝑅𝑚𝑙𝑡  
denote the material availability over time, for each material m of lot l. The parameters 𝜇𝑚
𝑖𝑛𝑖𝑡𝑖𝑎𝑙   
represent the initial material availability for each material m (being 0 for final products and 
intermediaries). The second term of constraints (3.4) is activated only for raw materials, and it 
defines the starting raw material quantity, that is limited by the given lot-sizes (𝜎𝑚𝑙). The total 
amount produced or consumed by each task is defined by the third term of these constraints in which 
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the parameters 𝑘𝑚 denote the proportion of material that is consumed (negative values) or 
produced (positive values) during the execution of the task. 
This modelling approach has been introduced by Pantelides (1994). The continuous variables 𝐷𝑚𝑙𝑡  
define the amount of material delivered in each period, being 0 for all materials except final products 
(m  P). The last term will be activated only for products under development, and it corresponds to 
the leftovers of the final product, at the end of each clinical trial phase i (to be considered as wastage).  
Constraints (3.5) define the excess resource capacity for each material and time interval, bounded by 
the given maximum materials availability 𝜇𝑚
𝑚𝑎𝑥 . Furthermore, since the excess amount of final 
products under development at the end of each clinical trial phase must be discarded and cannot be 
used in the following periods, expression (3.6) is introduced to ensure that the material availability 
of these products is 0 at the end of each clinical trial phase.  
Constraints (3.7) define the production requirements to meet the given demand (𝜔𝑚𝑡), and 
expression (3.8) guarantees that only final products can be delivered.  
Constraints (3.9) ensure that the total amount of material processed (𝐵𝑘𝑙𝑡) is bounded by the 
minimum and maximum processing unit capacities (𝛽𝑘𝑒
𝑚𝑖𝑛/ 𝛽𝑘𝑒
𝑚𝑎𝑥). The integer variable Nklt is defined 
as the number of instances (batches) of task k, for lot l, in period t.  
Constraints (3.10) are very similar to constraints (3.2) defined earlier, but even though they are 
necessary, since constraints (3.2) apply only for the starting raw materials m (𝑚 ∈ 𝐖). These 
additional constraints (3.10) are then used to activate the decision variables 𝐵𝑘𝑙𝑡  (total amount 
processed) associated to all tasks k (𝑘 ∈ 𝐊𝑒), and to force those variables to be 0 if no product p of 
lot l is assigned to processing unit e at period t (i.e. 𝑌𝑝𝑙𝑒𝑡 = 0). The  𝑏𝑖𝑔𝑀 represents a very large 
number (in relative terms), and 𝑌𝑝𝑙𝑒𝑡  are the binary variables for process activation. 
Constraints (3.11) and (3.12) define the production capacity, expressed in the total time availability 
for processing unit e and period t. Given that only capacity extensions for products under 
development are allowable in this formulation, a distinction must be done regarding the two types 
of products. Thus, constraints (3.11) denote the production capacity for products in 
commercialization, and constraints (3.12) for products under development. The first summation in 
(3.11) represents the total time required for the execution of tasks k, in which the coefficient 𝜏?̅?𝑒
𝑣𝑎𝑟 is 
known and denotes the time required per unit of processed material. The second summation defines 
the changeover times associated to product and lot changing. Parameter 𝜏𝑐ℎ𝑔  represents the 
changeover time. A third term (𝜏𝑐ℎ𝑔) is added to constraints (3.11) in order to ensure that the number 
of changeovers is equal to the number of products minus one. This is needed to prevent an 
overestimation of the changeover times across adjacent periods in which the last product of the 
previous period is equal to the first product of the following period (Grossmann, 2007). The last term 
(𝐹𝑒) expresses the capacity of each processing unit e unused by the products in commercialization. 
This free capacity will be used as available capacity for the products under development in 
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constraints (3.12). The right hand side of these constraints is the total available capacity of each 
processing unit e, in each period. The parameters 𝛿𝑒
𝑖𝑛𝑖𝑡  and 𝜏 are given, and denote respectively the 
number of processing units e initially available at the plant and the length of each period t. In 
constraints (3.12), the left hand side is equal to constraints (3.11), except for the decision variables 
𝐹𝑒, that, in this case, are in the right hand side, as they reflect the available capacity for the production 
of the under development products. However, because this available capacity is very limited, it is 
likely that some adjustments to the process design will be needed, and some capacity extensions 
performed. Accordingly, integer variables 𝐴𝑒𝑡  are introduced in constraints (3.12), to determine the 
additional amount of capacity (expressed in additional time) required for the production of each 
product p (p  PU) in processing unit e. Thus, the second term in the right hand side of these 
constraints refers to the total capacity added in previous periods (t = 0,…,t-1). This term guarantees 
that, if an increase in capacity occurs, the new processing units added to the plant will be available 
during the following periods until the end of the planning horizon. Finally, the last term of these 
constraints denotes the capacity extensions to be performed in period t, also reflecting the time 
required for the installation and commissioning of the added units before they are ready to start 
operating (?̂?𝑒). 
Constraints (3.13) and (3.14) are process design constraints needed to ensure that, after a processing 
unit has been selected for a given process, it cannot leave that process in a given period and be later 
assigned again to the same process (i.e., in a period ahead). Finally, expressions (3.15) are used to 
define the domain of the variables. 
 
3.5.1.2. Objective Function 
As referred above, and in order to reflect in the model the main concerns of the company, we have 
considered as objective function (eq.(3.16)) the maximization of the Net Present Value (NPV) of the 
operations related to these projects. This measure depends on the income from sales over the 
planning horizon (INCO) minus the operational costs (OC), storage costs (SC), disposal costs for 
wasted final products (WC), changeover costs (COC), scale-up costs (LC), and investment costs (IC) 
(costs associated with capacity extension): 
max 𝑁𝑃𝑉 = 𝐼𝑁𝐶𝑂 − 𝑂𝐶 − 𝑆𝐶 − 𝑊𝐶 − 𝐶𝑂𝐶 − 𝐿𝐶 − 𝐼𝐶 (3.16) 
Considering the discount factor (𝑑𝑡) given by expression (3.17), where 𝑟 is the interest rate and t the 
period (Bagajewicz, 2008), each term of the objective function (3.16) can be described individually as 
presented below. 
 𝑑𝑡 =
1
(1+𝑟)𝑡
     ∀ 𝑡 ∈ 𝐇 (3.17) 
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The income over the planning horizon results from the final product sales, and is given by expression 
(3.16)a, where 𝜋𝑚 denotes the given sale prices for each material m. 
         𝐼𝑁𝐶𝑂 =  ∑ 𝑑𝑡 ∑ ∑ ∑(𝜋𝑚𝐷𝑚𝑙𝑡)
𝑡∈𝐇𝑚∈𝐏𝑙∈𝐋𝑡∈𝐇
 (3.16)a 
The operational costs are associated with each task k, and are given by expression (3.16)b, where 
𝛼𝑘
𝑜𝑝𝑒𝑟.
is the operational cost of task k. 
𝑂𝐶 =  ∑ 𝑑𝑡 ∑ ∑ ∑(𝛼𝑘
𝑜𝑝𝑒𝑟.𝑁𝑘𝑙𝑡)
𝑡∈𝐇𝑘∈𝐊𝑒𝑙∈𝐋𝑡∈𝐇
 (3.16)b 
Storage costs are also considered in this model, and they are given by eq. (3.16)c, where 𝛼𝑚
𝑠𝑡𝑜𝑟. 
represents the holding costs for each material m. 
𝑆𝐶 =  ∑ 𝑑𝑡 ∑ ∑ ∑(𝛼𝑚
𝑠𝑡𝑜𝑟.𝑅𝑚𝑙𝑡)
𝑡∈𝐇𝑚∈𝐌𝑙∈𝐋𝑡∈𝐇
 (3.16)c 
The costs associated to the disposal of unused final products under development (waste) are given 
by expression (3.16)d. 
𝑊𝐶 =  ∑ 𝑑𝑡 ∑ ∑ ∑(𝛼𝑚
𝑤𝑎𝑠𝑡𝑒𝑊𝑚𝑙𝑡)
𝑡∈𝐇𝑚∈𝐏𝐔𝑙∈𝐋𝑡∈𝐇
 (3.16)d 
The changeover costs are given by eq. (3.16)e, where the given parameters 𝛼𝑒
𝑐ℎ𝑔
 denote the 
changeover costs associated to each processing unit e. 
          𝐶𝑂𝐶 =  ∑ 𝑑𝑡 ∑ ∑ ∑ ∑(𝛼𝑒
𝑐ℎ𝑔𝑌𝑝𝑙𝑒𝑡)
𝑡∈𝐇𝑝∈𝐏𝑒∈𝐄𝑙∈𝐋𝑡∈𝐇
 (3.16)e 
The costs associated to the scale-ups are given by eq. (3.16)f, where 𝛼𝑚𝑙
𝑙𝑜𝑡 𝑠𝑖𝑧𝑒denotes the cost 
associated to the selection of the lot size l for the starting raw material m. 
   𝐿𝐶 =  ∑ 𝑑𝑡 ∑ ∑ ∑(𝛼𝑚𝑙
𝑙𝑜𝑡 𝑠𝑖𝑧𝑒𝐿𝑚𝑙𝑡)
𝑡∈𝐇𝑙∈𝐋𝑤𝑚∈𝐖𝑡∈𝐇
 (3.16)f 
Finally, if a capacity expansion occurs (𝐴𝑒𝑡  > 0), an investment cost must be considered for each new 
processing unit that is added to the plant.  These costs are given by eq. (3.16)g, where the parameters 
𝛼𝑒
𝑖𝑛𝑣𝑒𝑠𝑡. are the investment costs associated to each new processing unit e added to the plant. 
𝐼𝐶 =  ∑ 𝑑𝑡 ∑ ∑(𝛼𝑒
𝑖𝑛𝑣𝑒𝑠𝑡.𝐴𝑒𝑡)
𝑡∈𝐇𝑒∈𝐄𝑡∈𝐇
 (3.16)g  
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3.6. Mathematical Results and Discussion 
3.6.1. Case description 
To validate the proposed framework and demonstrate its applicability, a case was designed based on 
a real problem of the chemical-pharmaceutical industry. In this case, the product portfolio is 
composed by 3 new products (PA, PB, and PC) entering the product development phase, and by 2 
products (PD and PE) already in commercialization. A planning horizon of 5 years is considered, 
discretized into 10 periods of 6 months each (4032 hours for a plant, operating 24 hours a day and 7 
days a week). The demand forecast profiles for the entire planning horizon and for each product are 
presented in Figure 3.5. To accommodate the three phases for the clinical trials, the planning horizon 
is divided, with 1.5 years to conduct each of the clinical trials phases I and II, and with 2 years for 
clinical trial phase III (see Figure 3.5). 
 
 
Figure 3.5 Demand profile for products under development (PA, PB and PC) and products already in 
commercialization  (PD and PE) (Sundaramoorthy et al., 2012) 
All products follow a similar production recipe in which the task sequence, unit suitability, reaction 
yields, and processing times are clearly identified (see Figure 3.6). All processes are composed by 3 
aggregate tasks that can be processed in 3 possible unit types ({R1, R2, R3}, {F1, F2, F3}, and {D1, D2, 
D3}) with different capacities, and different operational and investment costs (see Figure 3.7). These 
tasks have a variable duration (expressed in hour/kg) that is proportional to the batch size. 
Moreover, each product can only be produced in pre-determined lot-sizes, with four different lot-
sizes defined for each product. 
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Figure 3.6 Product recipes (task processing times and process yields) and probabilities of success for the 
products under development and for the products already in commercialization. 
 
 
Figure 3.7 Processing unit types and their maximum and minimum capacities. 
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To reflect the uncertainty of product demand, normal distributions are used with values, per period, 
for the mean and standard deviations, derived from the profiles presented in Figure 3.5. We have 
considered a standard deviation of 30% for the products under development, and 10% for the 
products in commercialization, since less demand variability is expected in this case. On the other 
hand, to capture the uncertainty associated to the clinical trials (pass/fail outcomes), Bernoulli 
distributions are used, considering the success probabilities depicted in Figure 3.6, and based on the 
available information from the literature (Fisher et al., 2015). 
3.6.2. Computational results 
The MILP model was implemented using IBM ILOG CPLEX Optimization studio, version 12.5.1, 
running on an Intel Xeon at 3.33 GHz machine with 24 GB of RAM. As stopping criterion, we 
considered a time limit of 3600 seconds, and an integrality gap of 5%. For the simulation component 
(MCS), an iterative model was also implemented in ILOG/CPLEX, and 1000 iterations were 
performed by randomly generating the uncertainty parameters from given probability distributions 
(normal and Bernoulli distributions). The number of iterations was defined based on a previous 
sensitivity analysis.  
For each iteration, a solution was found and the frequency of occurrence for each decision variable 
was determined and analysed. The MCS for the 1000 iterations took a total of 36 hours to be 
completed, with an average run time, for each iteration, of 129.35 seconds. The integrality gap ranges 
from a minimum of 1.43% to a maximum of 5.0% (according to the stopping criterion referred 
above). The main computational statistics are described in Table 3.1. 
Table 3.1 Computational statistics 
binary 
variables 
integer 
variables 
continuous 
variables 
constraints 
B&B 
nodes* 
optimality gap 
(%)* 
CPU time 
(seconds)* 
1,800 3,890 3,554 29,160 10,356.29 3.8 129.35 
* Average values for the 1000 iterations. 
 
3.6.2.1. NPV analysis 
The results obtained are presented in Figure 3.8, with the NPV histogram and the associated 
probability distribution. The resulting histogram presents a slightly skewed right pattern, due to the 
fact that the NPV highest values occur in the instances in which all products under development 
successfully pass all clinical trial phases, this fact having a very low frequency of occurrence, as it is 
highly unlikely to happen.  
The maximum NPV value obtained was 1.79 x 107 relative monetary units (rmu); the minimum value 
was 1.28 x 107 rmu and the average NPV was 1.50 x 107 rmu. The variation between the average and 
the minimum values is about 14%, which may be more or less penalizing for the company, depending 
on the particular context, the main established goals, and the risk aversion of the decision makers. 
On the other hand, the optimal profit for the deterministic reference case, which is based on the 
forecast values illustrated in Figure 3.5 was 1.69 x 107 rmu. According to Figure 3.8, the frequency of 
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occurrence of this value is just 3 in 1000 iterations, and the probability of the profit to be below this 
value is about 98% (see Figure 3.8), this meaning that the deterministic case is very unlikely to occur. 
These results clearly show that the decision-making process for a 5 years capacity planning entails a 
considerable risk if we only consider a deterministic analysis. 
 
 
Figure 3.8 NPV histogram and associated probability distribution. 
 
3.6.2.2. Scale-up analysis 
The determination of the lot-sizes to be produced, and of the scale-ups to be performed are very 
important decisions in the chemical-pharmaceutical industry. From a strict cost point of view, the 
production of larger, fewer lots is more desirable, as demonstrated in (Moniz et al., 2014b). Here, the 
results show that the most frequently selected lot-sizes and scale-ups over the entire planning 
horizon are in accordance with the previous statement, since there is a clear preference for single 
lots, particularly for the under development products. Exceptions occur when the demand is very 
high. Since no backlogs are allowed, when demand is high the model is forced to select several lots of 
a certain size in order to completely meet the product demand.  
The histograms in Figure 3.10 and in Figure 3.11 are for the products under development, and for 
the products in commercialization, respectively. These histograms only present the lot-sizes that are 
more frequently selected by the model in each period. For example, for product PA, at period t=0, all 
the lot-sizes selected by the model are depicted in Figure 3.9. However, only the most frequently 
selected (1L3_200) lot-size was picked for the histogram in Figure 3.10a). This procedure was 
performed for all products and periods. 
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Figure 3.9 Selected lot-sizes for product PA, at period t=0. 
 
When analysing the histograms of both types of products, we can notice that in the first case 
(products under development), there is a considerable decrease in the frequency values in each 
clinical trial phase, this being a direct consequence of the pass/fail probabilities associated to the 
products. For the products in commercialization, this decrease does not occur due to their much 
more stable demand. According to Figure 3.10, the most frequently selected lot-sizes for the products 
under development are: lot 3 and lot 4, for product PA; lot 1 and lot 4, for product PB; and finally, lot 
1, lot 2, lot 3 and lot 4, for product PC. These values correspond to one scale-up for product PA and 
product PB, and three scale-ups for product PC, over the planning horizon. In all the three products, 
we can observe that the scale-ups are closely related to the clinical trial phases, even if this is more 
evident in the case of product PC, because of the higher values of the product demand. In that sense, 
for product PA, it seems reasonable to consider lot 3 for clinical trial phase I, and lot 4 for the other 
two clinical trial phases. For product PB, it is clear that the most suitable lot for phase I is lot 1, and 
lot 4 for the last two clinical trials phases. Finally, for product PC, it seems reasonable to consider lot 
1 for clinical trial phase I, lot 2 and 3 for clinical trial phase II, and lot 4 for clinical trial phase III. On 
the other hand, for products in commercialization (PD, and PE), the larger lot (lot 4) is the most 
frequently selected, due to the larger and more stable values for the product demand. This is 
particularly evident for product PE that presents a higher product demand for almost the entire 
planning horizon. It is worth to notice that the product demand and the total amount processed 
(depicted in Figure 3.10 and in Figure 3.11) correspond to the starting raw materials associated to 
each final product, and derived from the forecasted values presented in Figure 3.5 (considering the 
associated production yields).  
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(a) 
 
 
(b) 
 
(c) 
Figure 3.10 Lot-size and scale-up decisions for products under development: (a) product PA, (b) product PB, 
and (c) product PC. 
 
 
 
(a) 
 
 
(b) 
Figure 3.11 Lot-size and scale-up decisions for products already in commercialization: (a) product PD, and (b) 
product PE. 
Finally, the most likely process design configurations for each product and clinical trial / planning 
period were determined. In the next section, the trade-offs between process design configuration and 
scale-ups are analysed. 
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3.6.2.3. Process design and scale-up analysis 
These results also allow us to identify the sets of processing units associated with the lot-sizes that 
have been selected with higher probabilities. They are presented as histograms in Figure 3.12 (a1, 
b1, c1), and in Figure 3.13 (d1, e1), for the products under development and in commercialization, 
respectively. In this case, the histograms were obtained by considering the three or four most 
frequently selected process configurations. 
We can also see that, when simultaneously considering process design and lot-size configuration, the 
most selected process designs seem to lead to more scale-ups (2 or 3) than in the previous analysis 
(with just scale-ups). This seems to show that the model tends to favor the process design stability 
over scale-ups and lot size increases. This is an interesting result, satisfying some of the main goals 
of the problem, such as the enhancement of process stability, the minimization of process changes, 
and the preservation of its life cycle.  
However, based on these results, it is not possible to guarantee that the most selected process 
configurations in each period / clinical trial phase, are obtained in the same iteration of the 
simulation framework. Thus, in order to minimize possible misinterpretations of the results, a 
robustness measure for each process design configuration was developed. This measure is computed 
for the three or four process designs more frequently selected in each period and reflects the 
percentage in which each process is repeated in more than two periods in the same iteration. These 
results are illustrated in Figure 3.12 (a2, b2, c2) for products under development, and in Figure 3.13 
(d2, e2) for products in commercialization.  
A combined analysis of the two results (frequency histograms and robustness charts) can be used to 
support the decision-making process in a more reliable way. Thus, from this analysis, it seems 
plausible to consider that the process design configuration {R1, F1, D1} is the most suitable for 
product PA, with one scale-up at the end of the clinical trials phase I, from lot 2 (100 kg) to lot 4 (400 
kg). Similarly, for product PB, the process design configuration {R1, F1, D1} seems to be the most 
adequate decision for clinical trials phases I and II, and {R2, F2, D1} for the last clinical trial phase. 
Also in this case, one scale-up occurs, but at the end of clinical trials phase II, from lot 1 (200 kg) to 
lot 4 (1600 kg). Finally, for product PC, it seems reasonable to consider that the most suitable process 
design configuration is {R1, F1, D1} for clinical trials phases I and II, and {R3, F2, D2} for clinical trials 
phase III. Again, one scale-up is expected at the end of clinical trials phase II, from lot 1 (400 kg) to 
lot 4 (3200 kg).  
A similar analysis is made for both products in commercialization (PD and PE). For product PD, the 
best process design configuration seems to be {R1, F1, D1}, associated with lot-size 1 (500 kg) for the 
first two periods (corresponding to the first year), and {R3, F3, D3}, associated with lot-size 4 (3000 
kg) for the rest of the planning horizon. For product PE, the most frequently selected and robust 
process design configuration is {R2, F1, D1} for the entire planning horizon, with one scale-up at the 
end of time period 3 (corresponding to the first 2 years), from lot 2 (1000 kg) to lot 4 (3500 kg).  
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Additionally, from the analysis of the robustness charts, we can see that in most of the cases, a change 
in the lot size is accompanied by a change in the process design configuration for higher capacity 
processing units. This means that lower capacity units tend to be chosen in the lower product 
demand periods / early stages of development, and the higher capacity units are more frequently 
selected in the higher product demand periods / last stages of development. Moreover, the higher 
capacity processing units seem to be more frequently chosen for the products already in 
commercialization. In that sense, the model seems to achieve a good trade-off between the capacity 
of processing units, and both product demand and process stability. Moreover, it is clear from the 
results obtained for the under-development products, that process design configurations and scale-
ups are strongly connected to the success of the clinical trials, this showing the relevance of this 
analysis, that provides reliable information to boost sooner decisions with minimal risk. 
 
(a1) 
 
(a2) 
 
(b1) 
 
(b2) 
 
(c1) 
 
(c2) 
Figure 3.12 Process design selection and solution robustness for the products under development. 
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(d2) 
 
(e1) 
 
(e2) 
Figure 3.13 Process design selection and solution robustness for the products in commercialization. 
When comparing these results to the deterministic case, for the products under development (see 
Table 3.2), we can see that in the earlier stages of development, the process design configurations 
are very similar (with the exception of product PB). This can be explained by the fact that one of the 
initial assumptions in this work was that all the three products enter clinical trial phase I at the same 
time, and also by the low levels of product demand and high capacity availability at this phase. 
However, moving forward through the time horizon, to the clinical trial phases II and III, the 
differences become significant in terms of capacity utilization. It is clear that, in the deterministic 
case, the decisions tend to benefit higher investments in capacity utilization. For example, in phase 
III, in almost all cases, the model selects two or more processing units of the same type in the same 
period. This reveals the conservative nature of the model that, in order not to fail any delivery, tends 
to oversize both the capacity utilization and the resource allocation. Additionally, according to the 
previous NPV analysis, the “deterministic case” is very unlikely to occur, this meaning that this high 
investment in capacity utilization is most likely not to be needed. 
In this context, the approach proposed in this work can provide valuable and robust information to 
support the medium and long-term decision-making process, in what concerns production planning 
and process design configurations, for new drug development. Even if this approach does not give a 
unique specific solution to the addressed planning problem, it provides robust guidelines for 
effective decision making, based on several possible solutions, and considering a highly stochastic 
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environment. It also supports the evaluation of the available solutions, considering the process 
design configurations and their maintenance throughout the entire life-cycle of the possible new 
commercial drugs. 
Table 3.2 Deterministic process design results for the under-development products 
 Product PA  Product PB  Product PC 
 t Process  t Process  t Process 
P
h
a
se
 I
 0 D1L2_F1L2_R1L2  0 D1L4_F2L4_R1L4_R2L4  0 D1L1_F1L1_R1L1 
1 D1L2_F1L2_R1L2  1 D1L4_F3L4_R1L4  1 D1L1_F1L1_R1L1 
2 D1L2_F1L2_R1L2  2 -  2 D1L1_F1L1_R1L1 
P
h
a
se
 I
I 3 D1L4_F1L4_R1L4  3 D2L4_F2L4_R1L4  3 D1L1_F1L1_R1L1_R2L1 
4 D1L4_F1L4_R1L4  4 D2L4_F2L4_R1L4  4 D2L1_F1L1_R1L1_R2L1 
5 D1L4_F1L4_R1L4_R2L4  5 D2L4_F1L4_F2L4_R1L4  5 D2L1_F2L1_R1L1_R2L1 
P
h
a
se
 I
II
 6 D1L4_F1L4_R1L4_R2L4_R3L4  6 D1L4_F1L4_F2L4_R1L4_R2L4  6 D2L1_F2L1_R1L1_R2L1 
7 D1L4_F1L4_R1L4_R2L4_R3L4  7 D1L4_F1L4_F2L4_R1L4_R2L4  7 D2L2_F2L2_R1L2_R3L2 
8 D1L4_F1L4_R1L4_R2L4_R3L4  8 D1L4_F1L4_F2L4_R1L4  8 D2L2_F2L2_R1L2_R2L2 
9 D1L4_F1L4_R1L4_R2L4  9 D1L4_F1L4_R1L4  9 D2L2_F2L2_R2L2 
 
3.6.2.4. Capacity extensions and inventory analysis 
In the case under analysis, the initial capacity appears to fit the production requirements, since 
capacity extensions over the entire planning horizon are negligible. In fact, the most significant 
capacity extensions occur for the reactors, particularly for unit R1. Figure 3.14 shows the histogram 
(a) and the average capacity extensions in kilograms (b) for the equipment type “reactor”. The most 
substantial capacity extension occurs in the first period, with a probability of occurrence of just 5.5% 
in the 1000 iterations, this representing an average capacity increase, in the same period, of just 28.5 
kg. 
 
(a) 
 
(b) 
Figure 3.14 Capacity extension for reactors: (a) frequency of occurrence of a capacity extension, and (b) 
capacity extension expressed in average of additional capacity in kg, over the 1000 iterations. 
On the other hand, when analysing the inventory levels shown in Figure 3.15, we can see these values 
are not significant (except for the initial periods when more capacity is available), when compared 
to the average product demand values presented in Figure 3.5.  The model not only minimizes the 
amount stored, but also maintains it relatively stable over the entire planning horizon, for all the 
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products (despite the increase in product demand over time). Note that for the products under 
development (PA, PB, and PC), the inventory drops to 0.0 kg at periods t=2, t=5, and t=9. This is due 
to the fact that the leftovers at the end of each clinical trial cannot be reused and therefore they are 
treated as waste and considered discarded. The average of the wastage levels, for each product under 
development, is shown in Figure 3.16. 
 
Figure 3.15 Average levels of inventory over the entire 
planning horizon, for each product. 
 
Figure 3.16 Wastage levels for the products under 
development, at the end of each clinical trial phase. 
 
These results show that the model is handling well the trade-off between capacity investments and 
inventory requirements. Moreover, since the model minimizes both types of costs, in order to keep a 
relatively stable inventory level over the planning horizon, the additional capacity needs are fulfilled 
by the smallest and cheapest equipment (R1). In this way additional flexibility is added to the plant. 
Finally, the average values of wastage shown in Figure 3.16 are really not significant, in particular for 
periods 5 and 9, with values around 1% and less than 0.5% of the average amount delivered 
respectively, revealing an efficient resource utilization (this aspect deserving to be further explored 
in future work). Furthermore, according to Figure 3.16, the values of wastage are decreasing over the 
planning horizon, even if the amounts delivered are increasing (contrary to the inventory levels that 
remain relatively stable), this denoting a good wastage management by the model.  
3.6.3. Two-step MCS framework Extension 
In this section an improvement is proposed to the previously developed methodology, in order to 
include an additional important source of uncertainty: the uncertainty in processing times. This 
extension has a twofold goal: firstly, to assess the easiness of incorporation and solving 
simultaneously additional sources of uncertainty within the developed approach, and secondly to 
determine the impact of considering simultaneously the additional uncertainty in processing times. 
The two-step MCS framework incorporating the additional source of uncertainty is depicted in Figure 
3.17, with the dark grey box highlighting the contribution of this section to the original framework.   
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Figure 3.17 Two-step MCS framework extended. 
As in the original framework, to model the variability in product demand and in the clinical trials, 
normal and Bernoulli distributions are considered respectively, while for the processing times 
variability, uniform distributions are considered. The uniform distribution has been widely used in 
the literature to capture the task processing times uncertainty as it is assumed to be a good 
approximation of its behaviour (Bassett et al., 1997; Subramanian et al., 2000; Chu et al., 2015a). 
Similarly to the previous description, in the case of the products already in commercialization, a 
simple random sample is computed in each iteration, but in this case for both: the product demand 
in each period, and the processing time of each task. For the products under development, the 
simulation framework starts with the random generation of the processing time of each task, and 
then the two-step sampling procedure is executed as described previously (see section 3.4) for the 
random generation of the product demand and clinical trials outcomes.  
3.6.3.1. Computational results 
For the sake of comparison, the same illustrative example described earlier (section 3.6.1) including 
the respective parameter values are used here to validate the extended framework. Regarding the 
uniform distribution for the processing times, a symmetric deviation of  33% around the average 
values was assumed, for both types of products. 
The MILP model and the MCS component were implemented using IBM ILOG CPLEX Optimization 
studio, version 12.6.0, and the results were obtained running the extended MCS framework (Figure 
3.17) for 1000 iterations. The complete simulation took about 93 hours with an average run time for 
each iteration of 335.60 seconds, and an average integrality gap of 3.86%. As in the original case, the 
results (objective function and decision variables) are presented as histograms and probabilistic 
distributions. 
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Regarding the objective function, Figure 3.18 shows the values obtained for the NPV, with the 
maximum value for the NPV observed under uncertainty being 1.78 x 107 relative monetary units 
(rmu), with a minimum value of 1.27 x 107 rmu, and an average of 1.49 x 107 rmu. These values are 
very similar (slightly lower) to those obtained without considering uncertainty in processing times. 
Not only the NPV values, but also the slightly skewed right pattern of the histograms are identical 
(the differences are less than 1%).  
This result is natural, since the major impact of uncertainty comes from the clinical trials “pass”/“fail” 
variability, leading to a further development of the product until its commercialization or to its 
abandonment, with the termination of the development process and the loss of all the investments 
made so far. Therefore, the effect of the additional uncertainty in processing times is almost 
unnoticed in the NPV values.  
 
 
Figure 3.18 NPV histogram and probability distribution. 
 
Nevertheless, regarding the process design, scale-up, and capacity extensions decisions, some 
relevant differences arise when considering the uncertainty in the processing times. Concerning the 
process design and scale-up results, the main difference occurs in the last periods of the planning 
horizon, with the selection of processing units with higher capacities in almost all the products 
considered. These results are particularly evident for the product PC (under development) as 
depicted in Figure 3.19.  
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(a1) 
 
(a2) 
 
(b1) 
 
(b2) 
 
(c1) 
 
 
(c2) 
Figure 3.19 Results for the products under development including uncertainty in processing times: (a) 
process design selection; (b) solution robustness. 
 
Figure 3.19 and Figure 3.20 present the most frequently selected set of processing units associated 
with lot-sizes, as well as the “solution robustness” as previously defined (see section 3.6.2.3), 
considering the additional uncertainty in processing times. Comparing these results with the 
previous ones obtained without considering the uncertainty on processing times (please refer to 
Figure 3.12 and Figure 3.13 in sub-section 3.6.2.3), we can state that when considering this additional 
uncertainty, scale-ups tend to occur earlier and associated with processing units of higher capacity. 
This seems to happen in almost every product, as it is the case for instance of product PC in which, a 
scale-up from lot-size L1 (400 kg) to L4 (3200 kg) occurs from clinical trial phase I to phase II, with 
the processing units also increasing in capacity from R1_F1_D1 to R3_F3_D3. When not considering 
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uncertainty in processing times, the combined analysis of frequency and robustness for product PC 
leads to the selection of lot-size L1 and processing units R1_F1_D1 for the clinical trial phase II. In 
this case, the equivalent scale-up will only occur from phase II to phase III (Figure 3.12 (c1) and (c2)). 
In what concerns to the products already in commercialization, a similar analysis is found in the case 
of product PE. It is observed that, not only the scale-up from L2 to L4 occurs earlier, but also the 
equipment sizes increase in all processing units. 
An exception seems to be the product PD, in which the analysis of the solution robustness depicted 
in Figure 3.20 (a2) indicates a scale-up later then its equivalent for the case that does not consider 
the uncertainty in processing times.  
 
(a1) 
 
(a2) 
 
(b1) 
 
 
(b2) 
Figure 3.20 Results for the products already in commercialization including uncertainty in processing times: 
(a) process design selection; (b) solution robustness. 
 
Finally, concerning the capacity extension, there are also some differences. Although the overall 
observed capacity extensions for both cases are not significant occurring almost exclusively for 
reactor R1 (Figure 3.21), when introducing uncertainty in processing times this has a significant 
increase of about 56% on average. The results obtained for the two situations are compared in Figure 
3.22 (these are average values for the 1000 iterations). 
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Figure 3.21 Capacity extension frequency for the processing unit type “Reactors” considering uncertainty 
in processing times. 
 
 
Figure 3.22 Capacity extension for reactor R1, with and without uncertainty in processing time. 
These results do therefore provide interesting information on the risks of the decision-making 
process if not all relevant uncertain parameters are taken into account. It is clear, that uncertainty in 
processing times is not negligible, even in situations where other types of uncertainty are present. 
Although, the impact of the processing time variability in the NPV is not significant, the results show 
that it will inevitably affect the decision-making process, by changing the best strategies in what 
concerns process design configuration, and times and sizes of scale-ups. This could be explained by 
the fact that the processing time has a strong influence on the capacity availability since it is 
expressed in available processing time. In this way, adding uncertainty to the processing times means 
that will be scenarios in which the processing times are higher than the average values, resulting in 
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a greater need for production capacity. This may also explain the increase observed in the average 
computational run time in each iteration. 
3.7. Conclusion 
This section presents an innovative approach, combining a MILP model and a two-step MCS 
framework, to address the product-launch planning problem, considering uncertainty on the product 
demand and on the pass/fail clinical trial tests. The MCS component explores the effects of both types 
of uncertainty, based on normal and Bernoulli distributions, embedded in a two-step sampling 
procedure. Later the approach is expanded to also include the uncertainty on processing times, in 
order to assess its implications on the proposed methodology and its impacts on the overall decision-
making process. In this case, the Monte Carlo simulation is performed based on uniform 
distributions. 
The product-launch planning problem is tackled by integrating both process design and planning 
decisions and considering the resource limitations due to resource sharing among products under 
development and products already in commercialization. A case study inspired on a real situation 
from the chemical-pharmaceutical industry was used to demonstrate the applicability of the 
proposed approach. This approach has proven to be able to efficiently assess the effects of 
uncertainty in process design and scale-up decisions, as well as in capacity and production planning 
decisions, during new product development. 
The obtained results clearly show the significant influence of the uncertainty parameters on the NPV, 
on the process design configurations, and on the scale-ups, thus strengthening the idea that 
deterministic models undoubtedly lead to poor decision-making. Particularly in new drug 
development, the decisions on process design and on scale-ups are strongly dependent on the 
uncertainty of pass/fail outcomes of the clinical trials. Since these decisions need to be taken before 
knowing if the new drugs will succeed in all the clinical trial phases, they are extremely critical in 
economic terms.  
The computational results also show that the proposed method is a robust tool to support this 
decision-making process, by clearly identifying process configurations and scale-ups that maximize 
profit, in a highly uncertain context. Moreover, the analysis performed in this study can be useful in 
the long-term assessment of the process design configurations and their lifetime management. It also 
provides valuable strategic information for developing solutions that not only maximize the NPV, but 
also reduce the likelihood of the company to undertake process design changes in the future. 
Furthermore, the incorporation of the uncertainty in processing times has demonstrated the ease of 
adapting the developed approach to additional sources of uncertainty. This is mainly because the 
MILP model size is independent of the number of uncertainty parameters. In that sense, increasing 
the number of uncertainties in the problem will not increase the model size or complexity, 
influencing only the sampling procedure. In that sense, the presented MCS framework proves to be 
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very flexible, allowing the inclusion of additional steps to the sample procedure to account for several 
uncertainty parameters simultaneously. 
We believe that one of the main benefits of this model is the provision of valuable and robust 
information in early stages of product development, thus supporting an on-time and better decision-
making process. Late decisions will therefore be avoided particularly regarding unnecessary or 
undersized investments, or possible future changes in the process design configuration. Additionally, 
this comprehensive analysis of the uncertainty parameters will allow a better coordination between 
the different decision levels within the company, with a clear gain in what concerns decision 
flexibility. 
Nevertheless, one main limitation of this approach (that is, at the same time, an interesting research 
challenge) is the inability to establish correlations between different process designs, and 
consequently to determine the unique here-and-now solution. This has motivated the subsequent 
work presented in the following chapter, in which a new methodology is developed to enhance the 
proposed decision-making framework and determine the unique strategic (here-and-now) solution. 
  
 
 
  
 
4. Strategic decision-making under 
uncertainty: a unified framework  
This chapter describes the developed multi-objective integer programming model embedded in a 
unified decision-making framework to determine the final strategic decisions, explicitly considering 
the decision-maker preferences.  
The content of this chapter is based on the work published in an international peer reviewed journal 
as follows: 
  
Journal publication 
 
Marques, C. M., Moniz, S., & de Sousa, J. P. (2018). Strategic decision-making in the pharmaceutical 
industry: A unified decision-making framework. Computers & Chemical Engineering, 119, 171-189.
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Abstract  
The implementation of efficient strategic decisions such as process design and 
capacity investment under uncertainty, during the product development 
process, is critical for the pharmaceutical industry. However, to tackle these 
problems the widely used multi-stage/scenario-based optimization 
formulations are still ineffective, especially for the first-stage (here-and-now) 
solutions where uncertainty has not yet been revealed. 
This study extends the work presented in the previous chapter addressing the 
stochastic product-launch planning problem, by developing a new Multi-
Objective Integer Programming model, embedded in a unified decision-making 
framework, to obtain the final design strategy that “maximizes” productivity 
while considering the decision-maker preferences. 
An approximation of the efficient Pareto-front is determined, and a subsequent 
Pareto solution analysis is made to guide the decision process. The developed 
approach clearly identifies the process designs and production capacities that 
“maximize” productivity as well as the most promising solutions region for 
investment. Moreover, a good balance between investment and capacity 
allocation was achieved.  
4.1. Introduction 
4.1.1. Motivation 
In the pharmaceutical industry the ability to bring new drugs into the market consistently is a central 
issue to remain competitive and maintain economic sustainability. The new product development 
(NPD) process is therefore a critical step towards this objective. Several challenges arise during this 
phase, and companies are typically faced with a twofold problem: (i) ensure a sound portfolio 
management in the development pipeline (Laínez et al., 2009a), and (ii) guarantee efficient process 
design and planning decisions during the clinical trials, in order to enhance R&D productivity and 
deliver medical drugs faster and more efficiently (Paul et al., 2010b). However, in the past years not 
only a decreasing number of approved new medicines have been experienced by the industry, but 
also the cost per approved new compound has been increasing (DiMasi et al., 2016), being the clinical 
trials the most expensive activity of the development process (EFPIA, 2016) (see Figure 2.4). As 
mentioned previously (chapter 2), more complex and larger clinical trials due to stringent 
regulations, as well as an increasing focus on the development of more complex molecular entities to 
address more challenging diseases, are pointed out by some authors as being the basis for this 
turnaround in the pharmaceutical business context (Pammolli et al., 2011a; DiMasi et al., 2016). In 
addition to this, the revenue losses due to a reduced market exclusivity and a growing generic 
competition also contribute to a generalized decrease in the R&D productivity (Grabowski & Vernon, 
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2000; Shah, 2004; Paul et al., 2010b; Pammolli et al., 2011a). According to Paul et al. (2010b), a 
dramatic increase in the R&D productivity will be needed in order to compensate the revenue losses 
due to patent expirations.  
Typically, the productivity is measured as the ratio of R&D outputs to inputs  or, as stated by Paul et 
al. (2010b), can be defined as the relation between  the “value created” by a new drug and the 
investment required to generate that new drug. Therefore, companies should focus on enhanced 
decision-making approaches that takes into consideration the trade-offs between these conflicting 
goals (Moniz et al., 2015a): increase the “value created” of the R&D activity, while minimizing both, 
costs and time-to-market. According to Federsel (2010), the focus for companies in this industry 
should be cost, speed (time-to-market) and decision-making. The implementation of efficient process 
design and planning decisions will definitely contribute to all of these goals. Therefore, improving 
the R&D productivity relies greatly in balancing specific strategic decisions during the development 
phase, such as: what should be the best long-term production process configuration and how much 
capacity should be allocated/reserved or invested for what products, while accounting the risks 
mainly associated to clinical trial failures. 
The complexity involved in these decisions is significantly amplified by the highly stochastic nature 
of the development process. Not only the technical uncertainty associated to the clinical trials 
pass/fail outcome, but also the market uncertainty due to the long development cycles have a 
significant impact in the decision process and cannot be neglected in these long-term planning 
decisions. Nevertheless, dealing with uncertainty leads to large-scale and very complex optimization 
problems hard to solve particularly when involving integer decision variables and multi-period 
formulations (Sahinidis, 2004; Moniz et al., 2013b). In that sense, predicting the best process design 
and/or the capacity needs for the uncertain future is still an unsolved problem and a challenge being 
pursued not only by the academic community, but also industrial practitioners.  
In the previous chapter a Monte Carlo simulation-based approach was presented in order to address 
this challenge. The developed approach gives insight of what might happen in the uncertain future 
regarding product demand and clinical trials outcomes, and it provides a robust sensitivity analysis 
for a wide range of scenarios by mapping the alternative decisions with greater probabilities of 
occurrence. In this manner decision-makers will have at their disposal a valuable set of structured 
information to support a better decision-making at the early stages of product development.  
Nevertheless, despite this methodology has proven to be effective in determining the impacts of 
several sources of uncertainty in the long-term decision-making process (Marques et al., 2017a; 
Marques et al., 2017b), the determination of a unique strict solution is not straightforward. Moreover, 
in this highly stochastic environment the involvement of the decision-maker in finding the “best” 
decision cannot be disregarded and his preferences as well as risk attitude should be reflected in the 
final solution.  
Thus, there are two fundamental research questions that now prevail:  
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(i) How to systematically determine the strategic process design solution based on the results 
of the simulation framework?  
 
(ii) How to “maximize” the productivity in a highly uncertain context while reflecting the 
decision-maker risk attitude?  
 
4.1.2. Background 
Uncertainty is present in almost every practical problem, although its relevance is particularly 
significant in planning problems where both technical and market uncertainties arise. As technical 
uncertainties, clinical trials outcomes, processing times, and production yields are among the most 
common. Despite the importance of all these uncertainty contributions, the clinical trial outcomes 
clear stands out as the most significant source of uncertainty (Colvin & Maravelias, 2008), not only 
because of its challenging discrete, binary nature (“success” or “failure”), but also due to its major 
economic impact in the product development process. On the other hand, as market uncertainties, 
product demand, raw material availability and prices are among the most relevant, since they occur 
during the long drug development cycles. 
Explicitly modeling uncertainty leads to great improvement of the solution robustness (Verderame 
et al., 2010), and the relevance of including it in Process System Engineering (PSE) applications is 
highlighted by several interesting surveys that have emerged in recent years. Sahinidis (2004), 
present a review of the main approaches that have been developed to address optimization problems 
under uncertainty, and identifies three major groups: stochastic programming (including: recourse 
models, robust stochastic programming, and probabilistic models), fuzzy programming and 
stochastic dynamic programming. Later, Li & Ierapetritou (2008) focused on production scheduling 
under uncertainty, presenting a review of the main methodologies developed to address this 
problem. The authors highlight the vital importance of develop a unified framework for planning and 
scheduling under uncertainty and to systematically consider all uncertain parameters. 
Also, Verderame et al. (2010) focused on planning and scheduling under uncertainty with a review 
across multiple sectors. Particularly for the chemical, petrochemical and pharmaceutical sector, the 
authors point out the Two-stage stochastic programming, chance constraint programming, robust 
optimization, and Value-at-Risk and Conditional Value-at-Risk as the most developed approaches. 
More recently, Grossmann et al. (2016a) present recent advances in mathematic programming 
techniques to address optimization under uncertainty in process systems. Stochastic programming, 
robust optimization, and chance constrain programming are also pointed as being the most relevant 
approaches to address uncertainty. As stated by the authors Grossmann et al. (2016a) one of the 
major concerns when modeling under uncertainty rely on the selection of the best optimization 
approach. The paradigms embedded in each one of these methodologies can give clues regarding the 
best strategy to follow, yet an efficient approach to tackle uncertainty is still far from being a reality. 
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While robust optimization is pointed as more suitable for scheduling purposes due to its more 
conservative orientation, two-stage stochastic programming has been most widely used in more 
strategic settings in which decisions can be broken into two or more stages (Grossmann et al., 2016a).   
Due to the highly strategic nature of the decisions typically involved in the management problems of 
the NPD process in the pharmaceutical industry, the Two-Stage Stochastic Programming (TSSP) has 
been one of the most common approaches used to tackle uncertainty. Particularly, when considering 
uncertainty in the clinical trials outcomes, works can be found covering areas such as, supply chain 
and capacity planning (Rotstein et al., 1999; Cheng et al., 2003; Gatica et al., 2003b; Gatica et al., 
2003a; Levis & Papageorgiou, 2004; Sundaramoorthy et al., 2012), and portfolio management and 
task scheduling (Schmidt & Grossmann, 1996b; Maravelias & Grossmann, 2001; Levis & 
Papageorgiou, 2004; Colvin & Maravelias, 2008; Colvin & Maravelias, 2011; Perez-Escobedo et al., 
2012; Christian & Cremaschi, 2015). 
The two-stage stochastic programming approach gains relevance with the seminal work of Dantzig 
(1955) in which the essential idea is that decisions are taken in two or more (for multi-stage 
applications) stages. The first-stage (“here-and-now”) decisions are made under significant 
uncertainty and the second-stage (“wait-and-see”) decisions are explicitly determined after the 
realization of the random events (Dantzig, 1955; Birge & Louveaux, 2011). Since the first-stage 
decisions do not depend on the outcomes of the uncertain parameters, these are typically associated 
with strategic decisions, such as network design, plant and process design, investment strategy, 
portfolio selection, etc. In the second-stage operational decisions such as detailed production plans, 
and resource allocation will take place. These decisions are quantitatively dependent on the random 
values and so, to a certain extent, will “correct” the first-stage decisions (Dantzig, 1955; Birge & 
Louveaux, 2011). According to Malik & Hughes (1979), the design of chemical processes is typically 
a two-stage problem with a design stage (first-stage) and an operational stage (second-stage) in 
which the design variables are fixed. However, the numerical complexity and computational burden 
associated with a monolithic stochastic “here-and-now” program limit their full application and 
decomposition schemes are usually inevitable to solve the problems.   
Moreover, the traditional neutral attitude toward risk of the classical formulation of the TSSP 
(Dantzig, 1955; Birge & Louveaux, 2011) also limits its application in more embracing problems, in 
which the decision-maker interaction is encouraged. Especially for the first-stage decisions where 
uncertainty has not yet been revealed, the decision-maker risk attitude is of great relevance. Despite 
several studies have been published considering the risk-averse attitude by changing the objective 
function through the incorporation of some risk measures (Applequist et al., 2000; Shapiro, 2012; 
Homem-de-Mello & Pagnoncelli, 2016), the effective incorporation of these measures is still a main 
challenge in TSSP approaches as stated by Grossmann et al. (2016a).  In that sense, the current 
paradigms to tackle uncertainty that lead us to a unique optimal decision without considering the 
decision maker preferences tends to be inadequate in more practical and realistic settings.  
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On the other hand, considering that simulation approaches are particularly suited to assess risk 
under uncertainty contexts, simulation-optimization based approaches seem to be a promising tool 
to undertake these challenges. Important contributions have been made using simulation-
optimization based approaches specifically addressing clinical trials outcomes uncertainty, mainly 
for portfolio selection and task scheduling (Subramanian et al., 2001; Subramanian et al., 2003; Blau 
et al., 2004b; Rajapakse et al., 2005; Varma et al., 2008b; Chen et al., 2012a; Perez-Escobedo et al., 
2012). Also, Monte Carlo Simulation based approaches have been proposed in the literature 
addressing different planning problems under uncertainty in the chemical-pharmaceutical industry 
(Bassett et al. (1997), Farid et al. (2005), Eberle et al. (2014)). All these approaches contribute to a 
more realistic representation of uncertainty while benefiting from the optimization advantages, 
however the determination of the final process design solution reflecting the decision-maker 
preferences have not yet been extensively explored.  
An extension of the previous work is presented here to address the stochastic product launch 
planning problem with an emphasis on the determination of the strategic solutions regarding process 
designs (including the respective processing units and lot sizes), and capacity planning, taking in 
consideration the decision-maker preferences and attitude towards risk. Therefore, a solution 
approach is presented to rigorously determine the unique (here-and-now) stochastic solution (based 
on the results of the previously developed Two-Step Monte Carlo simulation framework) by 
developing a Multi-Objective Integer Programming (MOIP) model embedded in a unified decision-
making framework, with the overall goal of improving the R&D productivity. A compromise solution 
will be then obtained by balancing the conflicting objectives of increasing the “value created” by the 
product development process, while minimizing the associated development costs. 
4.2. Problem description 
The problem considered here is based on the product launch planning problem under uncertainty 
addressed in the previous chapter in which a detailed description is provided. Nevertheless, for the 
sake of a better understanding of the present study, the most relevant features of the addressed 
problem will be briefly described here. 
In the previous work a multipurpose batch plant producing simultaneously products under 
development and products already in commercialization (competing for the same limited resources) 
was considered. A discrete-time formulation was proposed encompassing several years to 
accommodate the three clinical trials phases, and ending with the regulatory approval of both, 
products and production processes. Uncertainty in product demand (for both types of products) and 
in the clinical trials outcomes (for the products under development) were explicitly considered and 
captured through the developed Two-Step Monte Carlo Simulation (TSMCS) procedure. The main 
purpose was then to determine simultaneously process design and planning decisions for a known 
set of products reaching clinical trial phase I. The key decisions considered were: the best set of 
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processing units to each process (process design configuration), size and timings of scale-ups 
(including lot traceability), amounts to produce and store of each product and period, and the 
capacity extension requirements, in order to maximize the Net Present Value (NPV).  
Taking this as basis, in this work the same multipurpose batch plant sharing their resources between 
the two modes of production is considered as well as the same planning horizon. Although, in this 
case instead of determining the best production plan over the planning horizon, the goal is to select 
the “best” strategy to follow in order to guarantee the long-term capacity availability needed to fulfil 
both types of demand: the clinical trials demand, and the regular products demand, in face of 
significant uncertainty. 
Therefore, a pre-determined set of different process designs is given for each product and period to 
be selected by the developed optimization model. A “process design” as considered in this work 
emerges directly from the results obtained in the TSMCS framework previously developed, through 
the determination of the process/unit assignment binary variables and lot-size integer variables for 
each product and period. Hence, each “process design” aggregates all individual tasks to produce a 
specific product, and can be defined by two types of entities, namely: (i) the set of processing units 
used to perform each individual task (Reactors (R), Filters (F), and Dryers (D)), and (ii) the lot size 
(L1, L2, L3, and L4), that will guarantee production traceability and production bounds for each 
product. In that sense, instead of having a typical production recipe (Figure 4.1) to model and 
determine the best production plan (including capacity and scale-up decisions), a simplified version 
of the concept of campaign (Moniz et al., 2014a) is used here in which the complete recipe is 
embedded (Figure 4.2). Thus, each “process design” act like a specific “campaign” characterized by 
several parameters calculated from the results obtained in the previous simulation model for each 
period, such as: the cycle time, the minimum and maximum number of cycles, the minimum amount 
produced per cycle, and the operational and fixed costs.   
 
Figure 4.1 Resource-Task-Network process representation to produce a single final product P. 
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(a) 
 
 
(b) 
Figure 4.2 Process design detail. (a)  Each process design is composed by the production tasks and is 
defined by the Cycle Time (𝜸); minimum amount produced per cycle (𝝎𝒎𝒊𝒏); minimum and maximum 
Number of Cycles (𝜼𝒎𝒊𝒏/𝜼𝒎𝒂𝒙) and total costs (fixed and variable); (b) Example of a specific process design, 
composed by lot size “L1”, reactor “R1”, filter “F1”, and Dryer “D1”: L1R1_L1F1_L1D1. 
This pre-determined set of process designs correspond to the most frequently selected by the TSMCS 
framework. Thus, it is assumed that the stochastic nature of the problem has been captured in the 
simulation framework (TSMCS) and it's reflected in the pre-determined set of process designs 
considered here (including their respective parameter values). Moreover, the explicitly 
representation of the production recipes will not be considered in this work, since they are 
embedded in each process design (Figure 4.2) and the respective detailed production plans were 
already determined in the previous chapter. 
The minimum and maximum numbers of cycles associated to each process design and period as well 
as the respective cycle times, and minimum amount produced per cycle are considered given as they 
are obtained from the simulation results. The probabilities of market success for each product under 
development are also given in order to evaluate the most promising products in the development 
pipeline.   
Therefore, the problem under consideration consists in determining the final strategic solution, 
selecting for each product and period the “process designs” that “maximize” productivity while 
simultaneously, considering the decision-makers preferences. 
Additionally, process changes over the planning horizon are highly undesirable, due to the high cost, 
and time-consuming involved, so a penalty cost is introduced to minimize this problem. 
Considering the above description, the problem being addressed can be formally defined as follows. 
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Given:  
(i) a fixed time horizon, discretized into several time periods of equal duration (𝑡 ∈ 𝐇); 
(ii) the set of under development products entering clinical trials (𝑝 ∈ 𝐏U);  
(iii) the set of products already in commercialization (𝑝 ∈ 𝐏C); 
(iv) the set of candidate process designs for each product and period determined in the 
simulation model (TSMCS) (𝑗 ∈ 𝐉𝑝𝑡); 
(v) the lot sizes associated to each process design (l ∈ 𝐋j); 
(vi) the set of processing units initially available in the plant (𝑒 ∈ 𝐄); 
(vii) the maximum and minimum number of cycles for each process design determined from 
the simulation (TSMCS) results; 
(viii) the cycle times associated to each product, process design, and processing unit 
determined from the simulation (TSMCS) results; 
(ix) the probabilities of market success in each clinical trial phase for each under 
development product (𝑝 ∈ 𝐏U); 
(x) all operational, fixed, and penalty costs associated to each process design, as well as the 
sales prices of each product; 
 
Determine:  
(i) the “process design” allocation for each product and time period (𝑋𝑝𝑗𝑙𝑡); 
(ii) the number of cycles associated to each process design (𝑁𝐶𝑝𝑗𝑙𝑡); 
 
In order to: 
(i) “maximize” productivity through a proper balance between production costs and 
production capacity, and reflecting the decision-maker preferences.  
 
Figure 4.3 depicts a schematic representation of the problem being addressed and the main decisions 
involved, such as: process design allocation (𝑋𝑝𝑗𝑙𝑡), and the respective number of cycles (𝑁𝐶𝑝𝑗𝑙𝑡). 
 
Figure 4.3 Schematic representation of the problem under study. The set of candidate process designs Jpt for 
each product and period and the respective key decisions (𝑿𝒑𝒋𝒍𝒕 binary variables and 𝑵𝑪𝒑𝒋𝒍𝒕 integer variables) 
are presented. 
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4.3. Conceptual decision-making framework 
The proposed solution is an extension of the previously developed Two-Step Monte Carlo Simulation 
(TSMCS) framework in order to complete the decision-making process by determining the final 
design strategy of the stochastic product launch planning problem. 
Following the two-stage stochastic programming paradigm (Dantzig, 1955; Malik & Hughes, 1979; 
Birge & Louveaux, 2011), decisions under uncertainty may be taken in two main stages: the “here-
and-now” and the “wait-and-see” decisions. The focus of the proposed approach is therefore to find 
the unique strategic solution (i.e. the “here-and-now” solution in the TSSP paradigm) that was not 
directly achieved by the proposed TSMCS framework. 
According to Malik & Hughes (1979), to tackle the “here-and-now” problem three simpler problems 
usually arise: the Most Likely (deterministic) problem (ML) in which expected values are used for all 
uncertain parameters, the Expectation problem (EX) in which the most likely (deterministic) design 
is fixed and evaluated by computing the expected value over the probabilistic distributions of the 
uncertain parameters, and the Wait-and-See problem (WS) in which the expected value is 
determined over the probabilistic distributions of the uncertain parameters with respect to all 
variables (both design and operational variables). According to the authors, by assessing these three 
problems individually, some conclusions are possible to be taken regarding the final “here-and-now” 
solution. However, the underlying idea is based on the current strategies of finding a unique 
optimized solution without any involvement of the decision-maker. Therefore, based on the main 
paradigms embedded in the above concepts, and their existing gaps, a new unified conceptual 
framework is developed to tackle the “Here-and-Now” problem in which several sources of 
uncertainty can be considered simultaneously, and the decision-maker preferences are taken into 
account to guide the final solution. 
The proposed unified decision-making framework links the simulation procedure developed in 
chapter 3 with the Multi-Objective Integer Programming (MOIP) model developed in this study. In 
the first part of the framework (simulation procedure) the set of candidate process designs are 
determined under considerable uncertainty, and in the second part of the framework, the final 
solution is determined. The complete framework is depicted in Figure 4.4, including 5 main steps:  1. 
“Solutions generation”; 2. “Set of candidate solutions”; 3. “Pareto frontier”; 4. “Performance 
assessment”, and 5. Strategic final solution”. The main idea of this framework is to use  the MOIP 
model to select the final solution from the most frequently selected process designs obtained in the 
previous simulation procedure. 
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Figure 4.4 Unified decision-making framework, integrating the TSMCS framework with the MOIP model. 
 
The first part of the framework is divided in two steps (Step 1 and step 2). In the first step, solutions 
are generated through the TSMCS procedure in which the simultaneous impact of uncertainty in 
product demand and in clinical trials outcomes are assessed. In each iteration of the Monte Carlo 
sampling process a deterministic solution is obtained for a specific realization of the uncertain 
parameters with respect to all decision variables (both strategic and operational).  
A probabilistic distribution for the objective function and histograms for each decision variables are 
obtained and analysed. A parallelism may be found between this step and the Wait-and-See problem 
described in the work of Malik & Hughes (1979), but instead of computing the mean value to obtain 
a final solution, here the entire range of values is analysed by probabilistic distributions and 
frequency of occurrences, contributing to a more reliable and robust final solution. In the second 
step, the solutions found previously are ranked according to the most frequent solutions obtained 
for the process design configurations (the strategic design variables). The most frequent process 
designs for each product and period will integrate the set of candidate final solutions. These first two 
steps are described in detail in chapter 3 (see section 3.4 and 3.5). 
The second part of the proposed framework is performed in three steps (Step 3, 4, and 5) and is 
focused on the determination of the final decision. Starting with step 3, a Multi-Objective Integer 
Programming (MOIP) model is developed to select, for each product and period, the unique process 
design solution (from the candidate process designs obtained in step 2). The weighted-sum method 
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is used to determine a specific solution by assigning weights to each objective function, reflecting 
their relative importance (a detailed description of the MOIP model is presented in section 4.4). An 
approximation of the Pareto efficient frontier is then constructed by generating multiple sequential 
solutions through a consistent variation of the weight’s combination. A Pareto analysis is then 
performed by the decision-maker in order to select a unique solution. Nevertheless, the selection of 
the unique solution among all the others may be a challenging process and so a subsequent Pareto 
analysis with a performance assessment of the solutions is introduced in the framework (step 4) to 
help the decision-maker evaluate the available solutions and identify the preferred one. Therefore, 
in step 4, a performance assessment is made by determining different trade-off values and the 
respective indifferent lines to be analysed by the decision-maker (Keeney & Raiffa, 1993). Each trade-
off value corresponds to a productivity level associated to a specific solution in the Pareto frontier. 
Finally, in the last step of this framework (Step 5) the final solution (i.e. process design configuration) 
is determined based on the risk attitude of the decision-maker and his preferences. These three last 
steps (Steps 3, 4 and 5) correspond to the main contributions of this chapter and will be described in 
detail in the following sections. 
4.4. Multi-Objective Integer Programming (MOIP) model 
A Multi-Objective Integer Programming (MOIP) model is developed to select the process design 
configurations for each product and period, over a planning horizon of several years in order to 
“maximize” productivity. The key decision variables are the process design/product assignment 
binary variables (𝑋𝑝𝑗𝑙𝑡), and the number of cycles integer variables (𝑁𝐶𝑝𝑗𝑙𝑡). The detailed 
mathematical formulation of the model is presented in the next sections with the description of the 
constraints and objective functions. 
NOTATION 
Indices 
j Process design 
l Lot 
p Final product 
t Period 
e Processing units 
k Objective functions 
Sets 
H Planning horizon 
J Sub-set of candidate process designs 
Jp Process designs associated with product 𝑝 ∈ 𝐏 
Jpt Process designs associated with product 𝑝 ∈ 𝐏 and period 𝑡 ∈ 𝐇 
Jet Process designs associated with processing unit 𝑒 ∈ 𝐄 and period 𝑡 ∈ 𝐇 
L Lots 
Lj Lots associated with process 𝑗 ∈ 𝐉  
P Final products 
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E Processing units 
Ej Processing units associated with process design j 
  
  
Parameters 
𝛾𝑝𝑗𝑙𝑒𝑡  
Cycle time associated to each product p process design j lot l processing unit e and 
period t (h) 
𝛼𝑝𝑗𝑙
𝑣𝑎𝑟 Variable component of the operational cost of each process design j for product p 
and period t (rmu) 
𝛼𝑝𝑗𝑙
𝑓𝑖𝑥
 Fixed component of the operational cost of each process design j for product p and 
period t (rmu) 
𝛼𝑝𝑡
𝑝𝑐
 Penalty cost for process changes that occurs in each product p and period t (rmu) 
𝜏𝒆 Available capacity for each processing unit e expressed in time availability (h) 
𝜏𝑐ℎ𝑔  Changeover time (h) 
𝜂𝑝𝑗𝑙𝑡
𝑚𝑎𝑥/𝜂𝑝𝑗𝑙𝑡
𝑚𝑖𝑛 
Maximum and minimum number of cycles associated to each product p process 
design j lot l and period t 
𝜔𝑝𝑗𝑡
𝑚𝑖𝑛  
Minimum amount that can be produced in one cycle of the process design j 
associated to product p and period t (kg) 
𝜌𝑝𝑡  Probability of each product p to reach the market at each period t 
𝜗𝑝𝑡 Value of each product p at each period t (rmu) 
𝛽𝑘  Weighting factor for the multi-objective function k 
𝑓𝑘
𝑈𝐵/𝑓𝑘
𝐿𝐵  Upper and lower bound of objective function k 
Binary variables 
𝑋𝑝𝑗𝑙𝑡  Equal to 1 if process design j and lot l are selected for product p at period t 
Cpt Equal to 1 if process design of product p changes in period t (auxiliary variables) 
Integer variables 
𝑁𝐶𝑝𝑗𝑙𝑡  Number of cycles for product p of process j with lot size l in period t  
  
4.4.1. Constraints 
Assignment constraints 
∑ ∑ 𝑋𝑝𝑗𝑙𝑡
𝑙∈𝐋𝑗
= 1     
𝑗∈𝐉𝑝𝑡
∀𝑝 ∈ 𝐏, 𝑡 ∈ 𝐇 (4.1) 
Equation (4.1) concerns the assignment constraints and is used to select a process design j with a lot-
size l for each product p and period t through the binary variables 𝑋𝑝𝑗𝑙𝑡  (equal to 1 if a process is 
selected). These constraints guarantee that exactly one process design will be selected for each 
product and period.   
Lot constraints 
𝑋𝑝𝑗𝑙𝑡 + 𝑋𝑝𝑗′𝑙′𝑡′ ≤ 1      ∀𝑝 ∈ 𝐏, 𝑗, 𝑗
′ ∈ 𝐉𝑝𝑡: 𝑗 ≠ 𝑗
′, 𝑙, 𝑙′ ∈ 𝐋 ∶ 𝑙′ > 𝑙, 𝑡 ∈ 𝐇, 𝑡′ ∈ {0, … , 𝑡} (4.2) 
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Constraints (4.2) are used to model the scale-up decisions by ensuring that the size of the lots never 
decreases over the planning horizon.  
Process Changes constraints 
𝐶𝒑𝒕 ≥ 𝑋𝑝𝑗𝑙𝑡 + 𝑋𝑝𝑗′𝑙′𝑡−1 − 1       ∀𝑝 ∈ 𝐏, 𝑗, 𝑗
′ ∈ 𝐉𝑝𝑡 ∶  𝑗 ≠ 𝑗
′ , 𝑙 ∈ 𝐋𝑗 , 𝑙
′ ∈ 𝐋𝑗′ , 𝑡 ∈ 𝐇 ∶ t > 0 (4.3) 
Constraints (4.3) are used to model the process changes that may occur during the planning horizon. 
The binary variables 𝐶𝒑𝒕 represent the process changes of product p in period t, being equal to 1 if a 
process change occurs between t-1 and t, and 0 otherwise. 
Number of cycles constraints 
𝜂𝑝𝑗𝑙𝑡
𝑚𝑖𝑛𝑋𝑝𝑗𝑙𝑡 ≤ 𝑁𝐶𝑝𝑗𝑙𝑡 ≤  𝜂𝑝𝑗𝑙𝑡
𝑚𝑎𝑥𝑋𝑝𝑗𝑙𝑡       ∀ 𝑝 ∈ 𝐏, 𝑗 ∈ 𝐉𝑝, 𝑙 ∈ 𝐋𝑗 , 𝑒 ∈ 𝐄𝑗 , 𝑡 ∈ 𝐇 (4.4) 
Constraints (4.4) ensure that the integer variables number of cycles (𝑁𝐶𝑝𝑗𝑙𝑡) are bounded by the 
minimum and maximum values (𝜂𝑝𝑗𝑙𝑡
𝑚𝑖𝑛/𝜂𝑝𝑗𝑙𝑡
𝑚𝑎𝑥) determined based on the results of the TSMCS 
procedure. The maximum value is estimated in order to accommodate the higher production 
amounts found in the simulation results for each product p, process design j with lot-size l, and period 
t. 
Capacity constraints 
∑ ∑ ∑(𝑁𝐶𝑝𝑗𝑙𝑡𝛾𝑝𝑗𝑙𝑒𝑡)
𝑙∈𝐋𝑗𝑗∈𝐉𝑒𝑡𝑝∈𝐏
+ ∑ ∑ ∑(𝑋𝑝𝑗𝑙𝑡𝜏
𝑐ℎ𝑔)
𝒍∈𝑳𝒋
− 𝜏𝑐ℎ𝑔
𝑗∈𝑱𝒆𝒕𝑝∈𝐏
≤ 𝜏𝒆       ∀ 𝑒 ∈ 𝐄, 𝑡 ∈ 𝐇 (4.5) 
Equation (4.5) denotes the production capacity constraints expressed by the time availability of 
processing unit e in each time period t. The first summation represents the total time required to 
execute the process design j in equipment e. The parameter 𝛾𝑝𝑗𝑙𝑒𝑡  is given and represents the cycle 
time associated to a specific product p, process design j, equipment e, at period t. This value was 
obtained considering the minimum number of batches obtained in the simulation results, thus 
representing the minimum processing time associated to the processing units e and lot l of each 
process design. The integer variables  𝑁𝐶𝑝𝑗𝑙𝑡  represent the total number of cycles to be executed for 
the selected process design in period t. The second summation defines the changeover times 
associated to each equipment e. Since this formulation is an aggregate model, detailed task-
sequencing constraints are not considered, and so exact changeover times cannot be captured. 
Nevertheless, the minimum amount of changeovers is considered here to make the final solution 
more reliable. In that sense, the third term (𝜏𝑐ℎ𝑔) is added to the formulation in order to eliminate 
overestimation of changeovers in the cases in which the last product to be produced in period t is the 
same to be produced at the beginning of the following period (t + 1). This term ensures that the 
number of changeovers is equal to the number of products minus one (Erdirik-Dogan & Grossmann, 
2007; Moniz et al., 2014a). The parameter 𝜏𝑐ℎ𝑔denotes the changeover times and is considered given. 
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Variables domain 
𝑋𝑝𝑗𝑙𝑡 ∈ {0,1}          ∀ 𝑝 ∈ 𝐏, 𝑗 ∈ 𝐉, 𝑙 ∈ 𝐋, 𝑡 ∈ 𝐇 
𝐶𝒑𝒕 ∈ {0,1}                                  ∀ 𝑝 ∈ 𝐏, 𝑡 ∈ 𝐇 
𝑁𝐶𝑝𝑗𝑙𝑡 ∈ ℤ+          ∀  𝑝 ∈ 𝐏, 𝑗 ∈ 𝐉, 𝑙 ∈ 𝐋, 𝑡 ∈ 𝐇 
(4.6) 
Finally, equations (4.6) define the variables domain. 
4.4.2. Objectives 
4.4.2.1. Productivity level 
The main objective of the problem in study is the maximization of the productivity during the new 
drug development process considering the limited resources for the simultaneous production of 
products under development and products already in commercialization.  
The general definition of productivity is typically presented as the relation between the outputs and 
inputs of a process. Based on this, and on the concepts presented by Paul et al. (2010b) in which R&D 
productivity is defined as the relation between the value created by a new drug and the investment 
required to generate that drug, the productivity level as considered in this work is expressed by 
equation (4.7) for each product p. 
Productivity Level(𝑝) =
𝑉𝑎𝑙𝑢𝑒 𝐶𝑟𝑒𝑎𝑡𝑒𝑑(𝑝)
𝑇𝑜𝑡𝑎𝑙 𝐶𝑜𝑠𝑡(𝑝)
=
𝑝×𝑉𝑝
𝑇𝐶𝑝
      ∀𝑝 ∈ 𝐏         
(4.7) 
 
Here, 
𝑝
 represents the technical success of product p, which is the probability of that product 
successfully pass all clinical trial phases and reach the market. The 𝑉𝑝 corresponds to the product 
commercial value, and 𝑇𝐶𝑝 denotes the total cost invested (including design and operational costs) 
to develop the product p. 
In this work, the productivity concept has been adapted to consider not only the products in the 
development pipeline (as defined by Paul et al. (2010b)), but also the products already in 
commercialization to capture the effort that is made by the pharmaceutical companies in 
accommodating in the same plant the simultaneous production of these two types of products during 
the development phase. Thus, the value created is expressed in potential value for the products under 
development (since it depends on the probability of technical success) and in the “real” value for the 
products in commercialization (for which the 
𝑝
 value equals 1). 
Therefore, the general equation for the pharmaceutical productivity during the NPD process results 
from the summation of the productivity levels associated to each product over the entire planning 
horizon, as defined in Eq. (4.8).    
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Productivity Level =
∑ ∑  (𝜌𝑝𝑡 × 𝑉𝑝𝑡)𝑡∈𝐇𝑝∈𝐏
∑ ∑  (𝑇𝐶𝑝𝑡)𝑡∈𝐇𝑝∈𝐏
 (4.8) 
The difficulty in considering productivity as the main objective to be maximized is the non-linearity 
nature of equation (4.8). This, however, falls into a special case of nonlinear programming (NLP) 
known as linear fractional program (LFP) in which the objective function is the ratio between two 
linear functions subject to a set of linear constraints. Several methods can be used to solve LFP 
problems, including the Dinkelbach’s algorithm as proposed in (You et al., 2009). Nevertheless, in 
this work the productivity equation is broken in two terms and a multi-objective optimization model 
is developed allowing the decision-maker to express his preferences in the choice of the final 
solution. Thus, two objective functions are now considered: one for the numerator (maximization of 
value created) and another one for the denominator (minimization of total cost) of equation (4.8) as 
described below. 
4.4.2.2. Total cost (𝒇𝟏) 
The first objective function (Eq. (4.9)) is the minimization of Total Cost (TC) associated to the selected 
process designs.  
 
𝑓1 → min 𝑇𝐶 = ∑ ∑ ∑ ∑(𝛼𝑝𝑗𝑙
𝑣𝑎𝑟𝑁𝐶𝑝𝑗𝑙𝑡 + 𝛼𝑝𝑗𝑙
𝑓𝑖𝑥𝑋𝑝𝑗𝑙𝑡)
𝑡∈𝐇𝑙∈𝐋𝑗𝑗∈𝐉𝑝∈𝐏
+ ∑ ∑(𝛼𝑝𝑡
𝑝𝑐𝐶𝑝𝑡)
𝑡∈𝐇𝑝∈𝐏
 (4.9) 
 
In the first term, the cost is composed by a variable (𝛼𝑝𝑗𝑙
𝑣𝑎𝑟) and a fixed (𝛼𝑝𝑗𝑙
𝑓𝑖𝑥
) component. The variable 
component is dependent on the number of cycles (𝑁𝐶𝑝𝑗𝑙𝑡) to be performed for each process design 
and it includes the operational costs associated to the execution of each one of the production tasks 
(i.e. reaction, filtration, and drying), and the respective lot-size costs. The fixed component is 
associated to the process design allocation (𝑋𝑝𝑗𝑙𝑡) and includes the costs associated to the production 
activation in each one of the processing units that are part of that process design (i.e. reactor, filter, 
and dryer). 
In the second term a penalty cost is introduced to minimize the process changes over the planning 
horizon, reflecting the setup cost of changing a process. Since this is a critical issue in the 
pharmaceutical industry, decisions should be taken considering the minimization of the likelihood of 
future changes in the production process. The penalty cost (𝛼𝑝𝑡
𝑝𝑐
) varies with the clinical trial phase, 
being more penalizing as more advanced in its development the product is, since it is expected 
greater process stability closer to the end of the development process and the regulatory approval.  
The cost parameters (𝛼𝑝𝑗𝑙
𝑣𝑎𝑟 , and 𝛼𝑝𝑗𝑙
𝑓𝑖𝑥
) are determined based on the results obtained from the TSMCS 
framework.  Particularly for the variable cost (𝛼𝑝𝑗𝑙
𝑣𝑎𝑟), this is determined considering the cost of 
execution of all tasks associated to a specific process design (see Figure 4.2), considering the minimum 
number of batches obtained in the simulation results. In this manner a cost per cycle is obtained for 
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each process design configuration. Regarding the fixed cost (𝛼𝑝𝑗𝑙
𝑓𝑖𝑥
), this is determined based on the 
processing units allocation costs used in the TSMCS framework. 
4.4.2.3. Value created (𝒇𝟐) 
The second objective function (Eq. (4.10)) is the maximization of the “Value created” (V) by the 
company during the New Product Development process considering the simultaneous production of 
the products under development to supply the clinical trials and the regular products to fulfill the 
market demand. 
𝑓2 → max 𝑉 = ∑ ∑ ∑ ∑ 𝜔𝑝𝑗𝑡
𝑚𝑖𝑛𝜗𝑝𝑡𝜌𝑝𝑡𝑁𝐶𝑝𝑗𝑙𝑡
𝑡∈𝐇𝑙∈𝐋𝑗𝑗∈𝐉𝑝∈𝐏
 (4.10) 
 
The “Value created” as considered in this work is inspired by the concepts of pharmaceutical R&D 
productivity defined by Paul et al. (2010b), and results from the product of the following parameters: 
i) amount produced in each cycle for a specific process design and product (𝜔𝑝𝑗𝑡
𝑚𝑖𝑛); ii) sales value of 
each final product p and period t (𝜗𝑝𝑡); iii) probability of each product p to reach the market at period 
t (𝜌𝑝𝑡), with the decision variables number of cycles (𝑁𝐶𝑝𝑗𝑙𝑡). For the regular products (already in 
commercialization), the probability of market success is considered 1. On the other hand, for the 
products under development the probability of market success varies with the clinical trial phase, 
being lower at the first phase (when uncertainty is higher) and higher in the last phases of 
development (when more information about the product is available). These values are determined 
from the probabilities of clinical trial success used in the TSMCS procedure. 
Regarding the minimum amount produced in each cycle by a specific process design (𝜔𝑝𝑗𝑡
𝑚𝑖𝑛), this is 
defined by the lot-size of that process design and by the minimum number of lots that occurred in 
the TSMCS results for that specific process design (same assumption used in the estimation of the 
variable cost parameter). 
4.4.3. Multi-objective approach 
Taking in consideration the two objective functions defined above, the decisions involved in this 
problem need to accommodate several trade-offs arising from the production planning problem with 
the minimization of the production costs (“Total cost”- Eq. (4.9)), and from the product pipeline 
management problem with the maximization of the production capacity according to the most 
valuable (market value) and promising (most likely to reach the market) products  (“Value created” 
- Eq. (4.10)). Since increasing the number of cycles in Eq. (4.9) and (4.10), increases not only the value 
created but also the total cost, a proper balance between these two conflicting objectives should be 
achieved. Thus, a multi-objective approach is proposed, and instead of determining the optimal 
strategic solution, a compromise solution among these two objectives will be obtained, reflecting the 
decision-maker preferences. 
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Typically, the majority of multi-objective optimization methods fall into a priori or a posteriori 
methods, depending on the moment in which the decision maker preferences are expressed (Marler 
& Arora, 2004; Mavrotas, 2009). On one hand, in an a priori approach the decision maker must have 
a fully understanding about the importance of each objective which may not be easy, since it is 
seldom obvious or straightforward in the majority of the real-life problems. On the other hand, in a 
posteriori methods instead of a single global solution, a set of efficient solutions (Pareto optimal set 
or sub-set) are determined and then the decision-maker selects the most preferred solution among 
them. According to Pareto (1906), the Pareto optimal solutions are the ones that cannot be improved 
in one objective function without deteriorating at least one of the other objective functions. 
In this work an a posteriori based approach will be developed, using the well-known weighted sum 
method, in order to enable the decision maker to establish their preferences directly on the Pareto 
optimal solutions.   
The weighted sum method is one of the simplest and most widely used methods to solve multi-
objective optimization problems. In order to determine a single suitable solution, the decision-maker 
preferences should be incorporated for the different objectives (Zadeh, 1963; Marler & Arora, 2010).  
Mathematically, the general weighted sum method for the multi-objective optimization can be stated 
as follows: 
min 𝐹 = ∑ 𝛽𝑘𝑓?̅?
𝑘∈𝐊
 (4.11) 
0 ≤ 𝛽𝑘 ≤ 1     ∀ 𝑘 ∈ 𝐊 (4.12) 
∑ 𝛽𝑘
𝑘∈𝐊
= 1 (4.13) 
 
Where, 𝛽𝑘  correspond to the weighting factors reflecting the decision-maker preferences for the 
objective function k, and 𝑓?̅?, correspond to the normalized objective functions. Several approaches 
can be found in the literature for the normalization procedure, in this work the adopted methodology 
is given by Eq. (4.14), as it is considered one of the most robust approaches (Marler & Arora, 2004). 
𝑓?̅? =
𝑓𝑘−𝑓𝑘
𝐿𝐵
𝑓𝑘
𝑈𝐵−𝑓𝑘
𝐿𝐵                            ∀ 𝑘 ∈ 𝐊        
(4.14) 
Where the 𝑓𝑘
𝐿𝐵 and 𝑓𝑘
𝑈𝐵correspond to the lower and upper bounds respectively of the objective 
function k, resulting in all objective functions scaled from zero to one. The upper and lower bounds 
are obtained by optimizing each objective function individually.  
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4.5. Results and Discussion 
4.5.1. Case description 
The same case study described in chapter 3 is used here as a basis to validate the proposed decision-
making framework and its most relevant features will be outlined in this section. 
The product portfolio is composed by 3 products under development (PA, PB, and PC) entering 
clinical trials phase I, and 2 regular products (PD and PE) already in commercialization. A planning 
horizon of 5 years discretized into 10 periods of 6 months is considered. The planning horizon is 
divided in the three clinical trial phases: 1.5 years for clinical trial phases I and II, and 2 years for the 
clinical trial phase III. The product demand profiles for each one of the products are the same 
considered in chapter 3 (Figure 3.5).  
The probability of each product to reach the market (successfully pass all clinical trials) and the 
respective unitary values for each period are given and presented in Table 4.1. The probability values 
were calculated from the probabilities of technical success in each clinical trial phase (pass/fail) used 
in the Bernoulli distributions embedded in the TSMCS procedure, and based on the studies of DiMasi 
(DiMasi et al., 2010; DiMasi et al., 2013; DiMasi et al., 2016). In this work, only specific values are 
considered (rather than probability distributions), since they are used here as a criterion to identify 
the most promising (most likely to reach the market) products in which it is worth to invest in 
capacity. 
 
Table 4.1 Unitary value (𝝑𝒑𝒕) and probability to reach the market (𝝆𝒑𝒕) for each product and period 
t 
Products under development  Products in commercialization 
PA PB PC  PD PE 
𝝑𝒑𝒕 
(rmu) 
𝝆𝒑𝒕 
𝝑𝒑𝒕 
(rmu) 
𝝆𝒑𝒕 
𝝑𝒑𝒕 
(rmu) 
𝝆𝒑𝒕 
 𝝑𝒑𝒕 
(rmu) 
𝝆𝒑𝒕 
𝝑𝒑𝒕 
(rmu) 
𝝆𝒑𝒕 
0 50 0.20 35 0.26 45 0.14  55 1 70 1 
1 50 0.20 35 0.26 45 0.14  55 1 70 1 
2 50 0.20 35 0.26 45 0.14  55 1 70 1 
3 50 0.32 35 0.38 45 0.23  55 1 70 1 
4 50 0.32 35 0.38 45 0.23  55 1 70 1 
5 50 0.32 35 0.38 45 0.23  55 1 70 1 
6 50 0.70 35 0.75 45 0.65  55 1 70 1 
7 50 0.70 35 0.75 45 0.65  55 1 70 1 
8 50 0.70 35 0.75 45 0.65  55 1 70 1 
9 50 0.70 35 0.75 45 0.65  55 1 70 1 
 
The production of each product is made following an aggregated recipe embedded in each process 
design available to be selected in each period of the planning horizon (the recipe details and the 
respective production plan can be found in chapter 3). In that sense, the production needs to fulfil 
each product demand (considering uncertainty in product demand and clinical trials outcomes), 
were determined by the TSMCS procedure and transposed to the MOIP model through the set of 
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candidate process designs and their respective parameter values. The minimum amount produced 
per cycle for each process design and their respective minimum and maximum acceptable number 
of cycles expresses the production range observed in the simulation which in turn reflects the 
variability in the uncertainty parameters.  
The pre-determined set of candidate solutions is considered given and was obtained by the first two 
steps of the decision-making framework (Figure 4.4). The first step consists of generating all possible 
solutions by performing the Two-Step Monte Carlo Simulation (TSMCS) framework. The process 
designs configurations are then determined by the allocation binary variables of the MILP model 
integrated in the TSMCS framework, which assign the available processing units to tasks, lot-sizes 
and products. The processing unit types that are part of the process designs are the ones described 
in Figure 3.7. 
A total of more than 2,000 different process designs were obtained for 1000 iterations of the TSMCS 
framework. The complete set of solutions is depicted in Figure 4.5(a) for all products and periods. 
 
(a) 
Three most frequent 
process designs 
 
(b) 
 
(c) 
Figure 4.5 Solutions (process designs) obtained for 1000 iterations of the TSMCS framework: (a) complete set 
of solutions; (b) the sub-set composed by the three most frequent process designs for each product and period, 
and (c) detail of the three most frequent process designs obtained for product PA in each period t. 
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The size of the bubbles represents the frequency of occurrence of each process design, and for each 
product and period there is approximately three or four product designs that stand out with a higher 
frequency value. Since each iteration corresponds to a specific realization of the uncertainty 
parameters, the most frequent solutions will also correspond to the most probable scenarios of the 
uncertain future. Therefore, these most frequent process designs for each product and period are 
selected to integrate the candidate strategic solutions as depicted in Figure 4.5(b). The detailed 
information regarding the most frequent process designs selected for the product PA is illustrated in 
Figure 4.5(c) as an example. The complete set of candidate process designs (for all products and 
periods) is presented in Table 4.2 and the respective parameter data is presented in Appendix D -  
Table D.1. 
Table 4.2 Set of candidate solutions (𝐉𝒑𝒕) for each product and period 
t 
Products under development  Products in commercialization 
PA PB PC  PD PE 
0 
D1L1_F1L1_R1L1 D1L1_F1L1_R1L1 D1L1_F1L1_R1L1  D1L1_F1L1_R1L1 D1L1_F1L1_R1L1 
D1L2_F1L2_R1L2 D1L1_F1L1_R2L1 D1L1_F1L1_R2L1  D3L1_F1L1_R1L1 D1L1_F1L1_R1L1_R2L1 
D1L3_F1L3_R1L3 D1L2_F1L2_R1L2 D1L2_F2L2_R2L2  D1L1_F1L1_R2L1 D1L1_F1L1_R2L1 
1 
D1L1_F1L1_R1L1 D1L1_F1L1_R1L1 D1L1_F1L1_R1L1  D1L1_F1L1_R1L1 D1L1_F1L1_R1L1 
D1L2_F1L2_R1L2 D1L1_F2L1_R1L1 D1L1_F1L1_R2L1  D1L1_F1L1_R2L1 D1L1_F1L1_R2L1 
D1L3_F1L3_R1L3 D2L1_F1L1_R1L1 D2L1_F1L1_R1L1  D1L1_F2L1_R1L1 D1L1_F2L1_R1L1 
2 
D1L2_F1L2_R1L2 D1L1_F1L1_R1L1 D1L1_F1L1_R1L1  D1L1_F1L1_R1L1 D1L2_F1L2_R2L2 
D1L3_F1L3_R1L3 D1L2_F1L2_R1L2 D1L1_F1L1_R2L1  D1L1_F1L1_R2L1 D1L1_F2L1_R1L1_R2L1 
D1L4_F1L4_R1L4 D1L1_F2L1_R1L1 D2L1_F1L1_R1L1  D1L1_D3L1_F1L1_R2L1 D1L1_F1L1_R1L1_R2L1 
3 
D1L3_F1L3_R1L3 D1L1_F1L1_R1L1 D1L1_F1L1_R1L1  D1L1_F1L1_R2L1 D1L2_F1L2_R2L2 
D1L4_F1L4_R1L4 D1L2_F1L2_R1L2 D1L2_F1L2_R1L2  D1L1_F1L1_R1L1 D1L1_F2L1_R1L1_R2L1 
D1L3_F1L3_R2L3 D1L2_F1L2_R2L2 D1L2_F1L2_R2L2  D1L1_F1L1_R1L1_R2L1 D1L2_F2L2_R2L2 
4 
D1L3_F1L3_R1L3 D1L1_F1L1_R1L1 D1L1_F1L1_R1L1  D1L1_F1L1_R2L1 D1L2_F1L2_R2L2 
D1L4_F1L4_R1L4 D1L2_F1L2_R1L2 D1L2_F1L2_R2L2  D1L1_F1L1_R1L1 D1L3_F1L3_R2L3 
D1L3_F1L3_R1L3_R2L3 D1L2_F1L2_R2L2 D1L2_F1L2_R1L2  D1L1_F1L1_R1L1_R2L1 D1L2_F2L2_R2L2 
5 
D1L3_F1L3_R1L3_R2L3 D1L2_F1L2_R1L2 D1L2_F2L2_R2L2  D1L2_F1L2_R2L2 D1L2_F1L2_R2L2 
D1L4_F1L4_R1L4 D1L2_F1L2_R2L2 D1L2_F1L2_R2L2  D1L1_F1L1_R1L1 D1L2_F2L2_R2L2 
D1L4_F1L4_R1L4_R2L4 D1L3_F1L3_R1L3 D2L2_F1L2_R2L2  D1L1_F1L1_R2L1 D1L4_F1L4_R2L4 
6 
D1L4_F1L4_R1L4_R2L4 D1L3_F1L3_R2L3 D3L4_F3L4_R3L4  D1L2_F1L2_R2L2 D1L2_F1L2_R2L2 
D1L4_F1L4_R1L4 D1L3_F1L3_R1L3 D1L2_F1L2_R2L2  D2L2_F1L2_R2L2 D1L4_F1L4_R2L4 
D1L4_F1L4_R1L4_R3L4 D1L2_F1L2_R1L2 D2L3_F2L3_R3L3  D2L2_F2L2_R2L2 D1L3_F1L3_R2L3 
7 
D1L4_F1L4_R1L4_R2L4 D1L3_F1L3_R2L3 D1L3_F1L3_R2L3  D1L2_F1L2_R2L2 D1L4_F1L4_R2L4 
D1L4_F1L4_R1L4 D1L3_F1L3_R1L3 
D1L2_F2L2_R1L2_R2L
2 
 
D2L2_F1L2_R2L2 D1L2_F1L2_R2L2 
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t 
Products under development  Products in commercialization 
PA PB PC  PD PE 
D1L4_F1L4_R1L4_R3L4 D1L4_F1L4_R1L4 D2L3_F2L3_R3L3  D1L4_F1L4_R2L4 D1L3_F1L3_R2L3 
8 
D1L4_F1L4_R1L4_R2L4 D1L4_F1L4_R2L4 D2L3_F2L3_R2L3  D1L2_F1L2_R2L2 D1L4_F1L4_R2L4 
D1L4_F1L4_R1L4 D1L3_F1L3_R1L3 D1L3_F2L3_R3L3  D1L3_F1L3_R1L3 D1L2_F1L2_R2L2 
D1L4_F1L4_R1L4_R2L4_R
3L4 
D1L4_F1L4_R1L4 D2L3_F2L3_R3L3 
 
D1L4_F1L4_R2L4 D1L3_F1L3_R2L3 
9 
D1L4_F1L4_R1L4 D1L4_F1L4_R2L4 D2L4_F2L4_R3L4  D1L2_F1L2_R1L2 D1L4_F1L4_R2L4 
D1L4_F1L4_R1L4_R2L4 D1L4_F1L4_R1L4 D2L3_F2L3_R2L3  D1L2_F1L2_R2L2 D1L4_F1L4_R1L4 
D2L4_F1L4_R1L4_R2L4 D1L3_F1L3_R1L3 D1L3_F2L3_R3L3  D1L3_F1L3_R1L3 D1L3_F1L3_R2L3 
 
4.5.2. Computational results 
The MOIP model was implemented using IBM ILOG CPLEX Optimization studio, version 12.5.1, 
running on an Intel Core i7 up to 3.0 GHz machine with 8.0 GB of RAM. To obtain the Pareto efficiency 
curve an iterative model was also implemented in CPLEX by running the model for each weight 
combination regarding the two objective functions. The integrality gap obtained ranges from 0.00% 
to a maximum value of 4.97%, and the CPU time ranges from 0.53 to 1.12 seconds. The complete 
computational statistics is presented in Table 4.3. 
Table 4.3 Computational Statistics 
binary 
variables 
integer 
variables 
constraints 
B&B 
nodes* 
optimality gap 
(%)* 
CPU time 
(seconds)* 
3300 2800 153,272 71.67 3.10 0.87 
* Average values for the 20 runs. 
 
4.5.2.1. Pareto Frontier analysis (Step 3) 
Considering the two objective functions (“Total Cost” and “Value Created”) an approximation of the 
Pareto efficient frontier was determined by consistently changing the combination of weights in 
steps of 0.05. For each combination of weights, the MOIP is performed and a solution is obtained with 
the selection of a process design and the respective number of cycles for each product and period.  
The determined Pareto front is depicted in Figure 4.6 in which is possible to see the relation between 
the “Total cost” (objective function 1) and the “Value created” (objective function 2). Through an 
immediate observation is possible to conclude that the “Value created” increases rapidly with the 
“Total cost” until a total cost value of approximately 40,000 rmu (reference monetary units). From 
this value there is no significant increase of the “Value crated” with the increase of “Total cost”, 
meaning that no significant value is gained by changing over these solutions. 
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Figure 4.6 Pareto efficient frontier approximation. 
4.5.2.2. Solutions performance assessment (Step 4) 
For a better assessment of the solutions obtained in the Pareto frontier, a polynomial regression was 
used to adjust the respective values, and several lines with different slopes were determined (Figure 
4.7). The slopes represent trade-off values between “Value created” and “Total Cost”, measuring the 
Marginal Rate of Substitution (MRS) (Keeney & Raiffa, 1993), that is  the rate at which the decision-
maker is willing to pay to increase the “value created” or, in other words, how much he is ready to 
give up in “Value created” to gain in “Total cost”. In Figure 4.7(b), 5 different trade-off values are 
represented, and is possible to observe that the higher the trade-off values are, the greater the 
variation of the “Value created” with the “Total cost”. Thus, for a trade-off value of 150 the gain 
obtained in the “value created” with a small increase in the “total cost” is significantly larger than the 
one obtained for the trade-off value of 10, anticipating a possible region of good solutions for 
investment. 
These lines are known as “indifference lines” (Keeney & Raiffa, 1993) since, for each one of them, 
there is a set of alternative solutions that have the same equivalent value for the decision-maker 
(utility), and so reflecting his preferences. Thus, different decisions-makers will have different 
indifference lines (i.e. lines with different slopes) revealing their preferences and risk attitudes 
(Keeney & Raiffa, 1993).  
Nevertheless, the preferable solution in each trade-off (indifference) line will be the one that 
maximizes the decision-maker utility, corresponding to the tangency of the “Value created”/”Total 
cost” curve, and matching a Pareto optimal solution with a specific productivity level (Eq. (4.7)). For 
instance for a trade-off value of 250 the preferred solution has a total cost of approximately 27,000 
rmu and a productivity level of approximately 30, while for a trade-off value of 50 the total cost is 
approximately 40,000rmu and the productivity level is 63, revelling a decision-maker more averse 
to risk in the second case (i.e. the decision-maker is willing to pay more to guarantee an higher 
productivity level). 
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(a) 
 
(b) 
Figure 4.7  (a) Polynomial regression of the Pareto frontier, and (b) indifference lines for different trade-off 
values. 
Moreover, according to Figure 4.7(b) despite the trade-off value of 250 be the one that provides 
greater “value created” increase with total cost, the productivity level is the lower one when 
compared to the other trade-off lines. This can better be seen in Figure 4.8(a) and Figure 4.8(b) in 
which the evolution of the productivity level with the “Total cost” and the “Trade-off values” 
respectively are depicted. According to Figure 4.8(a), the productivity level increases with an 
increase in total cost until a maximum productivity level of 63 from which increasing the total cost 
leads to a decrease in the productivity level. The same conclusion is possible to observe in Figure 
4.8(b), although in this case it is important to notice that an increase in the trade-off value means a 
decrease in the total cost. This means that from a certain level of investment the “value” gained per 
unit of cost decreases, limiting the advantages of further investment. 
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Based on this analysis is possible to clearly determine the most attractive solution region for 
investment, as depicted in Figure 4.8(a) with the preferred investment region coloured in grey. 
Additionally, in an ideal setting in which uncertainty is absent from the decision process and 
investment resources are unlimited, the “best” solution is the one that falls in the dark grey region 
(Figure 4.8 (a) and (b)) where the productivity level reaches its maximum value. However, this is not 
the case in any real context, particularly for the pharmaceutical industry and its NPD process, and so 
a risk analysis should be performed combining the uncertainty factors and the decision-makers 
attitude toward risk.   
 
 
(a) 
 
(b) 
Figure 4.8 Productivity level variation with: (a) “Total cost”, and (b) Trade-off values. 
 
Risk analysis 
The main goal of the present study is to determine the “best” design strategy (process design 
configuration) under uncertainty in product demand and clinical trial outcomes in order to prevent 
on one hand over investment that will increase the development costs that are already extremely 
high, and on the other hand delivery failures that will contribute to immediate loss of income for the 
products already in commercialization and a delay on the time-to-market for the under development 
products with future losses in revenue. 
In that sense, risk as considered in this work is associated to the possibility of failing a delivery due 
to lack of production capacity associated to the design strategy adopted. Thus, a balance between the 
risk of delivery failure and the investment in production capacity should be made taking in 
consideration the decision-maker risk attitude. Figure 4.9 provides the relation between the “total 
cost” of a solution with its “capacity allocation”, i.e. the production capacity that is available when 
selecting the specific solution associated with each trade-off value and productivity level. As 
expected, increasing the capacity allocation also increases the investment cost, and choosing higher 
trade-off values gives lower cost solutions, but also with lower flexibility and responsiveness to 
product demand variability due to the lower capacity allocation. In a highly uncertain context this 
means a higher risk of failing a delivery due to lack of available capacity to fulfil the current demand. 
Hence, the risk involved in these decisions reflects the likelihood of the production capacity 
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associated to a specific decision (i.e. process design) will not be sufficient to meet the uncertain future 
demand.  
 
Figure 4.9 Relation between the capacity allocation and total cost expected for each trade-off value. 
A comparison between the global production capacity allocation and the deterministic global product 
demand (aggregated values for all products and the entire planning horizon) is presented in Figure 
4.10. Two extreme scenarios are considered: (i) considering that all under development products 
pass all clinical trial phases (extremely unlikely scenario), and (ii) considering that none of the under 
development products reach the market (more likely to occur). In this last scenario it is considered 
that all products will fail at the end of clinical trial phase I. 
 
Figure 4.10 Relation between the capacity allocation and total cost expected for each trade-off value, and 
the deterministic values for the total product demand in two extreme scenarios: (i) considering that all 
under development products pass all clinical trial phases, and (ii) considering that none of the under 
development products reach the market. 
Analysing Figure 4.10, and the two deterministic demand scenarios it become clear that any 
investment decision (i.e. design solution) below the value of 31,000 rmu is highly risky since with 
high probability it will not be able to accommodate the product demand associated to any product 
under development that may pass all the clinical trials. Also, the inherent variability of the product 
demand associated to the products already in commercialization may not be fully covered by design 
solutions under this value, and delivery fails may occur. On the contrary, solutions with a total cost 
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around 37,000 rmu or higher will probably result in a significant capacity excess due to the 
unlikelihood of all under development products reach the market. As a consequence, the total 
available capacity may not be entirely used, and the investment made will not be recovered. In this 
context, a decision-maker with high risk aversion will prefer to invest more in order to guarantee 
enough capacity to accommodate the production of all products even knowing that this will probably 
result in a strong suboptimal solution. 
It is worth to notice however, that for this investment range ( 31,000-37,000 rmu), the respective 
productivity levels fall out of the dark grey region depicted in Figure 4.8. That is, within this range it 
will never be possible to achieve the solutions that yield the maximum productivity level. This may 
happen because the developed model doesn’t make a distinction between capacity allocation and 
effective capacity utilization. Thus, all the available capacity in a specific solution determined by the 
MOIP model is converted in “Value created” by assuming full capacity utilization. Considering this, to 
be able to achieve the maximum values of productivity depicted in Figure 4.8, not only all the under 
development products need to reach the market, but also the respective product demands should be 
among the higher values possible according to each probability distribution curve. 
Cost analysis 
A cost analysis is performed in order to better understand the cost structure and the main 
contributions for the “Total cost” value. The Figure 4.11(a) presents the variation of the different cost 
contributions with the trade-off values, namely, the "variable cost", the "fixed cost" and the "process 
change cost". The "variable cost" seems to be the most relevant contributor to the total cost as the 
trade-off value increases. This can be explained by the fact that for each solution (selected process 
design) the "value created" can be increased by increasing the number of cycles of that process and 
consequently the amount of capacity that can be allocated for the same specific process design. 
However, for the lower trade-off values (below the value of 50) the “process change costs” seem to 
also assume a significant relevance. These values correspond to the most risk-averse attitudes, and 
therefore greater importance is given to the “value created” rather than to the “total cost”. In this 
situation, the capacity increase is mostly driven by a change in the process design instead of a change 
in the number of cycles of the same process. On the other hand, above the trade-off value of 50 the 
process changes seem to be stable since above this value a higher importance is given to the “total 
cost” and a better balance is made between “process design” and “number of cycles”. Additionally, in 
Figure 4.11(b) is depicted a comparison between the total cost variation with the trade-off values 
and the total cost obtained for the deterministic solution. The deterministic solution is obtained 
considering the expected average values for the product demands and considering that all under 
development products will reach the market (i.e. will successfully pass all clinical trials phases). 
Moreover, for the sake of comparison, the total cost of the deterministic solution only accounts for 
the variable, fixed and changeover costs (the inventory, waste, and investment costs were not 
considered for this analysis since they are not captured in the developed MOIP model). According to 
this figure (Figure 4.11(b)) above the trade-off value of 70 the total cost obtained considering the 
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developed approach (i.e. considering uncertainty) is always below the deterministic solution. It’s 
interesting to observe that this trade-off value also corresponds approximately (being slightly above) 
to the upper limit for capacity allocation investment determined previously in Figure 4.10 in order 
to prevent over investment in capacity. Thus, solutions equal or below a trade-off value of 90 will be 
not only more costly, but also with an excess in capacity availability.  
 
 
(a) 
 
(b) 
Figure 4.11 Total cost analysis for each trade-off value: (a) Total cost components (variable cos, fixed cost, 
and process changes costs); (b) Comparison between total cost obtained for each trade-off value and the total 
cost obtained in the deterministic solution. 
 
4.5.2.3. Strategic final solution (Step 5) 
The unique strategic final solution will be selected by the decision-maker taking into account the 
results obtained from the implementation of the unified decision-making framework depicted in 
Figure 4.4 and his own preferences and risk attitude. Therefore, based on the results and trade-off 
analysis presented in the above sections, and considering for instance a decision-maker with a more 
risk-prone attitude concerning the possibility of failing a delivery during the NPD process, the final 
decision may lay for instance on the trade-of values around 150 or 140 (Figure 4.9 and Figure 4.10). 
Selecting for example the value of 140 as the final solution to demonstrate the full implementation of 
the developed approach, the productivity level obtained is approximately 57 and the combination of 
weights associated to this solution is 𝛽1 = 0.85 and 𝛽2 = 0.15. The selected process designs and 
respective production capacities are depicted in Figure 4.12 (products in commercialization) and 
Figure 4.13(products under development) for each time period and product. As expected, for the 
under development products the capacity allocation after period t=2 (end of clinical trial phase I) is 
always under the average expected demand. Since the selected solution is closer to the scenario in 
which none of the under development products pass the clinical trials, the model only allocates a 
capacity safety level for each one of these products. Moreover, despite the fact that the available 
capacity is distributed among all products, the company may benefit from a capacity pooling system 
in which the unused capacity of one product is redistributed to the others as needed. In this way, if a 
product passes all clinical trial phases, it will still be possible to meet its expected demand. 
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(a) 
 
(b) 
Figure 4.12 Results obtained for the capacity allocation considering a risk-prone decision-maker for the 
products already in commercialization. 
 
Regarding the products already in commercialization (Figure 4.12), for this level of investment, the 
model clearly favours the production of the most valuable product (that is product PE) by 
guaranteeing enough capacity to accommodate the average expected demand and its variability. 
Once again, in this case the unused capacity of one product may be used for the other by consolidating 
the available resources. 
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(a) 
 
(b) 
 
(c) 
Figure 4.13 Results obtained for the capacity allocation considering a risk-prone decision-maker for the 
products under development. 
In addition to this, and in order to deeply explore the application of the developed decision-making 
framework, the results obtained considering a risk-averse decision maker can be seen in Figure 4.14 
and Figure 4.15 Figure 4.15. The solution obtained is for a trade-off value of 35 and a productivity level 
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of 62 (please refer to Figure 4.9 and Figure 4.10). In this case, the combination of weights associated 
to this solution is 𝛽1 = 0.46 and 𝛽2 = 0.54. A clear increase in production capacity is observed for all 
the products with the exception of product PA which presents an increase in the production capacity 
only in the last period when compared to the previous case. For the products already in 
commercialization the capacity allocation is almost always above the expected demand for both 
products, since these are the products that will guarantee a higher return for the company. On the 
other hand, for the products under development it is observed an approximation of the production 
capacity to the expected average demand (excepting for product PA). Considering that it is very 
unlikely that all products will reach the market, it is almost certain that not only all future production 
needs will be fully covered by this design solution, but also some overcapacity may be expected. 
 
(a) 
 
(b) 
 
(c) 
Figure 4.14 Results obtained for the capacity allocation considering a risk-averse decision-maker for the 
products under development. 
 
(a) 
 
(b) 
Figure 4.15 Results obtained for the capacity allocation considering a risk-averse decision-maker for the 
products already in commercialization. 
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Based on these results, obtained for two risk attitudes is possible to infer that not only the attitude 
toward risk, but also the level of investment that the company can afford has a great impact on the 
final solutions. A simple analysis of the Pareto optimal frontier is not sufficient to unveil the most 
adequate solution for the decision-maker or even for the company reality. Thus, the involvement of 
the decision-maker is crucial not only to impart a more realistic vision to the decision-making process 
but also to provide more meaningful solutions.    
4.5.2.4. Dinkelbach’s algorithm 
In order to determine the unique optimal solution considering the maximization of the productivity 
as expressed in Eq. (4.8)), the Dinkelbach’s algorithm was adopted by applying the algorithmic 
scheme presented in You et al. (2009). 
The algorithm was implemented using IBM ILOG CPLEX Optimization studio, version 12.5.1, running 
on an Intel Core i7 up to 3.0 GHz machine with 8.0 GB of RAM. The algorithm was started by step 1 
(please refer to You et al. (2009)) considering q2 = 0, for k = 2 with k being the number of iterations 
(see Table 4.4). 
The optimal value was obtained after 4 iterations and 36.14 sec, with a productivity level of 64.0185 
(Table 4.4). Considering the multi-objective approach, the best value obtained for the productivity 
level was 63.3. The slight difference (1%) in these values can be explained by the fact that only an 
approximation of the Pareto frontier is obtained through the multi-objective approach and a 
subsequent polynomial regression is applied.  
Nevertheless, when analyzing Figure 4.16 above, and considering the optimal solution obtained 
through the Dinkelbach’s algorithm, we can say that a good approximation of the optimal Pareto 
Front was determined, and the final results are reliable and efficiently assessed through the proposed 
approach. 
Moreover, as stated previously, the optimal solution may not reflect the real preferences of the 
decision-maker and his/her risk attitude toward uncertainty, and the rigorous assessment of this 
value is not the primary goal of this work. 
 
Table 4.4 Dinkelbach’s algorithm results 
k 
(iteration) 
qk=f2/f1 
f2  
(“Value Created”) 
f1  
(“Total Cost”) 
F(qk) 
2 0.0000 2.80x106 1.04x105 2.80x106 
3 26.9816 2.45x106 3.86x104 1.41x106 
4 63.4473 2.41x106 3.77x104 2.14x104 
5 64.0185 2.41x106 3.77x104 2.45x104 
6 64.0185 2.41x106 3.77x104 2.45x104 
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Figure 4.16 Optimal solution obtained by implementing the Dinkelbach’s algorithm. 
4.6. Conclusions 
In this chapter an extension of the proposed TSMCS framework is presented in order to complete the 
development of a new unified decision-making framework to address the stochastic product launch 
planning problem (including process design and capacity planning decisions) in the chemical-
pharmaceutical industry. The first part of the framework depicted in Figure 4.4 (Step 1 and 2) is 
developed in the previous chapter (chapter 3) by generating the complete set of solutions, 
considering uncertainty in product demand (for both types of products) and in the clinical trials 
outcomes (for the under development products). The most frequent process design solutions were 
then obtained and defined as part of the set of candidate possible final solutions considered here.  
In the present work, the focus is given to the determination of the unique design strategy to follow 
(the stochastic process design solution) through the development of a Multi-Objective Integer 
Programming (MOIP) model, embedded in the unified decision-making framework presented in 
Figure 4.4 (Steps 3, 4 and 5), in order to “maximize” productivity by balancing two conflicting 
objectives. The final solution is determined by explicitly considering the decision-maker preferences 
and attitude toward risk, filling the existing gap associated to the current paradigms to tackle 
uncertainty in which a unique optimal prescriptive decision is obtained. Given the highly strategic 
nature of the decisions considered here, the involvement of the decision-maker in the final solution 
is critical and its importance is highlighted through the obtained results.  
The developed MOIP model has proven to be efficient and effective in selecting the final solution, 
while the multi-objective approach allowed to explicitly considering the decision-maker risk attitude 
by obtaining an approximation of the Pareto-front. This, allowed the decision-maker to ponder all 
possibilities and trade-offs between the two objective functions (indifference lines) before selecting 
the final solution. Nevertheless, the selection of a single solution from the Pareto set is not a 
straightforward process or even sufficient to determine the most suitable solution for the decision-
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maker. Therefore, a subsequent Pareto analysis is performed with the assessment of the solutions 
performance (productivity level) and risk analysis (likelihood of failing the future production needs).  
The results obtained clearly show how the different trade-off values (indifference lines) reflects 
different attitudes towards risk, and how these different risk attitudes influence the final solution. A 
good balance between investment and capacity allocation has been achieved by the model according 
to the different decision-maker preferences. Additionally, interesting results were also obtained for 
the productivity level by clearly determining the most promising solutions region for investment. 
Finally, the complete unified decision-making framework developed has proven to be a robust and 
reliable tool to address the highly stochastic product launch planning problem in the pharmaceutical 
industry. On one hand, the framework clearly identifies the most promising process designs and 
scale-ups that maximize profit (NPV) under uncertainty by mapping a wide range of possible future 
scenarios. On the other hand, the final design strategy is determined based on the most promising 
process design candidates, and considering the decision-makers risk attitudes, to “maximize” 
pharmaceutical productivity. Moreover, the optimal solution of Dinkelbach’s algorithm shows that 
the results obtained through the multi-objective approach are robust and reliable.  
The final solution obtained at the early stages of the product development enables on-time decision-
making, while balancing the total investment and the production capacity allocation in order to 
achieve simultaneously three main goals: (i) prevent over investment; (ii) guarantee sufficient 
production capacity to fulfil all future product demand needs; and (iii) minimizing process design 
changes over the development process, by benefitting from a better management of the available 
capacity (through capacity pooling methods). 
Finally, when compared the proposed unified decision-making framework to the most widely used 
TSSP approaches, some advantages can be outlined, such as: (i) the ability to generate a wide range 
of possible realizations, considering several uncertainty parameters simultaneously, without 
increasing the model size and complexity; (ii) the ability to efficiently capture the binary nature of 
the clinical trials outcomes uncertainty; and (iii) the ability to incorporate the decision-maker 
preferences in the final solution, making it more robust and reliable.
  
 
 
 
 
 
 
 
 
  
 
5. Conclusion 
In this chapter the conclusion of this thesis is presented highlighting the main research contributions 
and recommendations for future development. 
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5.1. Research contributions 
In this work, the complexity of the pharmaceutical industry and its operations are investigated with 
the main objective to contribute to the improvement of the global efficiency. For this purpose, we 
attempted to provide answers to the three formulated research questions. In a first step, the major 
industry’s distinctive features, as well as its current state, operational fragilities, and research gaps 
are identified and thoroughly analysed (chapter 2). The general structure of the expected future 
pharmaceutical supply chain is outlined and, based on this, a comprehensive decision-making 
reference framework is proposed. 
In a second step, the stochastic product launch planning problem is addressed through the 
development of effective optimization-based approaches. An innovative two-step Monte Carlo 
simulation framework is then presented to determine the integrated process design and production 
planning decisions under uncertainty (chapter 3). Following this, a Multi-Objective Integer 
Programming model is developed to obtain the final strategic solution and complete the unified 
decision-making framework (chapter 4). 
Despite the detailed findings are already clearly described in each one of the chapters mentioned 
above, the major contributions achieved by this research work (for both practitioners and 
researchers) can be outlined in two different levels of analysis, as depicted in Figure 5.1.  
 
Figure 5.1 Addressed challenges and major contributions of the thesis. 
 
At a broader level, the materialization of the expected new paradigm into a structured view of the 
future supply chain (and its main components), reflects one of the first attempts to envision 
objectively the operational implications of the current market and technological pressures. It is clear 
 
5. Conclusion 
142 
 
that the old paradigm of the industry is no longer effective and companies, although discretely, are 
just starting to adapt by redefining its strategies and operational practices. 
On the other hand, the identified planning problems and solution approaches addressed in the 
literature unveil a still very narrow perspective from academia, demonstrating an overall 
misalignment with the main trends driving the industry. 
This highlights the notion that the changes imposed by the current business context are not only 
extremely ambitious, but also disruptive in the context of a highly traditional and conservative 
industrial sector, as it is the pharmaceutical industry. An effective change to a greater centrality of 
the patient together with the adoption of innovative technologies and decision-making tools is a 
highly complex and lengthy process, with the industry just starting to take its first steps. Main 
findings, however, also disclosure the most pressing needs related to the improvement of operational 
efficiency across the entire product life-cycle activities, particularly for the drug development 
process. Reducing not only the time-to-market, but also the overall supply chain costs are gradually 
becoming as important as quality assurance goals. 
In this way, at a narrower (problem-specific) level, important contributions were made regarding 
the approximation between optimization-based approaches and real settings by effectively 
incorporating industry-specific features into the developed models (see Figure 5.1). On one hand, the 
proposed simulation-optimization approach introduces an innovative way of dealing with several 
sources of uncertainty with very different inherent behaviours while, at the same time, providing a 
structured way to search for the optimal solutions. This methodology has proven that is possible to 
efficiently tackle uncertainty without using complex and large-scale multi-stage stochastic 
programming models. Moreover, the integration of production/capacity planning with process 
design decisions during clinical trials represents also an important contribution. Not only, because 
the strategic/tactical decision-levels integration is explored, but also due to the relevance of process 
design considerations during product development. 
On the other hand, the unique final strategic solution is determined through a multi-objective 
approach explicitly incorporating the decision-maker preferences, which are still very poorly 
explored in the literature, despite its practical relevance. Also, the exploitation of alternative 
performance metrics, such as the productivity level, to guide the final strategic decisions, adds an 
essential contribution to the current literature which has been highly focused on strictly profit goals. 
Overall, this work has contributed to bring the academia closer to industry by understanding its 
needs and converting them into decision-making requirements and novel modelling features. 
Figure 5.1 depicts not only the major contributions, but also the main challenges that have been 
addressed and have driven the further development of this work.  
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5.2. Future research work 
The main findings detailed in each chapter of this thesis already point to some of the possible future 
research paths. Nevertheless, supply chain and operational management within the pharmaceutical 
context is a fruitful area of development, worthy a more deep reflexion. In this way future 
recommendations for development will be presented following two lines of action.  
The first one dedicated to natural extensions of the developed methodologies, and the second one, 
more focused on general considerations regarding the pharmaceutical operational context. 
 
Further extensions 
1. Alternative demand patterns.  
As highlighted in this work, uncertainty plays a fundamental role in the NPD process. 
Exploring alternative ways of representing it will contribute to improve the analysis and 
enhance the methodology value. Thus, it would be interesting to evaluate not only different 
demand patterns, but also alternative distribution functions reflecting different behaviours 
regarding patient enrolment to trials (for products under development) or patient 
adherence to treatments (for products in commercialization). 
2. Multi-echelon approach 
The ability to produce and deliver the right quantities at the right time to the clinical sites is 
paramount to reduce the time-to-market. In that sense, further developments should include 
an extended analysis of the problem integrating the manufacturing component with the 
packaging and distribution functions. This will require the development of effective large-
scale formulations to deal simultaneously with process design, production/capacity 
planning, and inventory management decisions across the entire clinical trials supply chain. 
3. Dynamic portfolio considerations 
In a typical pharmaceutical company, the portfolio pipeline is composed by several products 
at different stages of development. During the development period some products are 
abandoned, while new ones may be added to the portfolio. This dynamic behaviour is not 
fully captured in this work, as it is considered (for the sake of clearness) that all the products 
reach clinical trial phase I at the same time. In this way, it would be interesting to explore 
more deeply this issue by a generalization of the model to account for this dynamic 
behaviour. 
 
New research areas  
1. Functional integration 
It is observed a lack of research exploring holistic approaches able to capture the full 
integration between the clinical development, product launch activities, and commercial 
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distribution. This is a fruitful area of development considering the modelling challenges 
involved and the expected operational gains for the industry. 
2. Multi-objective approaches 
The literature assessment reveals a mature development of optimization-based approaches 
focused on single objectives based on profit or cost metrics. The complexity of the planning 
problems in the pharmaceutical context, however, encompass a much wider range of 
dimensions and performance indicators. Therefore, there is high potential for the 
exploitation of multi-objective approaches accommodating novel performance metrics 
based on economic, environmental and social dimensions.   
3. Exploitation of market and technological trends 
As described in chapter 2, major technological (continuous manufacturing and digital 
capabilities) and market (personalization) trends are currently changing the pharmaceutical 
industry. Despite its impacts on decision-making tools, these changes are still seldom 
considered in the current modeling approaches. Exploring these new features within a 
modelling perspective (e.g. redefining variables or constraints) will be critical for the 
decision-making process and, undoubtedly, a promising area of future development.  
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Appendix A – Decision-levels hierarchical representations 
proposed in the literature 
 
 
Figure A.1 Hierarchical structure of decision problems  in the PSE community (Grossmann & Guillén-
Gosálbez, 2010) 
 
 
 
(a) 
 
(b) 
Figure A.2  Hierarchical structure of decision problems (a) presented by Garcia & You (2015); and (b) 
presented by Chu & You (2015) 
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Figure A.3 Chemical enterprise modeling framework (Heintz et al., 2014) 
 
 
 
Figure A.4 Delivery Trade-offs Matrix (Moniz et al., 2015a)  
 
 
 
Figure A.5 Decision-levels integration (Harjunkoski, 2017) 
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Appendix B – Literature review 
 
Table B.1 Main problems in the pharmaceutical industry addressed in the PSE and management literature 
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(Subramanian et al., 2000; Subramanian et al., 
2001); (Maravelias & Grossmann, 2001);  (Blau et 
al., 2000); (Rogers et al., 2002); (Subramanian et al., 
2003) (Blau et al., 2004a); (Gupta & Maranas, 2004)  
(Rajapakse et al., 2005); (Charalambous & Gittins, 
2008); (George & Farid, 2008; George & Farid, 
2009); (Zapata et al., 2008; Zapata & Reklaitis, 
2010); (Pérez-Escobedo et al., 2011);  (Perez-
Escobedo et al., 2012); (Hassanzadeh et al., 2014); 
(Christian & Cremaschi, 2015; Christian & 
Cremaschi, 2017);  (Zeng & Cremaschi, 2017) 
D - 
Scheduling of 
testing tasks / 
resource 
allocation 
29 
S 
(Schmidt & Grossmann, 1996b); (Schmidt & 
Grossmann, 1996a); (Subramanian et al., 2000); 
(Subramanian et al., 2001);  (Blau et al., 2000); 
(Maravelias & Grossmann, 2001); (Subramanian et 
al., 2003) (Blau et al., 2004a); (Choi et al., 2004); 
(Gupta & Maranas, 2004); (Colvin & Maravelias, 
2008; Colvin & Maravelias, 2009; Colvin & 
Maravelias, 2010; Colvin & Maravelias, 2011); 
(George & Farid, 2008; George & Farid, 2009); 
(Zapata et al., 2008; Zapata & Reklaitis, 2010); 
(Varma et al., 2008a); (Pérez-Escobedo et al., 2011); 
(Perez-Escobedo et al., 2012); (Hassanzadeh et al., 
2014); (Christian & Cremaschi, 2015; Christian & 
Cremaschi, 2017);  (Zeng & Cremaschi, 2017); 
(Christian & Cremaschi, 2018) 
 
D 
(Schmidt et al., 1998); (Jain & Grossmann, 1999); 
(Maravelias & Grossmann, 2004) 
C
li
n
ic
a
l 
tr
ia
l 
S
u
p
p
ly
 
C
h
a
in
 o
p
e
ra
ti
o
n
s 
SC design/ 
capacity 
planning 
5 
S 
(Farid et al., 2005) (Chen et al., 2012a); (Chen et al., 
2012b), (Fleischhacker et al., 2015),  (Marques et 
al., 2017b) 
D - 
Production/ 
inventory 
planning 
7 
S 
(Peterson et al., 2004); (Abdelkafi et al., 2009); 
(Fleischhacker & Zhao, 2011); (Chen et al., 2012a); 
(Chen et al., 2012b); (Fleischhacker et al., 2015); 
(Marques et al., 2017b) 
D - 
Scheduling 0 
S - 
D - 
S
u
p
p
ly
 C
h
a
in
 
O
p
e
ra
ti
o
n
s 
P
ro
d
u
ct
 L
a
u
n
ch
 /
 N
e
w
 
p
ro
d
u
ct
 i
n
tr
o
d
u
ct
io
n
s 
 
Portfolio 
selection 
8 
S 
(Rotstein et al., 1999); (Maravelias & Grossmann, 
2001); (Gatica et al., 2003b; Gatica et al., 2003a);  
(Levis & Papageorgiou, 2004); (Tsang et al., 2007a; 
Tsang et al., 2007b) 
 
D (Papageorgiou et al., 2001) 
SC design/ 
capacity 
planning  
15 S 
(Rotstein et al., 1999); (Maravelias & Grossmann, 
2001); (Gatica et al., 2003b; Gatica et al., 2003a);  
(Levis & Papageorgiou, 2004); (Wan et al., 2006b); 
(Tsang et al., 2007a; Tsang et al., 2007b); (Laínez et 
al., 2009b); (Sundaramoorthy et al., 2012); 
(Kaminsky & Yuen, 2014) 
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Functional 
area 
Main 
problem 
Sub-
problem 
# 
papers 
U(1) Publications 
D 
(Papageorgiou et al., 2001); (Sundaramoorthy & 
Karimi, 2004); (Naraharisetti & Karimi, 2010); 
(Hansen & Grunow, 2015a) 
Production / 
inventory 
planning 
(single- and 
multi-site) 
13 
S 
(Maravelias & Grossmann, 2001); (Gatica et al., 
2003b; Gatica et al., 2003a); (Levis & Papageorgiou, 
2004); (Tsang et al., 2007a; Tsang et al., 2007b); 
(Laínez et al., 2009b); (Sundaramoorthy et al., 
2012); (Hansen & Grunow, 2015b) 
 
D 
(Papageorgiou et al., 2001); (Sundaramoorthy & 
Karimi, 2004); (Naraharisetti & Karimi, 2010); 
(Hansen & Grunow, 2015a) 
G
lo
b
a
l 
S
u
p
p
ly
 C
h
a
in
 a
n
d
 M
a
n
u
fa
ct
u
ri
n
g
 
SC design/ 
capacity 
planning 
 
13 
S 
(George et al., 2007); (Mousazadeh et al., 2015); 
(Seifert et al., 2015); (Zahiri et al., 2017) 
 
D 
(Grunow et al., 2003);  (Sousa et al., 2008); 
(Nagurney et al., 2013); (Friemann & Schönsleben, 
2016); (Liu & Papageorgiou, 2013); (A. Narayana et 
al., 2014); (Weraikat et al., 2016); (Banimostafa et 
al., 2015); (Low et al., 2016) 
Production / 
inventory 
planning 
30 
S 
(Stefansson et al., 2006; Stefansson et al., 2009); 
(Lakhdar et al., 2006; Lakhdar & Papageorgiou, 
2008); (Mousazadeh et al., 2015); (Assid et al., 
2015); (Jia & Zhao, 2017); (Amaro & Barbosa-
Póvoa, 2006); (Amaro & Barbosa-Póvoa, 2009); 
(Linninger et al., 2000; Linninger & Chakraborty, 
2001); (Nematollahi et al., 2017; Nematollahi et al., 
2018) 
 
D 
(Gupta et al., 2002); (Berning et al., 2002); (Grunow 
et al., 2003); (Sundaramoorthy et al., 2006); 
(Meijboom & Obel, 2007); (Sousa et al., 2008; Sousa 
et al., 2011); (Ruiz-Torres et al., 2010); (Susarla & 
Karimi, 2012b);(Liu et al., 2014); (Moniz et al., 
2014a); (Meiler et al., 2015); (Vieira et al., 2016); 
(Liu & Papageorgiou, 2013); (Lücker & Seifert, 
2017); (Amaro & Barbosa-Póvoa, 2008); (Su et al., 
2017) 
 
Production 
scheduling 
26 
S 
(Stefansson et al., 2006; Stefansson et al., 2009); 
(Eberle et al., 2014); (Baumann & Trautmann, 
2014); (Pistikopoulos et al., 2015); 
 
D 
(Graells et al., 1998); (Raaymakers & Hoogeveen, 
2000); (Roslöf et al., 2001); (Berning et al., 2002); 
(Amaro & Barbosa-Póvoa, 2005); (Castro et al., 
2008); (Ciavotta et al., 2009); (Venditti et al., 2010); 
(Kopanos et al., 2010); (Stefansson et al., 2011); 
(Kabra et al., 2013); (Moniz et al., 2012; Moniz et al., 
2013a; Moniz et al., 2014a; Moniz et al., 2014c); 
(Meiler et al., 2015); (Costa, 2015); (Vieira et al., 
2016); (Eberle et al., 2016); (Amaro & Barbosa-
Póvoa, 2008); (Halim & Srinivasan, 2011) 
(1) Uncertainty: S – Stochastic; D – Deterministic. 
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Appendix C – Technology enablers 
 
Table C.1 Technology enablers and key features 
 
Tech. 
trends 
Technology key 
features/capabilities 
Potential impacts on PSC Adoption barriers Adoption enablers 
P
R
O
D
U
C
T
 
C
e
ll
 a
n
d
 G
e
n
e
ti
c 
T
h
e
ra
p
ie
s 
 
Development of personalized 
medicines 
 
 
- New patient-centric business models  
- Increased product value 
- Higher product variability and volume mix 
 
- Reduced clinical trials dimension  
- Reduced product development cycle time  
- Increased technical success during product  
Development 
 
 
 
- Scientific development 
- Lack of regulatory protocols and 
regulations to guarantee quality 
and patients safety 
- Encouragement and support 
from regulatory agencies (FDA, 
EMA) 
- Enhanced R&D productivity 
- Reduced time-to-market 
Development of innovative 
drugs to target unmet needs 
(e.g. Orphan Drugs) 
- New business models based on niche markets 
- Higher product variability and volume mix 
- Faster product development cycles and extended patent protection (due to the 
incentives from regulators) 
- Small market - less economically 
attractive for companies 
 
 
 
- Programs already 
implemented by regulators 
(FDA and EMA) with incentives 
for the prioritization of the 
development of drugs targeting 
rare diseases 
 
 
 
 
 
Patients are selected 
based on specific 
genome 
characteristics 
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Tech. 
trends 
Technology key 
features/capabilities 
Potential impacts on PSC Adoption barriers Adoption enablers 
P
R
O
C
E
S
S
 
C
o
n
ti
n
u
o
u
s 
m
a
n
u
fa
ct
u
ri
n
g
 
 
Seamless (continuous) 
production, eliminating 
holding times between the 
“stop-and-start” steps of the 
traditional batch production; 
 
- More responsive SC → Demand-driven supply 
- Shorter lead times; 
- Reduced Inventory Levels 
- Reduces variability between individual batches and the risk of adverse events 
(Martin, 2016) 
- Improved quality with less rework 
- Reduced overall operational costs and safety 
- Reduced product development cycle time and costs 
- Concerns about validation and 
approval 
- Mind-set readiness 
- Initial investments costs 
- Higher technical complexities in 
the design and operational phase 
- The need for a total redesign for 
the marketed products originally 
designed for batch production 
- Current inventory of batch 
facilities that are dimensioned for 
blockbuster’s production 
- Current lack of vendors of 
reliable process equipment 
compatible for continuous 
manufacturing 
- Encouragement and support 
from regulatory agencies (FDA, 
EMA) 
- More cost-effective technology 
demonstrated by academia and 
practitioners 
- Already adoption by some big 
players 
- Risk of being outpaced by 
competitors  
Reduction in manufacturing 
footprint (Small equipment 
and space required) 
- Smaller-scale processing units to manufacture similar quantities (when 
compared to batch units) 
- Reduced management burden 
- Reduced inventory levels, particularly for intermediates 
- Shorter lead times and higher throughputs 
- Reduced production and distribution costs 
Production of various scales 
with a given process due to its 
continuous nature as opposed 
to the discrete nature of batch 
sizes  
- Production flexibility (product/volume mix) 
- Improved responsiveness to market dynamic 
- Improved adaptability to different regional markets 
- Easy scale-up during product development and market launch  (Daszkowski, 
2013) 
- Better matching between production, inventory and market demand needs 
Better process understanding  
- Enable the identification of critical points affecting quality and the design of 
quality control strategies to address these critical points 
- Enable fundamental process understanding earlier in development phase 
Higher degree of automation 
and real-time monitoring 
- Enhanced process robustness and reliability 
- Real-time monitoring and control 
- Prevention of human errors 
- Enhanced quality and process control 
- Delivery of “Right-first-time” quality → Less rework 
-- Reduced inventory 
- Preventative/predictive maintenance and condition monitoring. 
Higher operational efficiency 
- Higher throughput  
- Higher process yields 
- Better resources and energy utilization → reduced environmental impact 
- Higher capacity utilization (OEE) 
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Tech. 
trends 
Technology key 
features/capabilities 
Potential impacts on PSC Adoption barriers Adoption enablers 
D
ig
it
a
li
za
ti
o
n
 (
In
d
u
st
ry
 4
.0
) 
 
 
Data-driven integrated 
systems  
- New data-driven business models; 
- Democratization of information in a real-time flow of data (patient data, 
product data, process data, and supply chain operations data) 
- Data-driven decision models focused on the patient and customization 
- Drug development based on update patient data → increased probability of 
technical success and of the perceived value for the enrolled patients 
- Reduced clinical trials dimension and costs 
- Reduced drug development cycle times - Need for greater understanding 
of the manufacturing processes 
- Requirement of accurate online 
sensing of key product and 
process parameters including 
closed-loop control and online 
optimization 
- The current level of automation 
is low 
- The current virtual 
manufacturing technology is 
absent 
- Traditional practices based on 
batch operating mode → the 
transition to continuous 
manufacturing is essential to the 
adoption of industry 4.0 
capabilities 
- Need for global standards and 
data sharing protocols 
- Safety, data security and data 
ownership → intellectual 
property data and particularly 
important the health patient data 
due to its sensitivity and 
confidentiality issues. 
- Wide range of process sensors 
installed, and available 
parameters data along the 
process plant 
- Some process industry key 
players already developing 
research programs based on 
Industry 4.0 paradigm 
Cyber-Physical-Systems 
- Self-organising and reconfigurable SC in which goods, machines, and 
organizations are connected to each other; 
- Decentralized decision-making processes; 
- New product-service solutions (e.g. novel packaging solutions that facilitate 
patient compliance and adherence to treatment) 
- Advanced simulation and optimization models 
- Move from mass-production to mass-customization 
- Flexibility and self-adaptation of the ongoing clinical trials to the patient needs 
- Reduced clinical trials dimension and costs 
- Reduced drug development cycle times 
Real-time monitoring  
- Real-time flow of data (patient data, product data, process data, and supply 
chain operations data) 
- Better process control and adaptability to sources of variability → improved 
quality 
- Real-time anticipation and self-reconfiguration to react to market disruptions 
- Real-time adjusting of process parameters throughout the manufacturing 
process → reducing waste and improving production yields. 
- Improved quality through predictive analytics  
Enhanced process safety and 
predictive maintenance 
- Self-aware production lines constantly monitoring themselves and reporting on 
their own condition 
- Reduced reactive maintenance 
- Improve capacity utilization 
- Improve process safety 
- Reduced production costs 
Enhanced “track-and-trace” 
capabilities 
- Critical for the personalized SC 
- Reconfigurable and adaptive supply chain around the patient, based on remote 
patient diagnostic data 
- Improved end-to-end visibility and efficient communication between all SC 
entities → better control of counterfeit drugs 
- Enhanced visibility across the entire clinical trial supply chain with improved 
communication between all stakeholders involved, including the patient. 
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Tech. 
trends 
Technology key 
features/capabilities 
Potential impacts on PSC Adoption barriers Adoption enablers 
D
E
C
IS
IO
N
-M
A
K
IN
G
 
D
e
ci
si
o
n
-m
a
k
in
g
  
Enhanced modelling, 
optimization and 
decomposition schemes 
- Improved decision-making capabilities 
- Effective integration across company functions, physical organisations and 
decision-making levels 
- Effective incorporation of uncertainty arising at different scales  
- Effective incorporation of sustainability aspects 
- New solution approaches to solve large-scale problems 
Current available computational 
tools 
Enhanced decision-making 
capabilities Data-driven optimization and 
simulation-optimization 
approaches 
- Integration of state-of-the-art optimization techniques with data analytics 
- On-line decision-making 
- Effective incorporation of uncertainty and risk assessment 
- Reduced model complexity for large-scale problems 
- Integration of high-level detail (simulation) with optimization techniques to 
find optimal or quasi-optimal solutions 
Virtualization and simulation 
- Improve operational performance 
- Simulation of scale-up processes before its implementation 
- Foster process safety opportunities 
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Appendix D – Process design data 
Table D.1 Process design data, including the minimum and maximum number of cycles, and the associated 
costs 
p t 
Process design 
(j) 
Min. nr. 
cycles 
(𝜼𝒑𝒋𝒍𝒕
𝒎𝒊𝒏) 
Max. nr. 
cycles 
(𝜼𝒑𝒋𝒍𝒕
𝒎𝒂𝒙) 
Variable 
cost (rmu) 
(𝜶𝒑𝒋𝒍
𝒗𝒂𝒓) 
Fixed cost 
(rmu) 
(𝜶𝒑𝒋𝒍
𝒇𝒊𝒙
) 
Process changes 
cost (rmu) 
(𝜶𝒑𝒕
𝒑𝒄
) 
PA 
0 
D1L1_F1L1_R1L1 1 5 49.5 150 225 
D1L2_F1L2_R1L2 1 5 54.5 150 225 
D1L3_F1L3_R1L3 1 3 64.5 150 225 
1 
D1L1_F1L1_R1L1 1 5 49.5 150 225 
D1L2_F1L2_R1L2 1 5 54.5 150 225 
D1L3_F1L3_R1L3 1 3 64.5 150 225 
2 
D1L2_F1L2_R1L2 1 5 54.5 150 225 
D1L3_F1L3_R1L3 1 4 64.5 150 225 
D1L4_F1L4_R1L4 1 2 84.5 150 225 
3 
D1L3_F1L3_R1L3 1 2 64.5 150 300 
D1L4_F1L4_R1L4 1 5 84.5 150 300 
D1L3_F1L3_R2L3 1 2 67.5 230 300 
4 
D1L3_F1L3_R1L3 1 5 64.5 150 300 
D1L4_F1L4_R1L4 1 5 84.5 150 300 
D1L3_F1L3_R1L3_R2L3 1 5 84.5 300 300 
5 
D1L3_F1L3_R1L3_R2L3 1 2 84.5 300 300 
D1L4_F1L4_R1L4 1 5 84.5 150 300 
D1L4_F1L4_R1L4_R2L4 1 3 104.5 300 300 
6 
D1L4_F1L4_R1L4_R2L4 1 2 132 300 525 
D1L4_F1L4_R1L4 1 1 163 150 525 
D1L4_F1L4_R1L4_R3L4 1 1 162.5 600 525 
7 
D1L4_F1L4_R1L4_R2L4 1 6 104.5 300 525 
D1L4_F1L4_R1L4 1 1 146 150 525 
D1L4_F1L4_R1L4_R3L4 1 5 107.5 600 525 
8 
D1L4_F1L4_R1L4_R2L4 1 4 117.5 300 525 
D1L4_F1L4_R1L4 1 5 84.5 150 525 
D1L4_F1L4_R1L4_R2L4_R
3L4 
1 2 182.5 750 525 
9 
D1L4_F1L4_R1L4 1 5 84.5 150 525 
D1L4_F1L4_R1L4_R2L4 1 6 104.5 300 525 
D2L4_F1L4_R1L4_R2L4 1 3 120 350 525 
PB 
0 
D1L1_F1L1_R1L1 1 5 54.5 150 345 
D1L1_F1L1_R2L1 1 3 57 230 345 
D1L2_F1L2_R1L2 1 2 74.5 150 345 
1 
D1L1_F1L1_R1L1 1 3 54.5 150 345 
D1L1_F2L1_R1L1 1 2 54.5 200 345 
D2L1_F1L1_R1L1 1 3 54.5 200 345 
2 D1L1_F1L1_R1L1 1 3 54.5 150 345 
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p t 
Process design 
(j) 
Min. nr. 
cycles 
(𝜼𝒑𝒋𝒍𝒕
𝒎𝒊𝒏) 
Max. nr. 
cycles 
(𝜼𝒑𝒋𝒍𝒕
𝒎𝒂𝒙) 
Variable 
cost (rmu) 
(𝜶𝒑𝒋𝒍
𝒗𝒂𝒓) 
Fixed cost 
(rmu) 
(𝜶𝒑𝒋𝒍
𝒇𝒊𝒙
) 
Process changes 
cost (rmu) 
(𝜶𝒑𝒕
𝒑𝒄
) 
D1L2_F1L2_R1L2 1 2 74.5 150 345 
D1L1_F2L1_R1L1 1 3 54.5 200 345 
3 
D1L1_F1L1_R1L1 1 5 54.5 150 450 
D1L2_F1L2_R1L2 1 5 74.5 150 450 
D1L2_F1L2_R2L2 1 3 77 230 450 
4 
D1L1_F1L1_R1L1 1 5 54.5 150 450 
D1L2_F1L2_R1L2 1 5 74.5 150 450 
D1L2_F1L2_R2L2 1 4 77 230 450 
5 
D1L2_F1L2_R1L2 1 5 74.5 150 450 
D1L2_F1L2_R2L2 1 5 77 230 450 
D1L3_F1L3_R1L3 1 3 129 150 450 
6 
D1L3_F1L3_R2L3 1 2 154 230 675 
D1L3_F1L3_R1L3 1 5 129 150 675 
D1L2_F1L2_R1L2 1 1 123.5 150 675 
7 
D1L3_F1L3_R2L3 1 5 117 230 675 
D1L3_F1L3_R1L3 1 2 178 150 675 
D1L4_F1L4_R1L4 1 2 258 150 675 
8 
D1L4_F1L4_R2L4 1 3 234 230 675 
D1L3_F1L3_R1L3 1 5 129 150 675 
D1L4_F1L4_R1L4 1 2 258 150 675 
9 
D1L4_F1L4_R2L4 1 3 234 230 675 
D1L4_F1L4_R1L4 1 2 258 150 675 
D1L3_F1L3_R1L3 1 5 129 150 675 
PC 
0 
D1L1_F1L1_R1L1 1 4 101 150 300 
D1L1_F1L1_R2L1 1 4 104 230 300 
D1L2_F2L2_R2L2 1 1 147 280 300 
1 
D1L1_F1L1_R1L1 1 3 101 150 300 
D1L1_F1L1_R2L1 1 2 104 230 300 
D2L1_F1L1_R1L1 1 2 103.5 200 300 
2 
D1L1_F1L1_R1L1 1 2 101 150 300 
D1L1_F1L1_R2L1 1 2 104 230 300 
D2L1_F1L1_R1L1 1 3 103.5 200 300 
3 
D1L1_F1L1_R1L1 1 4 101 150 420 
D1L2_F1L2_R1L2 1 3 163 150 420 
D1L2_F1L2_R2L2 1 5 144 230 420 
4 
D1L1_F1L1_R1L1 1 5 101 150 420 
D1L2_F1L2_R2L2 1 5 144 230 420 
D1L2_F1L2_R1L2 1 3 163 150 420 
5 
D1L2_F2L2_R2L2 1 5 147 280 420 
D1L2_F1L2_R2L2 1 5 144 230 420 
D2L2_F1L2_R2L2 1 2 193.5 280 420 
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p t 
Process design 
(j) 
Min. nr. 
cycles 
(𝜼𝒑𝒋𝒍𝒕
𝒎𝒊𝒏) 
Max. nr. 
cycles 
(𝜼𝒑𝒋𝒍𝒕
𝒎𝒂𝒙) 
Variable 
cost (rmu) 
(𝜶𝒑𝒋𝒍
𝒗𝒂𝒓) 
Fixed cost 
(rmu) 
(𝜶𝒑𝒋𝒍
𝒇𝒊𝒙
) 
Process changes 
cost (rmu) 
(𝜶𝒑𝒕
𝒑𝒄
) 
6 
D3L4_F3L4_R3L4 1 4 400 950 945 
D1L2_F1L2_R2L2 1 1 247 230 945 
D2L3_F2L3_R3L3 1 1 332 630 945 
7 
D1L3_F1L3_R2L3 1 1 391 230 945 
D1L2_F2L2_R1L2_R2L2 1 1 270 350 945 
D2L3_F2L3_R3L3 1 2 278 630 945 
8 
D2L3_F2L3_R2L3 1 1 324 330 945 
D1L3_F2L3_R3L3 1 4 248 580 945 
D2L3_F2L3_R3L3 1 1 332 630 945 
9 
D2L4_F2L4_R3L4 1 2 438 630 945 
D2L3_F2L3_R2L3 1 1 324 330 945 
D1L3_F2L3_R3L3 1 4 248 580 945 
PD 
0 
D1L1_F1L1_R1L1 1 5 111 150 4000 
D3L1_F1L1_R1L1 1 5 116 320 4000 
D1L1_F1L1_R2L1 1 5 115 230 4000 
1 
D1L1_F1L1_R1L1 1 5 111 150 4000 
D1L1_F1L1_R2L1 1 5 115 230 4000 
D1L1_F2L1_R1L1 1 4 113.5 200 4000 
2 
D1L1_F1L1_R1L1 1 5 111 150 4000 
D1L1_F1L1_R2L1 1 5 115 230 4000 
D1L1_D3L1_F1L1_R2L1 1 5 137 430 4000 
3 
D1L1_F1L1_R2L1 1 5 115 230 4000 
D1L1_F1L1_R1L1 1 5 111 150 4000 
D1L1_F1L1_R1L1_R2L1 1 4 176 300 4000 
4 
D1L1_F1L1_R2L1 1 5 115 230 4000 
D1L1_F1L1_R1L1 1 5 111 150 4000 
D1L1_F1L1_R1L1_R2L1 1 6 176 300 4000 
5 
D1L2_F1L2_R2L2 1 4 199 230 4000 
D1L1_F1L1_R1L1 1 5 111 150 4000 
D1L1_F1L1_R2L1 1 5 149 230 4000 
6 
D1L2_F1L2_R2L2 1 4 199 230 4000 
D2L2_F1L2_R2L2 1 5 184.5 280 4000 
D2L2_F2L2_R2L2 1 5 170 330 4000 
7 
D1L2_F1L2_R2L2 1 4 199 230 4000 
D2L2_F1L2_R2L2 1 4 184.5 280 4000 
D1L4_F1L4_R2L4 1 2 549 230 4000 
8 
D1L2_F1L2_R2L2 1 1 281 230 4000 
D1L3_F1L3_R1L3 1 2 427 150 4000 
D1L4_F1L4_R2L4 1 2 549 230 4000 
9 
D1L2_F1L2_R1L2 1 2 222 150 4000 
D1L2_F1L2_R2L2 1 3 199 230 4000 
D1L3_F1L3_R1L3 1 1 427 150 4000 
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p t 
Process design 
(j) 
Min. nr. 
cycles 
(𝜼𝒑𝒋𝒍𝒕
𝒎𝒊𝒏) 
Max. nr. 
cycles 
(𝜼𝒑𝒋𝒍𝒕
𝒎𝒂𝒙) 
Variable 
cost (rmu) 
(𝜶𝒑𝒋𝒍
𝒗𝒂𝒓) 
Fixed cost 
(rmu) 
(𝜶𝒑𝒋𝒍
𝒇𝒊𝒙
) 
Process changes 
cost (rmu) 
(𝜶𝒑𝒕
𝒑𝒄
) 
PE 
0 
D1L1_F1L1_R1L1 1 2 159.5 150 2000 
D1L1_F1L1_R1L1_R2L1 1 4 213.5 300 2000 
D1L1_F1L1_R2L1 1 5 113 230 2000 
1 
D1L1_F1L1_R1L1 1 5 109 150 2000 
D1L1_F1L1_R2L1 1 5 113 230 2000 
D1L1_F2L1_R1L1 1 5 111.5 200 2000 
2 
D1L2_F1L2_R2L2 1 5 188.5 230 2000 
D1L1_F2L1_R1L1_R2L1 1 4 149 350 2000 
D1L1_F1L1_R1L1_R2L1 1 4 163.5 300 2000 
3 
D1L2_F1L2_R2L2 1 5 188.5 230 2000 
D1L1_F2L1_R1L1_R2L1 1 3 149 350 2000 
D1L2_F2L2_R2L2 1 5 174 280 2000 
4 
D1L2_F1L2_R2L2 1 5 188.5 230 2000 
D1L3_F1L3_R2L3 1 2 368.5 230 2000 
D1L2_F2L2_R2L2 1 5 174 280 2000 
5 
D1L2_F1L2_R2L2 1 5 188.5 230 2000 
D1L2_F2L2_R2L2 1 5 203 280 2000 
D1L4_F1L4_R2L4 1 2 607 230 2000 
6 
D1L2_F1L2_R2L2 1 2 268.5 230 2000 
D1L4_F1L4_R2L4 1 2 607 230 2000 
D1L3_F1L3_R2L3 1 3 368.5 230 2000 
7 
D1L4_F1L4_R2L4 1 2 607 230 2000 
D1L2_F1L2_R2L2 1 1 302.5 230 2000 
D1L3_F1L3_R2L3 1 4 368.5 230 2000 
8 
D1L4_F1L4_R2L4 1 2 607 230 2000 
D1L2_F1L2_R2L2 1 5 188.5 230 2000 
D1L3_F1L3_R2L3 1 3 368.5 230 2000 
9 
D1L4_F1L4_R2L4 1 1 607 230 2000 
D1L4_F1L4_R1L4 1 1 695 150 2000 
D1L3_F1L3_R2L3 1 2 368.5 230 2000 
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